Bifunctional degradation agents of hematopoietic progenitor cell kinases and therapeutic uses thereof

By developing bifunctional compounds targeting HPK1, the ubiquitin ligase bundle part promotes HPK1 degradation, the problem of low response rate of existing immunotumor therapies is solved, and the anti-tumor immune response and checkpoint receptor blockers are enhanced. In response, new methods for treating HPK1-related diseases are provided.

CN118930560APending Publication Date: 2024-11-12NURIX THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410979063.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-05-06
Filing Date
2021-05-05
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing immunotumor therapies have low response rates to various cancers, especially the use of inhibitor antibodies of immune checkpoint receptors CTLA4, PD-1 and PD-L1 has limitations in improving anti-tumor immune response, which is difficult to effectively enhance hematopoiesis. The therapeutic effect of progenitor kinase (HPK1) regulates disease.

Method used

A bifunctional compound was developed to covalently conjugate to the ubiquitin ligase bundle moiety through linkers, targeting cerebellar protein (CRBN) or von Hippel-Lindau (VHL) proteins, promoting ubiquitination and proteasome degradation of HPK1, This achieves specific degradation of HPK1.

Benefits of technology

Through the degradation of HPK1, the anti-tumor immune response and response to checkpoint receptor blockers are enhanced, providing new methods for treating HPK1-related diseases, including the possibility of cancer, hepatitis B virus and human immunodeficiency virus infection. sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004955481630000021
    Figure BDA0004955481630000021
  • Figure BDA0004955481630000071
    Figure BDA0004955481630000071
  • Figure BDA0004955481630000081
    Figure BDA0004955481630000081
Patent Text Reader

Abstract

The present disclosure provides bifunctional compounds as HPK1 degrading agents through the ubiquitin proteasome pathway, and methods for treating diseases modulated by HPK1.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application No. 202180033394.9, filed on May 5, 2021, with the invention name “Dual-functional degrader of hematopoietic progenitor cell kinase and its therapeutic use”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 021,045, filed May 6, 2020, which is incorporated herein by reference in its entirety. Background Art Technical Field

[0004] The present invention provides novel bifunctional compounds for the proteolytic degradation of hematopoietic progenitor kinase (HPK1) and methods for treating diseases modulated by HPK1.

[0005] Description of Related Technology

[0006] Immuno-oncology utilizes inhibitor antibodies against the immune checkpoint receptors CTLA4, PD-1, and PD-L1. Targeted disruption of these checkpoint pathways frees immune cells from key regulatory pathways, thereby enhancing the immune response against cancer cells. Current therapies utilizing these antibodies are distinguished by significant and durable responses across many different cancers, as well as low overall response rates (<25%). These improvements in response rates can be attributed to the combination of checkpoint blockade with other immune activators or cell-based therapies.

[0007] Hematopoietic progenitor kinase 1 is a STE20 ser / thr kinase from the germinal center family of kinases that regulates the function of multiple immune populations, including T cells, B cells, and dendritic cells (Hu et al., Gens Dev, 1996; Alzabin et al., J Immunol 2009). In T cells, HPK1 acts as a negative regulator of T cell receptor (TCR) signaling (Liou et al., Immunity 2000; Sauer et al., JBC 2001) by phosphorylating SLP76 on serine 376, inducing the association of SLP76 with 14-3-3 proteins and leading to dissociation of the signaling complex (Di Bartolo et al., JEM 2007). Further supporting a role for HPK1 as a negative regulator of TCR signaling, mouse HPK1-deficient T cells or HPK1 kinase-inactive mutant T cells have enhanced ERK 1 / 2 activation and effector cytokine secretion upon TCR activation compared to their wild-type counterparts (Shui et al., Nat Immunol 2007; Hernandez et al., Cell Reports 2018).

[0008] Therefore, HPK1 can be targeted for degradation, providing therapeutic opportunities in enhancing anti-tumor immunity and increasing responses to checkpoint blockers.

[0009] Brief Overview

[0010] Provided herein are bifunctional compounds represented by the general formula (I):

[0011]

[0012] or a pharmaceutically acceptable salt thereof,

[0013] in:

[0014] m is 0, 1, 2, 3 or 4;

[0015] n is 0, 1, 2, 3, 4, 5 or 6;

[0016] A is C 3-7 a monocyclic cycloalkyl ring or a 4-6 membered monocyclic heterocyclyl ring having 1 or 2 heteroatoms independently selected from N, O and S;

[0017] L is a linker moiety having a length of 2 to 24 consecutive covalently bonded atoms selected from C, O, N and S;

[0018] LHM is the ligase harness part;

[0019] R 11 for

[0020] i) is selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 alkoxy; or

[0021] ii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0022] iii)-S(O)2C 1-6 alkyl,

[0023] iv)-S(O)2C 3-7 Monocyclic cycloalkyl,

[0024] v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0025] vi)-C(O)R 21 ;

[0026] Each R 12 Independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 alkoxy;

[0027] R 21 for

[0028] i)H,

[0029] ii)C 3-7 Monocyclic or bridged bicyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 The alkoxy group is optionally substituted wherein the C 1-3 The alkyl group is substituted by 1-3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0030] iii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3Alkoxy groups are optionally substituted,

[0031] iv) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is surrounded by 1-3 heteroatoms independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0032] v) -NH2,

[0033] vi)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0034] vii)-N(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0035] viii)C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0036] ix)C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from:

[0037] a)-CN,

[0038] b) -OH,

[0039] c) halogens,

[0040] d)C 1-3 Alkoxy,

[0041] e)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0042] f) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C1-3 The alkoxy groups are optionally substituted, and

[0043] g) -OC(O)C optionally substituted with one -OH 1-6 alkyl;

[0044] R 3 and R 13 Each is H, or

[0045] R 3 and R 13 Together they form =O;

[0046] X is -NR 15 R 16 , where R 15 and R 16 Independently

[0047] i)H,

[0048] ii)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0049] iii) a 4-7 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0050] iv)-C(O)C 1-6 Alkyl, wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or

[0051] v)C 1-6 Alkyl, which is optionally substituted with 1-6 groups independently selected from:

[0052] a)-CN,

[0053] b) -OH,

[0054] c) halogens,

[0055] d)C 1-3 Alkoxy,

[0056] e)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C1-3 The alkoxy groups are optionally substituted, and

[0057] f) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 The alkoxy group is optionally substituted; or

[0058] X is a 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclic group is surrounded by 1-5 R 18 optionally substituted;

[0059] Each R 18 Independently

[0060] i)-CN,

[0061] ii) halogen,

[0062] iii) -OH,

[0063] iv) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0064] v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0065] vi) -COOH, or

[0066] vii)-C(O)N(R 22 )2, where each R 22 are independently H or C 1-6 alkyl;

[0067] X 1 N or CR 17 ;

[0068] R 4 、R 5 、R 6 、R 10 and R 17 are independently H, halogen, C 1-3 Alkyl or C 1-3 alkoxy;

[0069] R 7 for

[0070] i)H,

[0071] ii)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0072] iii)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted;

[0073] Z is -O-, -C(R 8 )2-or-NR 8 -;

[0074] Each R 8 are independently H or C 1-3 alkyl;

[0075] R 9a 、R 9b 、R 9c 、R 9d and R 9e Independently

[0076] i)H,

[0077] ii) halogen,

[0078] iii)C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0079] iv) -NH2,

[0080] v)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0081] vi)-N(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0082] vii)-P(O)(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0083] viii)-S(O)2C 1-6 alkyl,

[0084] ix)-S(O)2N(R 23 )2, where each R 23 are independently H or C 1-6 alkyl,

[0085] x)C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from:

[0086] a) -OH,

[0087] b) halogens,

[0088] c)C 1-3 Alkoxy,

[0089] d)C 3-7 Monocyclic cycloalkyl,

[0090] e) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from oxo and C 1-3 The alkyl groups are optionally substituted, and

[0091] f)-NR 20 C(O)OC 1-3 Alkyl, where R 20 H or C 1-3 alkyl,

[0092] xi)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0093] xii) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is surrounded by 1-3 heteroatoms independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0094] xiii) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0095] xiv) -COOH,

[0096] xv)-C(O)N(R 19 )2, or

[0097] xvi)-C 1-3 Alkylene-C(O)N(R 19 )2,

[0098] where R 9a 、R 9b 、R 9c 、R 9d and R 9e One or more of -C(O)N(R 19 )2 or -C 1-3 Alkylene-C(O)N(R 19 )2; and

[0099] Each R 19 Independently

[0100] i)H,

[0101] ii)-S(O)2C 1-6 alkyl,

[0102] iii)C 1-6 Alkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0103] iv) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or

[0104] v) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-6 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3Alkyl and C 1-3 Alkoxy groups are optionally substituted.

[0105] In various embodiments, Z is NH, X 1 CH, R 6 is H, and the compound of general formula (I) has the structure of general formula (Ia):

[0106]

[0107] In a more specific embodiment, the compound of formula (I) has the structure of formula (Ib):

[0108]

[0109] In various more specific embodiments, each R 9a 、R 9b 、R 9c 、R 9d and R 9e are independently H, halogen, C 1-6 Alkyl or -C(O)N(R 19 )2, where R 19 C 1-6 Alkyl; R 4 、R 5 and R 10 Each is H; and R 7 C 1-6 alkyl.

[0110] In various more specific embodiments, R 3 and R 13 Together they form =0. Alternatively, X is piperidinyl.

[0111] In a more specific embodiment, the compound of formula (I) has the structure of formula (Ic):

[0112]

[0113] In various more specific embodiments, L is represented by:

[0114]

[0115] in,

[0116] t is 0, 1, 2, 3, 4, 5, 6, or 7;

[0117] q is 0, 1, 2, 3, 4, 5, 6, or 7;

[0118] L 1 is a direct bond, -C(O)NH- or -C(O)-; and

[0119] L 2 It is -C(O)NH-, -O- or -NH-.

[0120] In more specific embodiments, t is 0 and q is 3, 4, 5, 6 or 7.

[0121] In other more specific embodiments, q is 0 and t is 1, 3, 5 or 7.

[0122] In various other more specific embodiments, L is represented by:

[0123]

[0124] in,

[0125] w is 1, 2, or 3;

[0126] v is 1 or 2;

[0127] p is 1, 2, 3, 4, or 5;

[0128] Y 1 For direct connection, -(CH2) p - or –O-;

[0129] Y 2 For direct connection, -(CH2) p -, -C(O)- or -C(O)-CH2-,

[0130] X 3 and X 4 are independently N or C(R), wherein R is H or C 1-3 alkyl;

[0131] L 4 is a direct bond, –NH-, -NHC(O)- or

[0132] L 4 for

[0133]

[0134] In other embodiments, L comprises a rigid ring system, such as an aryl ring (eg, phenyl), a heteroaryl ring, a bridged ring, a spiro ring, or mixtures thereof.

[0135] In more specific embodiments, the LHM targets CRBN and has the structure of Formula (Id):

[0136]

[0137] in,

[0138] W is –C(R g )- or –N-;

[0139] Z1 is -C(O)-, -C(S)-, -C(NR g )-、-C(R g )2-、-C(R g )2-C(O)-、-C(O)-N(R g )-、–CR g =CR g -、–C(R g )=N-、-C(R g )2-C(S)-or-C(R g )2-C(R g )2-;

[0140] q is 0, 1, or 2;

[0141] R g is hydrogen or C 1-6 Alkyl; and

[0142] R a C 1-6 Alkyl, halogen, halogenated C 1-6 Alkyl, -N(R g )2, CN, nitro, hydroxyl or -OC 1-4 alkyl.

[0143] In other specific embodiments, the LHM targets VHL and has the structure of Formula (Ie) or (If):

[0144]

[0145] in,

[0146] p is 0 or 1;

[0147] R j For 1 to 3 R k optionally substituted 5-6 membered heteroaryl,

[0148] Each R k are independently halogen, oxo, -CN, -OH, C 1-6 Alkyl, C 3-8 Cycloalkyl or -OC 1-6 alkyl,

[0149] Each R e are independently hydrogen, C 1-6 Alkyl or C 3-8 Cycloalkyl;

[0150] R b is hydrogen or hydroxyl;

[0151] R c -C(O)R f , where R f C 1-6 Alkyl or C 3-8 Cycloalkyl, each of which is optionally substituted by halogen or —CN.

[0152] In other embodiments, the present disclosure provides compounds having the structure of Formula (II):

[0153]

[0154] or a pharmaceutically acceptable salt thereof,

[0155] in:

[0156] m is 0, 1, 2, 3, 4 or 5;

[0157] n is 0, 1, 2, 3, 4, 5 or 6;

[0158] B is a 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclyl ring having 1-3 heteroatoms independently selected from N, O and S;

[0159] L is a linker moiety having a length of 2 to 24 consecutive covalently bonded atoms selected from C, O, N and S;

[0160] LHM is the ligase bundle part;

[0161] R 1 and R 2 One of them is H, -CN, -OH, halogen or C 1-6 Alkyl, and R 1 and R 2 The other is H, halogen or C 1-6 Alkyl, where each C 1-6 The alkyl group is optionally substituted with 1 to 3 groups independently selected from -OH and halogen, or

[0162] R 1 and R 2 Together with the carbon to which they are attached, they form C 3-7 Monocyclic cycloalkyl or 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein said C 3-7 The monocyclic cycloalkyl group and the 4-6 membered monocyclic heterocyclic group are each replaced by one R 11 Optionally substituted and each with 1-3 independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, or

[0163] R 1 and R 2 Together they form =O;

[0164] R 11 for

[0165] i) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0166] ii)-S(O)2C 1-6 alkyl,

[0167] iii)-S(O)2C 3-7 Monocyclic cycloalkyl,

[0168] iv) C 1-6 Alkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0169] v)-C(O)R 21 ;

[0170] R 21 for

[0171] i)H,

[0172] ii)C 3-7 Monocyclic or bridged bicyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 The alkoxy group is optionally substituted, wherein the C 1-3 The alkyl group is substituted by 1-3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0173] iii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0174] iv) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is surrounded by 1-3 heteroatoms independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0175] v) -NH2,

[0176] vi)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0177] vii)-N(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0178] viii)C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0179] ix)C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from:

[0180] a)-CN,

[0181] b) -OH,

[0182] c) halogens,

[0183] d)C 1-3 Alkoxy,

[0184] e)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0185] f) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 The alkoxy groups are optionally substituted, and

[0186] g) -OC(O)C optionally substituted with one -OH 1-6 alkyl;

[0187] R 3 and R 13 Each is H, or

[0188] R 3 and R 13 Together they form =O;

[0189] Each R 12 Independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 alkoxy;

[0190] Each R 18 Independently

[0191] i)-CN,

[0192] ii) halogen,

[0193] iii) -OH,

[0194] iv) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0195] v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0196] vi) -COOH, or

[0197] vii)-C(O)N(R 22 )2, where each R 22 are independently H or C 1-6 alkyl;

[0198] X 1 N or CR 17 ;

[0199] R 4 、R 5 、R 6 、R 10 and R 17 are independently H, halogen, C 1-3 Alkyl or C 1-3 alkoxy;

[0200] R 7for

[0201] i)H,

[0202] ii)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0203] iii)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted;

[0204] Z is -O-, -C(R 8 )2-or-NR 8 -;

[0205] Each R 8 are independently H or C 1-3 alkyl;

[0206] R 9a 、R 9b 、R 9c 、R 9d and R 9e Independently

[0207] i)H,

[0208] ii) halogen,

[0209] iii)C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0210] iv) -NH2,

[0211] v)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0212] vi)-N(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0213] vii)-P(O)(C1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0214] viii)-S(O)2C 1-6 alkyl,

[0215] ix)-S(O)2N(R 23 )2, where each R 23 are independently H or C 1-6 alkyl,

[0216] x)C 1-6 Alkyl, optionally substituted by 1-3 groups independently selected from

[0217] a) -OH,

[0218] b) halogens,

[0219] c)C 1-3 Alkoxy,

[0220] d)C 3-7 Monocyclic cycloalkyl,

[0221] e) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from oxo and C 1-3 The alkyl groups are optionally substituted, and

[0222] f)-NR 20 C(O)OC 1-3 Alkyl, where R 20 H or C 1-3 alkyl,

[0223] xi)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0224] xii) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is surrounded by 1-3 heteroatoms independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0225] xiii) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0226] xiv) -COOH,

[0227] xv)-C(O)N(R 19 )2 or

[0228] xvi)-C 1-3 Alkylene-C(O)N(R 19 )2,

[0229] where R 9a 、R 9b 、R 9c 、R 9d and R 9e One or more of -C(O)N(R 19 )2 or -C 1-3 Alkylene-C(O)N(R 19 )2; and

[0230] Each R 19 Independently

[0231] i)H,

[0232] ii)-S(O)2C 1-6 alkyl,

[0233] iii)C 1-6 Alkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0234] iv) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or

[0235] v) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-6 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3Alkoxy groups are optionally substituted.

[0236] In more specific embodiments, Z is NH, X 1 CH, R 6 is H and the compound of general formula (II) has the structure of general formula (IIa):

[0237]

[0238] In a more specific embodiment, the compound of formula (II) has the structure of formula (IIb):

[0239]

[0240] In further embodiments, each R 9a 、R 9b 、R 9c 、R 9d and R 9e are independently H, halogen, C 1-6 Alkyl or -C(O)N(R 19 )2; where R 19 C 1-6 Alkyl; R 4 、R 5 and R 10 Each is H; and R 7 C 1-6 alkyl.

[0241] In a further more specific embodiment, R 3 and R 13 Together they form =O; and R 1 and R 2 Together with the carbon to which they are attached, they form a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, and wherein the 4-6 membered monocyclic heterocyclic group is replaced by one R 11 Optional substitution.

[0242] In a preferred embodiment, the compound of formula (II) has the structure of formula (IIc):

[0243]

[0244] In further embodiments, L has the following structure:

[0245]

[0246] Wherein, t is 0, 1, 2, 3, 4, 5, 6 or 7; q is 0, 1, 2, 3, 4, 5, 6 or 7; L 1 is -C(O)NH-; and L2 In a more specific embodiment, t is 0, and q is 3, 5 or 7.

[0247] In a more specific embodiment, the LHM targets VHL and has the structure of general formula (If):

[0248]

[0249] in,

[0250] p is 0 or 1;

[0251] R j For 1 to 3 R k optionally substituted 5-6 membered heteroaryl,

[0252] Each R k are independently halogen, oxo, -CN, -OH, C 1-6 Alkyl, C 3-8 Cycloalkyl or -OC 1-6 alkyl.

[0253] Each R e are independently hydrogen, C 1-6 Alkyl or C 3-8 Cycloalkyl;

[0254] R b is hydrogen or hydroxyl;

[0255] R c -C(O)R f , where R f C 1-6 Alkyl or C 3-8 Cycloalkyl, each of which is optionally substituted by halogen or —CN.

[0256] In other embodiments, the LHM targets CRBN and has the structure of Formula (Id):

[0257]

[0258] in,

[0259] W is –C(R g )- or –N-;

[0260] Z1 is -C(O)-, -C(S)-, -C(NR g )-、-C(R g )2-、-C(R g )2-C(O)-、-C(O)-N(R g )-、–CR g =CR g-、–C(R g )=N-、-C(R g )2-C(S)-or-C(R g )2-C(R g )2-;

[0261] q is 0, 1, or 2;

[0262] R g is hydrogen or C 1-6 Alkyl; and

[0263] R a C 1-6 Alkyl, halogen, halogenated C 1-6 Alkyl, -N(R g )2, CN, nitro, hydroxyl or -OC 1-4 alkyl.

[0264] Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or Formula (II), or any substructure or specific compound of Examples 1-97, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

[0265] Other embodiments provide methods for treating a disease or condition associated with increased hematopoietic progenitor kinase 1 (HPK1) activity, methods for increasing T cell activation, methods for treating cancer, methods for inhibiting the growth or proliferation of cancer cells, methods for treating or preventing hepatitis B virus (HBV) infection, or methods for treating or preventing human immunodeficiency virus (HIV) infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or Formula (II), any substructure, or a compound of Examples 1-97. Detailed description

[0266] Specific degradation of HPK1 can be achieved by recruiting HPK1 to ubiquitin ligases using heterobifunctional small molecules and thereby promoting ubiquitination and proteasomal degradation of HPK1. Therefore, bifunctional compounds are provided herein, each of which comprises an HPK1 conjugate covalently conjugated to a ligase bundle moiety (LHM) for targeting ubiquitin ligases via a linker. Preferably, the LHM targets cerebellum protein (CRBN) or von Hippel-Lindau (VHL) proteins, which are substrate recognition subunits of two ubiquitously expressed biologically important Cullin RING E3 ubiquitin ligase complexes. See, for example, WO2019 / 099926, WO2020 / 023851, and U.S. Published Application No. 2019 / 0192668.

[0267] One embodiment provides a bifunctional compound of formula (I):

[0268]

[0269] or a pharmaceutically acceptable salt, isotopic form, isolated stereoisomer or mixture of stereoisomers thereof, wherein

[0270] m is 0, 1, 2, 3 or 4;

[0271] n is 0, 1, 2, 3, 4, 5 or 6;

[0272] A is C 3-7 a monocyclic cycloalkyl ring or a 4-6 membered monocyclic heterocyclyl ring having 1 or 2 heteroatoms independently selected from N, O and S;

[0273] L is a linker moiety having a length of 2 to 24 consecutive covalently bonded atoms selected from C, O, N and S;

[0274] LHM is the ligase bundle part;

[0275] R 11 for

[0276] i) is selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 alkoxy; or

[0277] ii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0278] iii)-S(O)2C 1-6 alkyl,

[0279] iv)-S(O)2C 3-7 Monocyclic cycloalkyl,

[0280] v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0281] vi)-C(O)R 21 ;

[0282] Each R 12 Independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 alkoxy;

[0283] R 21 for

[0284] i)H,

[0285] ii)C 3-7 Monocyclic or bridged bicyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 The alkoxy group is optionally substituted wherein the C 1-3 The alkyl group is substituted by 1-3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0286] iii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0287] iv) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is surrounded by 1-3 heteroatoms independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0288] v) -NH2,

[0289] vi)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0290] vii)-N(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0291] viii)C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0292] ix)C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from:

[0293] a)-CN,

[0294] b) -OH,

[0295] c) halogens,

[0296] d)C 1-3 Alkoxy,

[0297] e)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0298] f) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 The alkoxy groups are optionally substituted, and

[0299] g) -OC(O)C optionally substituted with one -OH 1-6 alkyl;

[0300] R 3 and R 13 Each is H, or

[0301] R 3 and R 13 Together they form =O;

[0302] X is -NR 15 R 16 , where R 15 and R 16 Independently

[0303] i)H,

[0304] ii)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0305] iii) a 4-7 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0306] iv)-C(O)C 1-6Alkyl, wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or

[0307] v)C 1-6 Alkyl, which is optionally substituted with 1-6 groups independently selected from:

[0308] a)-CN,

[0309] b) -OH,

[0310] c) halogens,

[0311] d)C 1-3 Alkoxy,

[0312] e)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 The alkoxy groups are optionally substituted, and

[0313] f) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 The alkoxy group is optionally substituted; or

[0314] X is a 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclic group is surrounded by 1-5 R 18 optionally substituted;

[0315] Each R 18 Independently

[0316] i)-CN,

[0317] ii) halogen,

[0318] iii) -OH,

[0319] iv) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0320] v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0321] vi) -COOH, or

[0322] vii)-C(O)N(R 22 )2, where each R 22 are independently H or C 1-6 alkyl;

[0323] X 1 N or CR 17 ;

[0324] R 4 、R 5 、R 6 、R 10 and R 17 are independently H, halogen, C 1-3 Alkyl or C 1-3 alkoxy;

[0325] R 7 for

[0326] i)H,

[0327] ii)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0328] iii)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted;

[0329] Z is -O-, -C(R 8 )2-or-NR 8 -;

[0330] Each R 8 are independently H or C 1-3 alkyl;

[0331] R 9a 、R 9b 、R 9c 、R 9d and R 9e Independently

[0332] i)H,

[0333] ii) halogen,

[0334] iii)C 1-6Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0335] iv) -NH2,

[0336] v)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0337] vi)-N(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0338] vii)-P(O)(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0339] viii)-S(O)2C 1-6 alkyl,

[0340] ix)-S(O)2N(R 23 )2, where each R 23 are independently H or C 1-6 alkyl,

[0341] x)C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from:

[0342] a) -OH,

[0343] b) halogens,

[0344] c)C 1-3 Alkoxy,

[0345] d)C 3-7 Monocyclic cycloalkyl,

[0346] e) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from oxo and C 1-3 The alkyl groups are optionally substituted, and

[0347] f)-NR 20 C(O)OC 1-3 Alkyl, where R 20 H or C 1-3 alkyl,

[0348] xi)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0349] xii) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is surrounded by 1-3 heteroatoms independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0350] xiii) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0351] xiv) -COOH,

[0352] xv)-C(O)N(R 19 )2, or

[0353] xvi)-C 1-3 Alkylene-C(O)N(R 19 )2,

[0354] The condition is R 9a 、R 9b 、R 9c 、R 9d and R 9e One or more of -C(O)N(R 19 )2 or -C 1-3 Alkylene-C(O)N(R19)2; and

[0355] Each R 19 Independently

[0356] i)H,

[0357] ii)-S(O)2C 1-6 alkyl,

[0358] iii)C 1-6Alkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0359] iv) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or

[0360] v) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-6 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted.

[0361] Alternative embodiments provide compounds of formula (II):

[0362]

[0363] or a pharmaceutically acceptable salt, isotopic form, isolated stereoisomer or mixture of stereoisomers thereof,

[0364] in:

[0365] m is 0, 1, 2, 3, 4 or 5;

[0366] n is 0, 1, 2, 3, 4, 5 or 6;

[0367] B is a 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclyl ring having 1-3 heteroatoms independently selected from N, O and S;

[0368] L is a linker moiety having a length of 2 to 24 consecutive covalently bonded atoms selected from C, O, N and S;

[0369] LHM is the ligase bundle part;

[0370] R 1 and R 2 One of them is H, -CN, -OH, halogen or C 1-6 Alkyl, and R 1 and R 2 The other is H, halogen or C 1-6 Alkyl, where each C 1-6The alkyl group is optionally substituted with 1 to 3 groups independently selected from -OH and halogen, or

[0371] R 1 and R 2 Together with the carbon to which they are attached, they form C 3-7 Monocyclic cycloalkyl or 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein said C 3-7 The monocyclic cycloalkyl group and the 4-6 membered monocyclic heterocyclic group are each replaced by one R 11 are optionally substituted and each is independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, or

[0372] R 1 and R 2 Together they form =O;

[0373] R 11 for

[0374] i) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0375] ii)-S(O)2C 1-6 alkyl,

[0376] iii)-S(O)2C 3-7 Monocyclic cycloalkyl,

[0377] iv) C 1-6 Alkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0378] v)-C(O)R 21 ;

[0379] R 21 for

[0380] i)H,

[0381] ii)C 3-7 Monocyclic or bridged bicyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 The alkoxy group is optionally substituted wherein the C 1-3The alkyl group is substituted by 1-3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0382] iii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0383] iv) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is surrounded by 1-3 heteroatoms independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0384] v) -NH2,

[0385] vi)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0386] vii)-N(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0387] viii)C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0388] ix)C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from:

[0389] a)-CN,

[0390] b) -OH,

[0391] c) halogens,

[0392] d)C 1-3 Alkoxy,

[0393] e)C 3-7Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0394] f) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 The alkoxy groups are optionally substituted, and

[0395] g) -OC(O)C optionally substituted with one -OH 1-6 alkyl;

[0396] R 3 and R 13 Each is H, or

[0397] R 3 and R 13 Together they form =O;

[0398] Each R 12 Independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 alkoxy;

[0399] Each R 18 Independently

[0400] i)-CN,

[0401] ii) halogen,

[0402] iii) -OH,

[0403] iv) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0404] v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0405] vi) -COOH, or

[0406] vii)-C(O)N(R 22 )2, where each R 22 are independently H or C 1-6 alkyl;

[0407] X 1 N or CR 17 ;

[0408] R 4 、R 5 、R 6 、R 10 and R 17 are independently H, halogen, C 1-3 Alkyl or C 1-3 alkoxy;

[0409] R 7 for

[0410] i)H,

[0411] ii)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, or

[0412] iii)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted;

[0413] Z is -O-, -C(R 8 )2-or-NR 8 -;

[0414] Each R 8 are independently H or C 1-3 alkyl;

[0415] R 9a 、R 9b 、R 9c 、R 9d and R 9e Independently

[0416] i)H,

[0417] ii) halogen,

[0418] iii)C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0419] iv) -NH2,

[0420] v)-NH(C 1-6 alkyl), wherein the C 1-6The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0421] vi)-N(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0422] vii)-P(O)(C 1-6 alkyl)2, wherein each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted,

[0423] viii)-S(O)2C 1-6 alkyl,

[0424] ix)-S(O)2N(R 23 )2, where each R 23 are independently H or C 1-6 alkyl,

[0425] x)C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from:

[0426] a) -OH,

[0427] b) halogens,

[0428] c)C 1-3 Alkoxy,

[0429] d)C 3-7 Monocyclic cycloalkyl,

[0430] e) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 groups independently selected from oxo and C 1-3 The alkyl groups are optionally substituted, and

[0431] f)-NR 20 C(O)OC 1-3 Alkyl, where R 20 H or C 1-3 alkyl,

[0432] xi)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0433] xii) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is surrounded by 1-3 heteroatoms independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0434] xiii) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted,

[0435] xiv) -COOH,

[0436] xv)-C(O)N(R 19 )2, or

[0437] xvi)-C 1-3 Alkylene-C(O)N(R 19 )2,

[0438] where R 9a 、R 9b 、R 9c 、R 9d and R 9e One or more of -C(O)N(R 19 )2 or -C 1-3 Alkylene-C(O)N(R 19 )2; and

[0439] Each R 19 Independently

[0440] i)H,

[0441] ii)-S(O)2C 1-6 alkyl,

[0442] iii)C 1-6 Alkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted,

[0443] iv) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-6 Alkyl and C 1-6The alkoxy group is optionally substituted wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or

[0444] v) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-6 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted.

[0445] HPK1 binders

[0446] HPK1 conjugates of bifunctional compounds of general formula (I) or (II) generally have a 6-azabenzimidazole core that is further derivatized to include a cyclobutyl-substituted indoline or 4-azaindoline moiety and a benzamide moiety. The HPK1 conjugate provides various sites for coupling to the LHM via a linker (i.e., a linker-LHM moiety). More specifically, in the bifunctional compounds of general formula (I), the HPK1 conjugate moiety is coupled to the linker-LHM moiety via the A ring, as shown in the structure represented by general formula (A) (the wavy line indicates the coupling site to the linker-LHM moiety):

[0447]

[0448] Among them, R 3 、R 4 、R 5 、R 6 、R 7 、R 9a 、R 9b 、R 9c 、R 9d 、R 9e ; R 10 ; R 11 、R 12 and R 13 、X 1 , Z, m and n are as defined above.

[0449] In a more specific embodiment, Z is NH, X 1 CH, R 6 is H, and some HPK1 binder compounds have the structure of general formula (Aa):

[0450]

[0451] In a preferred embodiment, Ring A is piperidinyl and the HPK1 binder moiety has the following structure:

[0452]

[0453] In various embodiments, each R 9a 、R 9b 、R 9c 、R 9d and R 9e are independently H, halogen, C 1-6 Alkyl or -C(O)N(R 19 )2, where R 19 C 1-6 Alkyl; R 4 、R 5 and R 10 Each is H; and R 7 C 1-6 alkyl.

[0454] In other embodiments, R 3 and R 13 Together they form =O.

[0455] In other embodiments, X is piperidinyl.

[0456] In other embodiments, n is 0 and p is 0.

[0457] In a preferred embodiment, the HPK1 binder moiety has the structure of Formula (Ac):

[0458]

[0459] In more specific embodiments, the compound of formula (Ac) may have one of the following diastereomeric structures:

[0460]

[0461] Alternatively, for the bifunctional compound of formula (II), the HPK1 binder portion is coupled to the linker-LHM portion via the B ring, as shown in the structure represented by formula (B) (the wavy line indicates the coupling site with the linker-LHM portion):

[0462]

[0463] Among them, R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、R 9a 、R 9b 、R 9c 、R9d 、R 9e ; R 10 ; R 12 、R 13 、R 18 、X 1 , Z, m and n are as defined above.

[0464] In a preferred embodiment, Z is NH, X 1 CH, R 6 is H, and the HPK1 binding compound has the general formula (Ba):

[0465]

[0466] In a preferred embodiment, Ring B is piperidinyl, and the HPK1 binder moiety has the structure of Formula (Bb):

[0467]

[0468] In various other embodiments, each R 9a 、R 9b 、R 9c 、R 9d and R 9e are independently H, halogen, C 1-6 Alkyl or -C(O)N(R 19 )2, where R 19 C 1-6 Alkyl; R 4 、R 5 and R 10 Each is H; and R 7 C 1-6 alkyl.

[0469] In various other embodiments, R 3 and R 13 Together they form =O; and R 1 and R 2 Together with the carbon to which they are attached, they form a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, and wherein the 4-6 membered monocyclic heterocyclic group is replaced by one R 11 Optionally substituted. 11 As defined herein.

[0470] In a preferred embodiment, the HPK1 binder moiety has the structure of Formula (Bc):

[0471]

[0472] Ligase tract moiety (LHM)

[0473] The LHM of the compound of formula (I) or formula (II) targets the E3 ligase VHL or CRBN, which is controlled and harnessed by the bifunctional compound to induce the ubiquitination and subsequent proteasomal degradation of HPK1.

[0474] Thalidomide derivatives, such as lenalidomide or pomalidomide, can be used to recruit potential substrates to CRBN, a component of the ubiquitin ligase complex.

[0475] One embodiment provides a CRBN-targeting LHM having the following structure (the wavy line shows the bond to the rest of the compound of formula (I)):

[0476]

[0477] in,

[0478] W is –C(R g )- or –N-;

[0479] Z1 is -C(O)-, -C(S)-, -C(NR g )-、-C(R g )2-、-C(R g )2-C(O)-、-C(O)-N(R g )-、–CR g =CR g -、–C(R g )=N-、-C(R g )2-C(S)-or-C(R g )2-C(R g )2-;

[0480] q is 0, 1, or 2;

[0481] R g is hydrogen or C 1-6 Alkyl; and

[0482] R a C 1-6 Alkyl, halogen, halogenated C 1-6 Alkyl, -N(R g )2, CN, nitro, hydroxyl or -OC 1-4 alkyl.

[0483] In more specific embodiments, the LHM has one of the following structures:

[0484]

[0485] In other embodiments, the LHM targets VHL and has the structure of Formula (Ie) or (If):

[0486]

[0487] in,

[0488] p is 0 or 1;

[0489] R j For 1 to 3 R k optionally substituted 5-6 membered heteroaryl,

[0490] Each R k are independently halogen, oxo, -CN, -OH, C 1-6 Alkyl, C 3-8 Cycloalkyl or -OC 1-6 alkyl.

[0491] Each R e are independently hydrogen, C 1-6 Alkyl or C 3-8 Cycloalkyl;

[0492] R b is hydrogen or hydroxyl;

[0493] R c -C(O)R f , where R f C 1-6 Alkyl or C 3-8 Cycloalkyl, each of which is optionally substituted by halogen or —CN.

[0494] In more specific embodiments, the LHM has one of the following structures:

[0495]

[0496] connector

[0497] Each bifunctional compound of Formula (I) or Formula (II) comprises a linker, a divalent moiety that couples the HPK1 binder moiety to the LHM. The structure (e.g., length or rigidity) of the linker moiety can influence the efficiency or selectivity of the degradation process. Typically, in addition to providing respective attachment points for the HPK1 binder moiety and the LHM, the linker moiety comprises multiple segments that contribute to the overall length and rigidity of the linker.

[0498] As used herein, a linker moiety generally has a length of 2-24 consecutive covalently bonded atoms selected from C, O, N, and S. Specifically, the linker moiety comprises a continuous sequence of covalent bonds between the respective points of attachment to the HPK1 binder moiety and the LHM, including the bonds indicated by the wavy lines of Formulas (A), (B), (Id), (Ie), and (If), and their respective substructures.

[0499] In some embodiments, the linker moiety has the following chain structure:

[0500]

[0501] in,

[0502] t is 0, 1, 2, 3, 4, 5, 6, or 7;

[0503] q is 0, 1, 2, 3, 4, 5, 6, or 7;

[0504] L 1 is a direct bond, -C(O)NH- or -C(O)-; and

[0505] L 2 It is -C(O)NH-, -O- or -NH-.

[0506] In more specific embodiments, t is 0 and q is 3, 4, 5, 6 or 7.

[0507] In other more specific embodiments, q is 0 and t is 1, 3, 5 or 7.

[0508] In further more specific embodiments, said linker has one of the following structures:

[0509]

[0510] As used herein, the * of a bivalent moiety generally indicates the respective points of attachment to the rest of the compound, eg, the HPK1 binder moiety and the LHM; or other linker fragment. The * and the wavy line should be understood to be interchangeable.

[0511] The length of the linker can be determined by the total number of atoms that form consecutive bonds. Using the above linker moieties as an example, the total number of atoms from the atoms directly attached to the HPK1 binder moiety (e.g., L 1 C atom of the linker moiety (e.g., C, N, or O), and the atom forming the continuous covalent bond (e.g., C, N, or O), to the atom directly attached to the linker moiety (e.g., L 2 C, O, or N) are counted. Atoms not involved in continuous covalent bonding (e.g., H or O when connected by a double bond) are excluded from the total number of atoms. For linker moieties containing one or more ring structures, the total number of atoms is counted only along a single linear sequence of atoms, not around the ring. For example, a divalent 1,6-cyclohexyl ring moiety is counted as 4 atoms rather than 6 atoms.

[0512] It is understood that unless otherwise indicated and provided that valences are satisfied, the divalent moieties described herein (e.g., L 1 or L2 ) are not limited to expressing their directions. For example, for a given L 1 , such as -C(O)-NH-, can be attached to the rest of the molecule in either orientation: that is, -C(O)-NH- or -NH-C(O)-, provided that the attachment does not violate valence rules.

[0513] One or more linker fragments can be direct bonds.For illustrative purposes, in a sequence of a linker fragment represented by -L2-L3-L4-, when L3 is a direct bond, it is effectively absent because L2 and L4 are directly connected to each other.

[0514] In another embodiment, the linker moiety has one or more rings, which tend to increase the rigidity of the linker.The combination of linkages and rings can be used to adjust the relative orientation of the bifunctional groups or the distance between them.

[0515] In more specific embodiments, the linker moiety has the following structure:

[0516]

[0517] in,

[0518] p is 1 or 2;

[0519] q is 0, 1, 2, or 3;

[0520] X 2 is CH or N;

[0521] L 3 for

[0522] i)-(CH2) q -;

[0523] ii)–(CH2) q -C(O)NH-; or

[0524]

[0525] In another embodiment, the linker moiety has the structure:

[0526]

[0527] in,

[0528] w is 1, 2, or 3;

[0529] v is 1 or 2;

[0530] p is 1, 2, 3, 4, or 5;

[0531] Y 1For direct connection, -(CH2) p - or –O-;

[0532] Y 2 For direct connection, -(CH2) p -, -C(O)- or -C(O)-CH2-;

[0533] X 3 and X 4 are independently N or C(R), wherein R is H or C 1-3 alkyl;

[0534] L 4 is a direct bond, –NH-, -NHC(O)-, or

[0535] L 4 for

[0536] In other specific embodiments, the linker moiety has the structure:

[0537]

[0538]

[0539]

[0540] In other embodiments, the linker moiety comprises a rigid ring system, such as an aryl ring (eg, phenyl), a heteroaryl ring, a bridged ring, a spiro ring, or mixtures thereof.

[0541] In more specific embodiments, the linker moiety has one of the following structures:

[0542]

[0543]

[0544] Construction of compounds of formula (I) and (II)

[0545] The synthesis or construction of the compounds of formula (I) or (II) can be carried out in multiple steps, generally involving the preparation of the building blocks of the HPK1 binder and the LHM portion separately, followed by the formation of covalent bonds to link the building blocks. In general, one or more linker precursors (LHM) can be used. x ) to prepare either one or both building blocks. The linker precursor comprises one or more linker fragments (L s ) and have terminal reactive groups for further coupling. These two building blocks can be finally coupled (by forming L sfragment) to provide a compound of formula (I) or formula (II).

[0546] The following scheme demonstrates a general method for preparing the building blocks. Specific examples (Examples 1-97) were synthesized according to the general scheme described herein and characterized by their respective physicochemical properties.

[0547] A. General Protocol for Preparation of HPK1 Binder Building Blocks

[0548] HPK1 binder building blocks can be prepared using a method similar to that shown in Reaction Scheme A below. For compounds of formula (I), R 1 and R 2 Together with the carbon to which they are attached, they form the A ring; for compounds of formula (II), X is the B ring.

[0549] Reaction Scheme A

[0550]

[0551] Step 1 - Preparation of compound of formula (3)

[0552] The compound of formula (3) can be prepared by combining compounds (1) and (2). Compounds (1) and (2) are commercially available or can be prepared by methods known in the art. Compounds (1) and (2) can be mixed in a suitable solvent such as THF. Stir at a temperature of 0°C to 100°C for 10 minutes to 24 hours or until the reaction is complete, and then cool the reaction to room temperature. The compound of formula (3) can be obtained by filtration or precipitation.

[0553] Step 2 - Preparation of compound of formula (4)

[0554] The compound of formula (4) can be prepared by chlorinating the compound of formula (3) by methods known in the art. The compound of formula (3) can be mixed with POCl3 in a suitable solvent such as toluene. After stirring at a temperature of 0°C to 100°C for 10 minutes to 24 hours or until the reaction is completed, the reaction is cooled to room temperature. The solvent can then be removed under reduced pressure. In order to extract the compound of formula (4), an organic solvent such as ethyl acetate can be added, followed by washing with water and brine. The organic phase can be concentrated to obtain the compound of formula (4). The compound of formula (4) can be purified by any suitable method known in the art, such as silica gel chromatography, grinding, precipitation or crystallization.

[0555] Step 3 - Preparation of compound of formula (5)

[0556] The compound of formula (5) can be prepared by reducing the compound of formula (4) by methods known in the art. The compound of formula (4) can be mixed with zinc powder and ammonium chloride in a suitable solvent such as THF, MeOH or water, or a mixture of solvents consisting of THF, MeOH and water. After stirring at a temperature of 0° C. to 100° C. for 1 to 24 hours or until the reaction is complete, the reaction is cooled to room temperature and filtered through a diatomaceous earth bed. In order to extract the compound of formula (5), an organic solvent such as ethyl acetate can be added, followed by washing with water and brine. The organic phase can be concentrated to obtain the compound of formula (5). The compound of formula (5) can be purified by any suitable method known in the art, such as silica gel chromatography, grinding, precipitation or crystallization.

[0557] Step 4 - Preparation of compound of formula (6)

[0558] The compound of formula (6) can be prepared by cyclizing the compound of formula (5) by methods known in the art. The compound of formula (5) can be mixed with trimethyl orthoformate and formic acid. After stirring at a temperature of 0° C. to 100° C. for 1 to 24 hours or until the reaction is complete, the remaining solvent is removed by distillation. In order to extract the compound of formula (6), an organic solvent such as dichloromethane can be added, followed by washing with water and brine. The organic phase can be concentrated to obtain the compound of formula (6). The compound of formula (6) can be purified by any suitable method known in the art, such as silica gel chromatography, grinding, precipitation, crystallization, or washing with an organic solvent such as ether (including but not limited to methyl tert-butyl ether).

[0559] Step 5 - Preparation of compound of formula (7)

[0560] The compound of formula (7) can be prepared by fluorinating the compound of formula (6) by methods known in the art. The compound of formula (6) can be mixed with cesium fluoride in a solvent such as DMF. Stir at a temperature of room temperature to 110°C for 1 to 24 hours or until the reaction is complete, and then cool the reaction to 0°C to room temperature by adding ice water or by adding the reaction mixture to ice water. In order to extract the compound of formula (7), an organic solvent such as ethyl acetate can be added, followed by washing with water and brine. The organic phase can be concentrated to obtain the compound of formula (7). The compound of formula (7) can be purified by any suitable method known in the art, such as silica gel chromatography, grinding, precipitation or crystallization.

[0561] Step 6 - Preparation of compound of formula (9)

[0562] The compound of formula (9) can be prepared by combining compounds of formula (6) and (8) or by combining compounds of formula (7) and (8) by methods known in the art. The compound of formula (8) is commercially available or can be prepared by methods known in the art. The compound of formula (8) can be mixed with a compound of formula (6) or (7) in the presence of a base such as sodium hydride in a suitable solvent such as NMP or DMA. After stirring at a temperature of room temperature to 100° C. for 1 to 24 hours or until the reaction is complete, the reaction can be added to water and treated with an acid such as 10% citric acid. The compound of formula (7) can be obtained by filtration or precipitation.

[0563] Step 7 - Preparation of compound of formula (12)

[0564] The compound of formula (12) can be prepared by combining the compounds of formula (10) and (11) by methods known in the art. The compounds of formula (10) and (11) are commercially available or can be prepared by methods known in the art. The compounds of formula (10) and (11) can be mixed in a suitable solvent such as DMF in the presence of a base such as potassium carbonate. After stirring at a temperature of room temperature to 50° C. for 1 hour to 24 hours or until the reaction is completed, the reaction is cooled to room temperature. In order to extract the compound of formula (12), an organic solvent such as ethyl acetate can be added, followed by washing with water and brine. The organic phase can be concentrated to obtain the compound of formula (12). The compound of formula (12) can be purified by any suitable method known in the art, such as silica gel chromatography, grinding, precipitation or crystallization.

[0565] Step 8 - Preparation of compound of formula (13)

[0566] The compound of formula (13) can be prepared by reductive amination of the compound of formula (12) by methods known in the art. The compound of formula (12) and an amine commercially available or synthesized by methods known in the art can be mixed with a reducing agent (e.g., sodium triacetoxyborohydride or sodium cyanoborohydride) in the presence of an acid (e.g., acetic acid) or a Lewis acid (e.g., zinc chloride) in a suitable solvent (e.g., dichloroethane or methanol). After stirring at a temperature of 0°C to room temperature for 1 to 24 hours or until the reaction is complete, the reaction can be added to an aqueous solution such as a saturated sodium bicarbonate aqueous solution. In order to extract the compound of formula (13), an organic solvent such as dichloromethane can be added, followed by washing with water and brine. The organic phase can be concentrated to obtain the compound of formula (13). The compound of formula (13) can be purified by any suitable method known in the art, such as silica gel chromatography, grinding, precipitation, or crystallization.

[0567] Step 9 - Preparation of HPK1 binder building blocks

[0568] HPK1 binder building blocks can be prepared by combining compounds of formula (9) and (13) by methods known in the art. Compounds of formula (9) and (13) can be mixed in the presence of a catalyst such as tetrakis(triphenylphosphine)palladium and a base such as cesium carbonate, sodium carbonate, or tripotassium phosphate in a suitable solvent such as a mixture of dimethoxyethane and water or a mixture of DMAc and water. After stirring at a temperature of 50° C. to 150° C. for 1 to 24 hours, the reaction is allowed to cool to room temperature. The crude product can be filtered and concentrated under reduced pressure. To extract the compound, an organic solvent such as dichloromethane can be added, followed by washing with water and brine. The organic phase can be concentrated, and the resulting product can be purified by any suitable method known in the art, such as silica gel chromatography, reverse phase chromatography, trituration, precipitation, or crystallization. The resulting HPK1 binder building block is used as an intermediate for further coupling with a linker moiety.

[0569] The HPK1 binder building blocks prepared according to Reaction Scheme A have at least one reactive site, typically an amine moiety or a carboxyl moiety, which can be further coupled to the remainder of the molecule of general formula (I) or (II) by forming a covalent bond. In the specific examples of HPK1 binder building blocks shown below, the -NH- moiety of the spiro[indole-piperidinyl] of Intermediate 1 and the carboxylic acid of Intermediate 2 (structures shown below) represent respective reactive sites.

[0570]

[0571] These intermediates are described in further detail below:

[0572] Intermediate 1: 4-Fluoro-N-isopropyl-5-((3-isopropyl-6-(2-oxo-1-((1s,3s)-3-piperidin-1-yl) (cyclobutyl)spiro[dihydroindole-3,4'-piperidin-6-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino)-2-methylbenzene Formamide

[0573] Step 1: Synthesis of tert-butyl 2-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[indoline-3,4'-piperidine]-1'-carboxylate. In a 100 mL single-necked round-bottom flask equipped with a reflux condenser were placed tert-butyl 6-bromo-2-oxospiro[indoline-3,4'-piperidine]-1'-carboxylate (1) (0.99 g, 2.6 mmol), bis(pinacolato)borane (0.86 g, 3.4 mmol), potassium acetate (0.76 g, 7.8 mmol), [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride complex with dichloromethane (0.21 g, 0.26 mmol), and dioxane (10 mL). After the mixture was degassed by bubbling N for 5 minutes, it was stirred at 80° C. for 16 hours. Then, it was cooled to room temperature, quenched with water, and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na 2 SO 4 , concentrated, and purified by flash chromatography (0-100% EtOAc / hexane) to give the title compound product.

[0574] Step 2: Synthesis of tert-butyl 2-oxo-1-(3-oxocyclobutyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[dihydroindole-3,4'-piperidine]-1'-carboxylate. In a 100 mL single-necked round-bottom flask equipped with a reflux condenser, tert-butyl 2-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[dihydroindole-3,4'-piperidine]-1'-carboxylate (2) (0.81 g, 1.9 mmol), potassium carbonate (0.65 g, 4.7 mmol, 325 mesh), 3-bromocyclobutanone (0.21 mL, 2.53 mmol) and DMF (10 mL) were placed. After the mixture was stirred at 50° C. for 1 h, it was cooled to RT and filtered to remove potassium carbonate. The filtrate was diluted with EtOAc, quenched with water, and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na 2 SO 4 , filtered, and purified by flash chromatography (0-100% EtOAc / hexane) to give the title compound.

[0575] Step 3: Synthesis of tert-butyl 2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[indole-3,4'-piperidine]-1'-carboxylate. To a stirred solution of tert-butyl 2-oxo-1-(3-oxocyclobutyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[indole-3,4'-piperidine]-1'-carboxylate (2.60 g, 5.24 mmol), acetic acid (0.60 mL, 10.5 mmol), and piperidine (1.55 mL, 15.7 mmol) in DCM (29 mL) was added STAB (3.33 g, 15.7 mmol) in three equal portions over 10 minutes. After stirring for 3 hours, the reaction was diluted with aqueous sodium bicarbonate (100 mL), and the organic layer was separated. The aqueous layer was extracted with DCM (2 x 75 mL), and the combined organic layers were washed with brine (2 x 100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (2.9 g, 96%).

[0576] Step 4: Synthesis of 5-((6-bromo-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-2-methylbenzoic acid. In a 250 mL round-bottom single-necked flask equipped with a reflux condenser were placed 5-amino-4-fluoro-2-methyl-benzoic acid (2.0 g, 11 mmol) and DMF (40 mL). NaH (60%, 1.6 g, 39 mmol) was added thereto, and the resulting mixture was stirred at room temperature for 15 minutes, followed by the addition of 6-bromo-4-fluoro-3-isopropyl-imidazo[4,5-c]pyridine (7) (2.0 g, 7.8 mmol). After the mixture was stirred at 60°C for 16 hours, it was cooled to room temperature and quenched with water, followed by the addition of 10% citric acid to adjust its pH to ~5. The precipitate was filtered, washed with water, and dried to afford the title compound.

[0577] Step 5: Synthesis of 5-({6-bromo-3-isopropylimidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-N-isopropyl-2-methylbenzamide. To a solution of 5-((6-bromo-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-2-methylbenzoic acid (1.0 g, 2.5 mmol), isopropylamine (0.43 mL, 5.0 mmol), and DIPEA (2.58 mL, 14.8 mmol) in DMF (16 mL) was added HATU (1.91 g, 5.03 mmol) in one portion. The reaction was stirred at room temperature for 16 hours, then cooled to 0°C and quenched by the addition of water (30 mL). The mixture was stirred at room temperature for 20 minutes, and the solid was then filtered. The solid was rinsed with water and then dried under reduced pressure overnight to yield the title compound (0.95 g, 86%).

[0578] Step 6: Synthesis of tert-butyl 6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]spiro[indole-3,4'-piperidine]-1'-carboxylate. In a microwave vial equipped with a stir bar, 5-({6-bromo-3-isopropylimidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-N-isopropyl-2-methylbenzamide (500 mg, 1.12 mmol), tert-butyl 2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[indole-3,4'-piperidine]-1'-carboxylate (694 mg, 1.23 mmol), sodium carbonate (438 mg, 4.13 mmol) and tetrakis(triphenylphosphine)palladium(0) (91 mg, 0.08 mmol) were combined in a mixture of 1,2-dimethoxyethane (12 mL) and water (4.1 mL). The reaction was then heated in a microwave with stirring at 125° C. for 50 minutes. After cooling to room temperature, the reaction was concentrated onto silica gel and purified according to chromatography B to give the title compound (650 mg, 72%).

[0579] Step 7: Synthesis of 4-fluoro-N-isopropyl-5-((3-isopropyl-6-(2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[indoline-3,4'-piperidin]-6-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino)-2-methylbenzamide. To a solution of tert-butyl 6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]spiro[indole-3,4'-piperidine]-1'-carboxylate (900 mg, 1.12 mmol) in DCM (9 mL) was added HCl (4N in dioxane, 4.5 mL). The mixture was stirred for 3 hours, then the solvent was removed under reduced pressure. The crude residue was purified according to chromatography method C to provide the title compound (750 mg, 90%).

[0580] Intermediate 2: (3R)-1-[(1s,3s)-3-[1'-acetyl-6-(4-{[2-fluoro-5-(isopropylcarbamoyl) yl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxospiro[indole-3,4'-piperidin- [pyridinyl]-1-yl]cyclobutyl]piperidine-3-carboxylic acid

[0581] Step 1: Synthesis of tert-butyl 2-oxo-1-[(1s,3s)-3-[(3R)-3-(ethoxycarbonyl)piperidin-1-yl]cyclobutyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[indole-3,4'-piperidine]-1'-carboxylate. The reaction was carried out according to General Procedure D using tert-butyl 2-oxo-1-(3-oxocyclobutyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[indole-3,4'-piperidine]-1'-carboxylate (1.5 g, 3.0 mmol), ethyl (3R)-piperidine-3-carboxylate hydrochloride (761 mg, 3.93 mmol, 1.3 eq) and TEA (0.42 mL, 3.02 mmol, 1 eq) to provide the title compound (1.9 g, 3.0 mmol, 99%).

[0582] Step 2: Synthesis of tert-butyl 6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxo-1-[(1s,3s)-3-[(3R)-3-(ethoxycarbonyl)piperidin-1-yl]cyclobutyl]spiro[indole-3,4'-piperidine]-1'-carboxylate. Into a microwave vial equipped with a stir bar was placed 5-({6-bromo-3-isopropylimidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-N-isopropyl-2-methylbenzamide (500 mg, 1.12 mmol, 1 eq), 2-oxo-1-[(1s,3s)-3-[(3R)-3-(ethoxycarbonyl)piperidin-1-yl]cyclobutyl]-6-(4,4,5,5-tetramethyl-1 To the mixture of tert-butyl (3,2-dioxaborolan-2-yl)spiro[indole-3,4'-piperidine]-1'-carboxylate (782 mg, 1.1 eq, 1.23 mmol), sodium carbonate (438 mg, 4.13 mmol, 3.7 eq) and tetrakis(triphenylphosphine)palladium (91 mg, 0.08 mmol, 0.07 eq) and 1,2-dimethoxyethane (12 mL) and water (4.1 mL) was added. The reaction mixture was heated at 125°C for 25 min by microwave. The reaction was filtered through celite, and the filter cake was rinsed with a 1:1 mixture of DCM and methanol. The filtrate was concentrated and purified by chromatography B to give the title product (0.9 g 1.0 mmol, 92%).

[0583] Step 3: Synthesis of ethyl (3R)-1-[(1s,3s)-3-[6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxospiro[indole-3,4'-piperidin]-1-yl]cyclobutyl]piperidine-3-carboxylate. The reaction was carried out according to General Procedure B using tert-butyl 6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxo-1-[(1s,3s)-3-[(3R)-3-(ethoxycarbonyl)piperidin-1-yl]cyclobutyl]spiro[indole-3,4'-piperidine]-1'-carboxylate (1.8 g, 2.1 mmol) to provide the title compound (1.9 g, quantitative).

[0584] Step 4: Synthesis of ethyl (3R)-1-[(1s,3s)-3-[1'-acetyl-6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxospiro[indole-3,4'-piperidin]-1-yl]cyclobutyl]piperidine-3-carboxylate. To a solution of (3R)-1-[(1s,3s)-3-[6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxospiro[indole-3,4'-piperidin]-1-yl]cyclobutyl]piperidine-3-carboxylic acid ethyl ester (1.90 g, 2.44 mmol, 1 eq), HATU (1.95 g, 5.12 mmol, 2.1 eq) and acetic acid (0.35 mL, 6.1 mmol) in dimethylformamide (28.7 mL, 0.85 M) was slowly added DIPEA (2.76 mL, 15.9 mmol, 6.5 eq). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with water (30 mL) and the solid precipitate was removed by filtration and dried in vacuo under a stream of nitrogen overnight to give the title compound (0.9 g, 1.10 mmol, 45%).

[0585] Step 5: (3R)-1-[(1s,3s)-3-[1'-acetyl-6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxospiro[indole-3,4'-piperidin]-1-yl]cyclobutyl]piperidine-3-carboxylic acid. The reaction was carried out according to General Procedure C using (R)-ethyl 1-((1s,3S)-3-(1′-acetyl-6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxospiro[dihydroindole-3,4′-piperidin-1-yl)cyclobutyl)piperidine-3-carboxylate (900 mg, 1.10 mmol) to provide the title compound (790 mg, 1.0 mmol, 91%).

[0586] B. General protocol for preparing LHM building blocks

[0587] The CRBN-targeting LHM can first be coupled to a linker precursor, and the resulting building block can be further coupled to an HPK1 binder building block (eg, Intermediate 1 or Intermediate 2).

[0588] In certain embodiments, a CRBN-targeting LHM-linker building block can generally be prepared according to Reaction Scheme B1:

[0589] Reaction Scheme B1

[0590]

[0591] In Reaction Scheme B1, functionalized thalidomide is first coupled to a linker precursor. The linker precursor (aminoester) comprises "Linker A" (representing one or more linker fragments) and two terminal reactive groups, an amine and an ester of a protected carboxylic acid. Using an exemplary aminoester linker precursor, Step 1 describes the initial coupling step in more detail.

[0592] Step 1: A mixture of 2-(2,6-dioxopiperidin-3-yl)-4-fluoro-2,3-dihydro-1H-isoindole-1,3-dione (0.26 mmol), amino ester (0.26 mmol), ethylbis(propan-2-yl)amine (0.52 mmol) and DMF (1 mL) was stirred overnight at 90° C. The mixture was cooled and purified by HPLC (5-95% MeCN in H 0 containing 0.1% TFA) to give the tert-butyl ester intermediate.

[0593] The tert-butyl ester intermediate is then hydrolyzed (see step 2) to provide a CRBN-targeted LHM building block with a "Linker A" terminated in a carboxylic acid group, which can be further reactively coupled to another moiety (e.g., an HPK1 binder building block) or another linker fragment.

[0594] Step 2: A mixture of tert-butyl 4-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}butanoate (0.10 mmol), CH2Cl2 (1 mL) and TFA (1 mL) was stirred at room temperature for 2 h. The mixture was concentrated to give the carboxylic acid product.

[0595] Described below are additional examples of LHM building blocks targeting CRBN that can be prepared according to Reaction Scheme B1. More detailed descriptions can be found in WO2020038415, WO2019207538, WO2018089736, which are incorporated herein by reference in their entirety.

[0596] Intermediate 3: 3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino (4-(2-Methyl)ethoxy)propionic acid

[0597]

[0598] Step 1 product: tert-Butyl 3-[2-[[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]propanoate (1.8 g, 52%). LCMS; C22 H 27 N3O7 theoretical value: 445, measured value: m / z=468[M + Na] + .

[0599] Step 2 product: 3-[2-[[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxo-isoindolin-4-yl]amino]ethoxy]propanoic acid (526 mg, 32%). LCMS; C 18 H 19 N3O7 theoretical value: 389, found value: m / z = 390 [M+H] + .

[0600] Intermediate 4: 3-(2-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5- 1-Hydroxy)ethoxy)ethoxy)propionic acid.

[0601]

[0602] Step 1 product: Tert-butyl 3-[2-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxoisoindolin-5-yl]amino]ethoxy]ethoxy]ethoxy]propanoate.

[0603] Step 2 product: 3-[2-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxo-isoindolin-5-yl]amino]ethoxy]ethoxy]ethoxy]propanoic acid.

[0604] Intermediate 5: 6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)hexane acid

[0605]

[0606] Step 1: tert-Butyl 6-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}hexanoate ester

[0607] To a mixture of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (250 mg, 0.91 mmol) and tert-butyl 6-aminohexanoate hydrochloride (203 mg, 0.91 mmol) in 3 ml of NMP was added N,N-diisopropylethylamine (0.6 mL) and heated at 85° C. overnight. The crude reaction mixture was purified by silica gel chromatography using EtOAc / hexane (0-100%) to give tert-butyl 6-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}hexanoate (111 mg, 28%). LCMS: C 23 H 29N3O6, theoretical value: 443.5, found value: m / z = 444.4 [M+H] + .

[0608] Step 2: 6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)hexanoic acid

[0609] To a solution of tert-butyl 6-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}hexanoate (111 mg, 0.25 mmol) in DCM was added TFA (0.5 mL). The reaction mixture was stirred at room temperature for 30 min, and then the reaction mixture was concentrated to give 6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)amino)hexanoic acid (78 mg, 78%). 1 H NMR (500MHz, DMSO-d6) δ12.00(s,1H),11.06(s,1H),7.57(d,J=8.3Hz,1H),7.11(s,1H),6.95(d,J=2.1Hz,1H),6.85(dd,J=8.4,2.1Hz,1H),5.0 4(dd,J=12.7,5.4Hz,1H),3.16(q,J=6.4Hz,2H),2.23(t,J=7.4Hz,2H),2.03–1.97(m,1H),1.56(dq,J=14.8,7.2Hz,4H),1.39(q,J=7.9Hz,2H). LCMS:C 19 H 21 N3O 6, Theoretical value: 387.4, Found: m / z = 388.4 [M+H] + .

[0610] Intermediate 6: 8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino}octanoic acid

[0611] Intermediate 6 can be prepared in the same manner as Intermediate 5, except that octanoic acid is used instead of hexanoic acid.

[0612] Reaction Scheme B2 shows an alternative method for preparing LHM building blocks targeting -CRBN, which are constructed using linker precursors with a ring. The linker precursor typically contains an aldehyde reactive group, which can be further coupled to another building block by reductive amination (see, for example, General Reaction G)

[0613] Reaction Scheme B2

[0614]

[0615] Step 1: 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione

[0616] A mixture of 5-fluoro-1,3-dihydro-2-benzofuran-1,3-dione (5.0 g, 30.10 mmol), 3-aminopiperidine-2,6-dione hydrochloride (6.9 g, 42.14 mmol), and NaOAc (4.2 g, 51.17 mmol) in HOAc (50 mL) was stirred at 120°C for 5 hours and then concentrated under vacuum. The residue was washed with water and the solid was collected by filtration. The crude product was washed twice with water and twice with ethyl acetate and dried in an oven to give 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (7.7 g, 92%) as a light brown solid. 1 H NMR(300MHz,DMSO-d6)δ11.16(s,1H),8.03–8.00(m,1H),7.87–7.85(m,1H),7.75–7.7 0(m,1H),5.19–5.15(m,1H),2.94–2.86(m,1H),2.63–2.48(m,2H),2.12–2.06(m,1H).

[0617] Step 2: Amine displacement of aryl fluoride

[0618] To a solution of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione (1.0 g, 3.62 mmol) in NMP (10 mL) was added an amine (3.60 mmol) and DIPEA (1.4 g, 10.83 mmol). The resulting solution was stirred at 80°C for 16 hours. The reaction mixture was cooled to room temperature and purified by reverse-phase flash chromatography to yield the corresponding final product.

[0619] Step 3: Oxidation of alcohol to aldehyde

[0620] To a mixture of alcohol (1.06 mmol) in CH2Cl2 (10 mL) was added Dess-Martin periodinane (2.12 mmol). The mixture was stirred at room temperature for 1 h. The mixture was purified by column chromatography to give the desired aldehyde.

[0621] It will be appreciated that the use of 4-fluoro-1,3-dihydro-2-benzofuran-1,3-dione as the starting material will provide an alternative position for attaching the linker to thalidomide.

[0622] Described below are additional examples of CRBN-targeting LHM building blocks that can be prepared according to Reaction Scheme B2.

[0623] Intermediate 7: (3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidone Pyrrolidine-3-carboxaldehyde

[0624]

[0625] Step 2: 2-(2,6-dioxopiperidin-3-yl)-5-((S)-3-(hydroxymethyl)pyrrolidin-1-yl)isoindole Indole-1,3-dione

[0626] Following Scheme B2, Step 1, reaction of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione with (S)-pyrrolidin-3-ylmethanol provided 2-(2,6-dioxopiperidin-3-yl)-5-((S)-3-(hydroxymethyl)pyrrolidin-1-yl)isoindoline-1,3-dione (643.1 mg, 33%) as a yellow solid. 1 H NMR (300MHz, DMSO-d6) δ11.08(s,1H),7.64(d,J=8.4Hz,1H),6.89(d,J=2.1Hz,1H),6.80(dd,J=8.4,2.1Hz,1H),5.06(dd,J=12.9,5.4Hz,1H ), 4.78(t,J=5.4Hz,1H),3.59–3.41(m,5H),3.22–3.17(m,1H),2.95–2.83(m,1H),2.67–2.44(m,3H),2.12–1.88(m,2H),1.87–1.76(m,1H). MS(ESI)(C 18 H 19 N3O5)[M+H] + Theoretical value: 358.1; measured value: 358.1.

[0627] Step 3: (3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrole Alkane-3-carboxaldehyde

[0628] To a mixture of 2-(2,6-dioxopiperidin-3-yl)-5-[(3S)-3-(hydroxymethyl)pyrrolidin-1-yl]isoindole-1,3-dione (258 mg, 0.72 mmol) in DCM (5 mL) was added 1,1-bis(acetoxy)-3-oxo-1λ 5 ,2-benziodaoxol-1-yl acetate (0.61 g, 1.44 mmol). After 90 minutes, silica gel was added and the mixture was concentrated to dryness. The resulting powder was transferred to a loading cartridge and the mixture was purified by flash chromatography on a 24 g column, eluting with 0 to 100% ethyl acetate / hexane to give (3S)-1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl]pyrrolidine-3-carbaldehyde (198 mg, 77%). LCMS C 18 H 17 N3O5 theoretical value: 355, found value: m / z = 356 [M+H]+ .

[0629] Intermediate 8: (3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pyrrolidone Pyrrolidine-3-carboxaldehyde

[0630]

[0631] Intermediate 8 can be prepared in the same manner as Intermediate 7, except that 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (which is prepared from 4-fluoro-1,3-dihydro-2-benzofuran-1,3-dione) is used instead of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione.

[0632] Intermediate 9: 3-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazine-1- propionic acid

[0633]

[0634] Step 1: 3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-yl tert-Butyl propionate

[0635] To a mixture of tert-butyl 3-(piperazin-1-yl)propanoate (400.00 mg, 1.87 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (516 mg, 1.87 mmol) in 10 ml of NMP was added N,N-diisopropylethylamine (0.65 mL, 0.48 g, 3.73 mmol) and then heated at 85-90 ° C for 16 hours. The resulting reaction mixture was then cooled to room temperature and partitioned between EtOAc / water. The organic layer was then washed with brine, dried, and concentrated. Purification on a silica gel column using 10-100% EtOAc / hexane gave 823 mg of the title compound. LCMS: C 24 H 30 N4O6, theoretical value: 470.5, found value: m / z = 471.8 [M+H] + .

[0636] Step 2: 3-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazin-1-yl} Propionic acid

[0637] Tert-butyl 3-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazin-1-yl}propanoate (820.00 mg, 1.74 mmol) was dissolved in trifluoroacetic acid (9.94 g, 87.14 mmol). After 1 hour, TFA was evaporated. The product was lyophilized to dryness to give 3-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazin-1-yl}propanoic acid (722 mg, 100% yield). LCMS: C20 H 22 N4O6, theoretical value: 414.4, found value: m / z = 415.4 [M+H] + .

[0638] Intermediate 10: 3-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazine-1- Acetic acid

[0639] Intermediate 10 was prepared in a similar manner to Intermediate 9, except that tert-butyl 3-(piperazin-1-yl)acetate was used instead of tert-butyl 3-(piperazin-1-yl)propanoate.

[0640] Intermediate 11: 2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2, 7-diazaspiro[3.5]nonan-7-yl)acetic acid

[0641]

[0642] Step 1: 2-{2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]-2,7-diazepine Benzyl spiro[3.5]nonan-7-yl}acetate

[0643] To a mixture of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (70.00 mg, 0.25 mmol) and 2-{2,7-diazaspiro[3.5]non-7-yl}benzyl acetate (69.53 mg, 0.25 mmol) in 2 ml of NMP was added N,N-diisopropylethylamine (0.13 mL) and heated to 85° C. overnight. The crude mixture was purified by column chromatography using EtOAc / hexane (10-100%) as the eluent to give 2-{2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]-2,7-diazaspiro[3.5]non-7-yl}benzyl acetate (68 mg, 51%). LCMS C 29 H 30 N4O6 theoretical value: 530, found value: m / z = 532 [M+H] + .

[0644] Step 2: 2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-dioxopiperidin-3-yl Azaspiro[3.5]nonan-7-yl)acetic acid

[0645] To a solution of 2-{2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]-2,7-diazaspiro[3.5]non-7-yl}benzyl acetate (68 mg, 0.13 mmol) in EtOH (5 mL) and DCM (2 mL) was added palladium on carbon (6 mg, 0.06 mmol). The reaction mixture was sparged with hydrogen and maintained at one atmosphere of hydrogen using a balloon and stirred at room temperature for 48 hours. The reaction mixture was filtered through a pad of celite and concentrated to give 2-{2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]-2,7-diazaspiro[3.5]non-7-yl}benzyl acetate (56 mg, 99%). LCMSC 22 H 24 N4O6 theoretical value: 440, found value: m / z = 441 [M+H] + .

[0646] Intermediate 12: 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl formaldehyde

[0647]

[0648] Step 2: 2-(2,6-dioxopiperidin-3-yl)-5-(4-(hydroxymethyl)piperidin-1-yl)isoindoline-1, 3-diketone

[0649] Following Scheme B2, Step 1, the reaction of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione with piperidin-4-ylmethanol provided 2-(2,6-dioxopiperidin-3-yl)-5-(4-(hydroxymethyl)piperidin-1-yl)isoindoline-1,3-dione (939 mg, 70%) as a yellow solid. 1 H NMR (300MHz, DMSO-d6) δ11.09(s,1H),7.65(d,J=8.4Hz,1H),7.30(d,J=2.4H z,1H),7.23(dd,J=8.4,2.4Hz,1H),5.07(dd,J=12.6,5.4Hz,1H),4.51(t,J= 5.1Hz,1H),4.07(d,J=13.2Hz,2H),3.27(t,J=5.7Hz,2H),2.99–2.80(m,3H) ,2.62–2.55(m,2H),2.17–1.95(m,1H),1.76–1.67(m,3H),1.24–1.12(m,2H). MS(ESI)(C 19 H 21 N3O5)[M+H] + Calculated value: 372.1; measured value: 372.2.

[0650] Step 3: 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-carboxylate aldehyde

[0651] According to Scheme B2, 2-(2,6-dioxopiperidin-3-yl)-5-(4-(hydroxymethyl)piperidin-1-yl)isoindole-1,3-dione was oxidized to provide 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl)piperidine-4-carbaldehyde. LCMS C 19 H 19 N3O5 theoretical value: 369, found value: m / z = 370 [M+H] + .

[0652] The LHM building block targeting VHL can generally be prepared according to Reaction Scheme B3, wherein the LHM is first coupled to a linker precursor comprising a "linker A" (representing one or more linker fragments) and two terminal reactive groups. One of the reactive groups is a carboxylic acid or its reactive equivalent; the other reactive group, X, can be, for example, a carboxylic acid, a hydroxyl group, or an aldehyde group. The resulting LHM building block has a reactive moiety (X) that can be further coupled to another moiety.

[0653] Reaction Scheme B3

[0654]

[0655] Described below are further examples of VHL-targeting LHM building blocks that can be prepared according to Reaction Scheme B3.

[0656] Intermediate 13: 5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)amino (acyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentanoic acid

[0657]

[0658] To a solution of glutaric acid (135 mg, 1.0 mmol) in THF (10 mL) and methanol (5 mL) was added HATU (0.39 g, 1.0 mmol) and N,N-diisopropylethylamine (0.33 mL, 1.9 mmol), and the reaction mixture was stirred for 5 minutes before the addition of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (0.40 g, 0.93 mmol). The reaction mixture was stirred for 16 hours before being quenched with 4N HCl in dioxane (0.25 mL). The crude mixture was then concentrated onto silica gel and purified by reverse phase chromatography. LCMSC 27 H 36 N4O6S theoretical value: 544, measured value: m / z=567.5[M + Na]+ .

[0659] 1 H NMR (500MHz, DMSO-d6) δ12.01(s,1H),9.00(s,1H),8.58(d,J=6.4Hz,1H),7.91(d,J=9.3Hz,1H),7 .43(p,J=7.8,6.7Hz,4H),5.14(d,J=3.7Hz,1H),4.55(d,J=9.2Hz,1H),4.53–4.43(m,2H),4.37(s ,1H),4.23(dd,J=16.0,5.2Hz,1H),3.78–3.52(m,2H),2.46(s,3H),2.28(dt,J=15.7,7.7Hz,1H), 2.25–2.15(m,3H),2.05(t,J=10.6Hz,1H),1.98–1.83(m,1H),1.72(h,J=6.4Hz,2H),0.95(s,9H).

[0660] Intermediate 14: 6-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazole-5- 1-O-[3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]hexanoic acid

[0661] Intermediate 14 can be prepared in the same manner as Intermediate 13, except that hexanoic acid is used instead of glutaric acid, and (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}pyrrolidine-2-carboxamide is used instead of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide.

[0662] Intermediate 15: 10-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazole- 5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}decyl acid

[0663] Intermediate 15 can be prepared in the same manner as Intermediate 13, except that glutaric acid is replaced with decanoic acid, and (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}pyrrolidine-2-carboxamide is used instead of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide.

[0664] Reaction Scheme B4 shows another approach to generate LHM building blocks targeting VHL through different points of attachment to LHM:

[0665] Reaction Scheme B4

[0666]

[0667] Reaction Scheme B4 begins by coupling a linker precursor with a VHL-targeting LHM, (2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide. The VHL-targeting LHM was prepared according to the following steps.

[0668]

[0669] Step 1: 2-Hydroxy-4-(4-methyl-1,3-thiazol-5-yl)benzonitrile

[0670] A solution of 4-bromo-2-hydroxybenzonitrile (25.0 g, 126 mmol), 4-methylthiazole (25.0 g, 253 mmol, 2.0 eq), and anhydrous KOAc (24.78 g, 252.5 mmol) in DMF (210.42 mL, 0.6 M) was bubbled with argon on an ultrasonic bath for 10 min. Pd(OAc)2 (0.567 g, 2.52 mmol) was then added. The resulting mixture was stirred at 110°C under argon for 5 hours, with additional Pd(OAc)2 (0.283 g, 1.26 mmol) added three times every hour until the total amount of Pd(OAc)2 (1.417 g, 6.31 mmol) was reached. The reaction mixture was cooled to room temperature, filtered through celite, diluted with water, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH) to provide 2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)benzonitrile (17.6 g, 65%) as a yellow solid. LCMS: C 11 H8N2OS theoretical value: 216.3, found: m / z = 217.5 [M+H] +

[0671] 1 H NMR (300MHz, DMSO-d6) δ11.36(s,1H),9.08(s,1H),7.71(d,J=8.1Hz,1H),7.14(d,J=1.6Hz,1H),7.08(dd,J=8.0,1.7Hz,1H),2.50(s,3H).

[0672] Step 2: 2-(Aminomethyl)-5-(4-methyl-1,3-thiazol-5-yl)phenol

[0673] To a 1M LAH solution in THF (203.9 mL, 203.9 mmol) was slowly added a solution of 2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)benzonitrile (17.64 g, 81.57 mmol) in THF (203.92 mL, 0.4 M) under argon at -10 ° C. After the addition was complete, the reaction mixture was allowed to slowly warm to room temperature over 5 hours. The reaction was quenched by adding Na2SO4·10H2O and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH) to provide (aminomethyl)-5-(4-methyl-1,3-thiazol-5-yl)phenol (9.18 g, 52%) as an amber oil. LCMS: C 11 H 12 N2OS theoretical value: 220.3, found: m / z = 221.5 [M+H] +

[0674] 1 H NMR (300MHz, DMSO-d6) δ8.96(s,1H),7.23–7.15(m,1H),6.87–6.81(m,2H),3.88(s,2H),2.45(s,3H).

[0675] Step 3: (2S,4R)-1-[(2S)-2-{[(tert-Butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxy Methyl 2-pyrrolidine-2-carboxylate

[0676] To a solution of methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoic acid (41.0 g, 0.177 mol) and DIPEA (46.3 mL, 0.266 mol) in anhydrous THF (1770 mL, 0.1 M) at 10°C was added solid HATU (70.8 g, 0.186 mol) portionwise to form the activated ester over 30 minutes. In a separate reactor, a solution of (2S,4R)-4-hydroxypyrrolidine-2-carboxylate hydrochloride (48.0 g, 1.266 mol) and DIPEA (46.3 mL, 0.266 mol, 1.5 eq) was prepared and cooled to -45°C under an inert atmosphere. The activated ester solution was added dropwise over 0.5 hours at -45°C to -40°C, and the RM was allowed to slowly warm to room temperature overnight. Water (~500 mL) was added in one portion to quench the reaction and the volatiles were concentrated under vacuum. The oily residue was extracted with EtOAc (3x400 mL), washed with saturated aqueous NaHCO3 (250 mL), 10% aqueous KHSO4 (250 mL), brine (300 mL), dried over MgSO4, filtered and evaporated to give a crude product which was purified by FC. The corresponding fractions were concentrated to give (2S,4R)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxylic acid methyl ester as a light yellow oil (64 g, 99%). LCMS: C 17 H 30 N2O6 theoretical value: 358.4, measured value: m / z = 359.3 [M+H] +

[0677] 1 H NMR (300MHz, DMSO-d6) δ6.54(d,J=9.3Hz,1H),5.23(d,J=3.8Hz,1H),4.42–4.29(m,2H),4.16(d,J=9.4 Hz,1H),3.71–3.61(m,2H),2.11(dd,J=12.2,9.2Hz,1H),1.95–1.85(m,1H),1.38(s,10H),0.94(s,9H).

[0678] Step 4: (2S,4R)-1-[(2S)-2-{[(tert-Butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxy 2-Pyrrolidine-2-carboxylic acid

[0679] To a solution of methyl (2S,4R)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxylate (63.5 g, 0.177 mol) in THF (220 mL, 0.8 M) was added a solution of LiOH·H₂O (14.9 g, 0.355 mol) in water (86 mL, 0.2 M) in one portion at room temperature. The RM was stirred at room temperature for 3 h and monitored by TLC / UPLC. Once the reaction was complete, 10% aqueous KHSO₄ was added until the pH was ~3. The THF was concentrated under reduced pressure, and the residue was extracted with EtOAc (3 x 400 mL). The combined organic fractions were washed with 10% aqueous KHSO₄ (200 mL), brine (300 mL), dried over MgSO₄, filtered, and evaporated to dryness. The viscous, light yellow oily residue was sonicated with anhydrous THF (300 ml) to give an off-white precipitate, which was filtered and dried in vacuo at 50° C. to give 69.6 g of (2S,4R)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxylic acid (69.6 g, including THF -15 wt%). LCMS: C 16 H 28 N2O6 theoretical value: 344.4, measured value: m / z = 345.2 [M+H] +

[0680] 1 H NMR (300MHz, DMSO-d6) δ12.43(s,1H),6.49(d,J=9.4Hz,1H),5.18(d,J=3.7Hz,1H),4.33(bs,1H),4.26(t,J=8.4Hz,1H),4 .16(d,J=9.4Hz,1H),3.69-3.52(m,2H),2.18–2.02(m,1H),1.89(ddd,J=13.2,9.1,4.6Hz,1H),1.38(s,9H),0.94(s,9H).

[0681] Step 5: N-[(2S)-1-[(2S,4R)-4-hydroxy-2-({[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl) tert-Butyl]phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate

[0682] To a solution of (2S,4R)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxylic acid (14.352 g, 41.67 mmol) in DMF (138.9 mL, 0.3 M) cooled in an ice-water bath under argon was added DIPEA (10.89 mL, 62.5 mmol) and HATU (16.64 g, 43.8 mmol). The resulting mixture was allowed to warm to room temperature over 0.5 h and slowly added dropwise to a solution of 2-(aminomethyl)-5-(4-methyl-1,3-thiazol-5-yl)phenol (9.180 g, 41.7 mmol) and DIPEA (7.26 mL, 42.7 mmol) in DMF (83.3 mL, 0.5 M) at -40°C under argon. After addition, the reaction mixture was placed in a cooling bath and slowly warmed to room temperature over 5 hours. The reaction was quenched by adding 5 mL of water and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (DCM / MeOH) to provide (2S,4R)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxylic acid (13.4 g, 58%) as a light yellow solid. LCMS: C 27 H 38 N4O6S theoretical value: 546.7, found: m / z = 547.9 [M+H] + .

[0683] After purification by flash chromatography, the bis-acylated byproduct, 2-({[(2S,4R)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenyl (2S)-1-(2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl)pyrrolidine-2-carboxylate, was also obtained. The acyl group can be cleaved according to step 5a.

[0684] 1H NMR (300MHz, chloroform-d) δ9.28 (br s,1H),8.70(s,1H),8.11(t,J=6.6Hz,1H),7.13(d,J=7.8Hz,1H),6.98(d,J=1.8Hz,1H),6.88(dd,J=7.7,1.8Hz,1H),5.19(d,J=8. 9Hz,1H),4.77(t,J=7.9Hz,1H),4.51(dd,J=15.0,6.9Hz,2H),4.12(td,J=20.4,8.4Hz,3H),3.57(dd,J=11.4,3.6Hz,1H),2.85(br s,2H),2.53(m,4H),2.11(dd,J=13.5,8.1Hz,1H),1.56–1.43(m,2H),1.41(s,9H),0.84(s,9H).

[0685] Step 5a: N-[(2S)-1-[(2S,4R)-4-hydroxy-2-({[2-hydroxy-4-(4-methyl-1,3-thiazole-5- tert-Butyl]-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate

[0686] To a solution of 2-({[(2S,4R)-1-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenyl (2S)-1-(2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoyl)pyrrolidine-2-carboxylate (3.0 g, 3.5 mmol) in MeOH (70 mL, 0.05 M) was added KCO (0.48 g, 3.5 mmol). The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated, and the residue was diluted with water, neutralized with KHSO, and extracted with DCM (x3 times). The obtained organic layer was dried over NaSO and concentrated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel (5% DCM / MeOH) to give tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-({[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate (2.14 g, 99%) as a light yellow solid. LCMS: C 27 H 38 N4O6S theoretical value: 546.7, found: m / z = 547.2 [M+H] +

[0687] 1H NMR (300MHz, chloroform-d) δ9.29 (s, 1H), 8.80 (s, 1H), 8.19 (s, 1H), 7.14 (d, J = 7.8Hz, 1H),6.98(d,J=1.8Hz,1H),6.87(dd,J=7.7,1.8Hz,1H),5.14(d,J=8.9Hz,1H), 4.81(t,J=7.9Hz,1H),4.56(q,J=7.8Hz,2H),4.12(td,J=13.6,12.6,4.7Hz,3H ), 3.56 (dd, J = 11.4, 3.5Hz, 1H), 2.56 (s, 4H), 2.19–2.05 (m, 1H), 0.83 (s, 10H).

[0688] Step 6: (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[2-hydroxy-4- (4-Methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide

[0689] To a solution of tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-({[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate (5.27 g, 9.64 mmol) in DCM (48.2 mL, 0.2 M) was added 2 M HCl in EtO (38.56 mL, 77.12 mmol). The reaction mixture was stirred at room temperature for 2 hours. The solid was triturated on an ultrasonic bath, filtered, washed with DCM on the filter and dried in vacuo to provide (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (5.05 g, 99%) as a white solid. LCMS: C 22 H 30 N4O4S theoretical value: 446.6, found: m / z = 447.7 [M+H] +

[0690] 1H NMR(300MHz,D2O)δ9.50(d,J=1.0Hz,1H),7.30(d,J=7.8Hz,1H),7.04–6.89(m,2H),4.5 8(dd,J=9.9,7.6Hz,1H),4.52(s,1H),4.44–4.23(m,2H),4.08(s,1H),3.80(d,J=11.9H z,1H),3.68(dd,J=11.9,3.4Hz,1H),3.46(q,J=7.1Hz,1H),2.45(s,3H),2.28(dd,J=13 .9,7.7Hz,1H),2.01(ddd,J=14.0,9.9,4.2Hz,1H),1.08(t,J=7.1Hz,2H),0.98(s,9H).

[0691] Step 7: (2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxy N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide

[0692] To a solution of 1-fluorocyclopropane-1-carboxylic acid (1.337 g, 12.85 mmol) in DMF (128 mL, 0.1 M) cooled in an ice-water bath was added HATU (5.129 g, 13.49 mmol) and DIPEA (3.36 mL, 19.3 mmol). The resulting mixture was allowed to warm to room temperature over 0.5 h and then added dropwise to a solution of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (5.05 g, quantitative yield) (6.674 g, 12.85 mmol) and DIPEA (7.83 mL, 45.0 mmol) in DMF (42 mL, 0.3 M) at -40°C. After addition, the reaction mixture was placed in a cooling bath to slowly warm to room temperature over 16 hours. The reaction was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH) to provide (2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (5.05 g, 74%) as a yellow solid. LCMS: C 26 H 33 N4O5SF theoretical value: 532.6, found value: m / z = 533.8 [M+H] +

[0693] 1H NMR (300MHz, chloroform-d) δ9.29(s,1H),8.70(s,1H),8.09(dd,J=7.5,5.5Hz,1H),7.13(d,J=7.8Hz,1H),7.01( dd,J=8.5,3.7Hz,1H),6.98(d,J=1.8Hz,1H),6.88(dd,J=7.7,1.8Hz,1H),4.73(t,J=7.9Hz,1H),4.53(br s,1H),4.51–4.40(m,2H),4.18(dd,J=14.6,5.4Hz,1H),3.99(d,J=11.3Hz,1H),3.63(dd,J=11.2,3.7Hz, 1H), 2.53 (s, 3H), 2.47 (ddd, J=12.9, 7.9, 4.6Hz, 1H), 2.15–2.01 (m, 1H), 1.36–1.22 (m, 4H), 0.91 (s, 9H).

[0694] Described below are further examples of VHL-targeted LHM building blocks that can be prepared according to Reaction Scheme B4.

[0695] Intermediate 16: 10-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethyl butyryl]-4-hydroxypyrrolidin-2-yl]formylamino}methyl)-5-(4-methyl- 1,3-thiazol-5-yl)phenoxy]decanoic acid

[0696]

[0697] Step 1: tert-Butyl 10-bromodecanoate

[0698] To a solution of 10-bromodecanoic acid (CAS: 50530-12-6, 10.0 g, 39.8 mmol, 1.0 eq) in anhydrous dichloromethane (0.25 M) at 0°C under nitrogen was added tert-butanol (18.9 mL, 199 mmol, 5.0 eq), followed by DMAP (0.96 g, 4.0 mmol, 0.1 equiv). After 5 minutes, dicyclohexylcarbodiimide (9.04 g, 44 mmol, 1.1 equiv) was added to the solution at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 20 hours. The volatiles were concentrated and the crude residue was directly loaded onto silica (5-10% EtOAc in hexanes). The title compound (9.0 g) was isolated, contaminated with DCC as an impurity. Additional purification by FC (eluent: 10-50% DCM in hexanes) gave 5.8 g of tert-butyl 10-bromodecanoate (47% yield) as a colorless oil.

[0699] 1H NMR (300MHz, chloroform-d) δ3.42(t,J=6.9Hz,2H),2.22(t,J=7.5Hz,2H),1.87(p,J= 6.9Hz,2H),1.68–1.51(m,2H),1.46(s,9H),1.45–1.37(m,2H),1.31(s,8H).

[0700] Step 2: 10-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutane tert-(4-methyl-1,3-thiazol-5-yl)phenoxy)-4-hydroxypyrrolidin-2-yl)formamido)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy)decanoic acid Butyl ester

[0701] To (2S, 4R) -1- [(2S) -2- [(1- fluorocyclopropyl) formamido] -3,3- dimethylbutanoyl] -4- hydroxy -N- { [2- hydroxy -4- (4- methyl -1,3- thiazol-5-yl) phenyl] methyl} pyrrolidine -2- carboxamide (0.8g, 1.5mmol, 1.0eq) in anhydrous DMF (15mL, 0.1M) solution was added CsCO (0.734g, 2.25mmol, 1.5eq) and tert-butyl 10-bromodecanoate (0.646g, 2.10mmol, 1.4eq). The reaction mixture was purged with argon, sealed and stirred at 25 ° C for 16 hours. The solid was filtered, washed with EtOAc (5mL) and discarded. The filtrate obtained was diluted with water (60mL) and extracted with ethyl acetate (3x20mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by flash chromatography (hexane / ethyl acetate) to give 0.99 g of the title compound as a white solid (87% yield). ESI (+) [M+H] + =782.4

[0702] 1H NMR (300MHz, chloroform-d) δ8.70(s,1H),7.34(d,J=7.7Hz,1H),7.25(t,J=5.9Hz,1H),7.05(dd,J=8.7,3.6Hz,1H),6.96(d d,J=7.6,1.6Hz,1H),6.89(d,J=1.6Hz,1H),4.76(t,J=7.7Hz,1H),4.61–4.49(m,3H),4.44(dd,J=14.8,5.4Hz,1H), 4.09–3.97(m,3H),3.64(dd,J=11.3,3.9Hz,1H),2.65–2.56(m,1H),2.55(s,3H),2.22(t,J=7.5Hz,2H),2.15(d,J=2 .6Hz,1H),1.87(p,J=6.6Hz,2H),1.59(t,J=7.1Hz,2H),1.52(m,2H),1.46(s,9H),1.43–1.32(m,10H),0.96(s,9H).

[0703] Step 3: 10-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutane [4-(4-methyl-1,3-thiazol-5-yl)phenoxy]decanoic acid]

[0704] To a solution of tert-butyl 10-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]decanoate (0.993 g, 1.31 mmol, 1.0 eq) in anhydrous DCM (6.5 mL, 0.2 M) was added TFA (2.00 mL, 26.17 mmol, 20 eq). The reaction was stirred at 25 °C for 3 hours. The reaction was evaporated in vacuo and the resulting oil was treated with aqueous ammonia (20%, 5 mL). Stirring for 1 hour resulted in the formation of an oil. The supernatant was decanted. The oil was dried in vacuo and purified using reverse phase flash chromatography (20% to 60% acetonitrile / 0.1% aqueous formic acid) to give 0.703 g of the title compound as a white solid (77% yield). LCMS (254 nm): RT = 3.037 min, 100% purity, ESI (+) [M+H] + =703.2

[0705] 1H NMR (300MHz, DMSO-d6) δ12.00(s,1H),8.99(s,1H),8.51(t,J=5.9Hz,1H),7.41(d,J=7.8Hz,1H),7.31(dd,J=9.3,2.9Hz, 1H),7.01(d,J=1.7Hz,1H),6.96(dd,J=7.7,1.6Hz,1H),5.19(s,1H),4.66–4.57(m,1H),4.53(t,J=8.2Hz,1H),4.36(s,1 H),4.25(qd,J=16.7,5.9Hz,2H),4.05(t,J=6.3Hz,2H),3.73–3.56(m,2H),2.47(s,3H),2.19(t,J=7.3Hz,2H),2.15–2.0 9(m,1H),1.93(ddd,J=13.0,8.9,4.5Hz,1H),1.76(p,J=6.4Hz,2H),1.57–1.38(m,6H),1.38–1.15(m,12H),0.97(s,9H).

[0706] Intermediate 17: 3-{2-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3-methylbutane 4-(4-methyl-1,3-thiazol-5-yl)phenoxy]ethoxy} Propionic acid

[0707]

[0708] Step 1: tert-Butyl 3-(2-bromoethoxy)propionate

[0709] A solution of tert-butyl 3-(2-hydroxyethoxy)propanoate (3.0 g, 16 mmol, 1 eq) and carbon tetrabromide (7.8 g, 24 mmol, 1.5 eq) in dichloromethane (15 mL) was prepared in a 50 mL flask and cooled to 0°C. Triphenylphosphine (6.2 g, 24 mmol, 1.5 eq) was added portionwise via a powder funnel under vigorous stirring over 30 minutes. After the addition of phosphine, the colorless solution turned light brown and was stirred at room temperature for another 2 hours. The mixture was concentrated and quickly added to stirred hexane (50 mL). The white precipitate was filtered, the remaining solution was concentrated, and the obtained residue was purified by FC (eluted DCM / MeOH-9 / 1) to give 4.1 g of the title compound (yield 62%).

[0710] Step 2: 3-{2-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethyl [butyryl]-4-hydroxypyrrolidin-2-yl]formamido]methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]ethoxy tert-Butyl propionate

[0711] To a solution of (2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (1.5 g, 2.82 mmol, 1.0 eq) in DMF (18.77 mL, 0.15 M) was added CsCO (1.376 g, 4.22 mmol, 1.5 eq) and tert-butyl 3-(2-bromoethoxy)propanoate (2.18 g, 3.94 mmol, 1.4 eq). The resulting mixture was stirred at room temperature overnight. The reaction mixture was diluted with water and extracted with EtOAc (3x). The organic layer was dried over Na2SO4 and concentrated. The resulting residue was purified by FC using DCM / MeOH-9 / 1 as eluent to give 1.8 g of the title compound as a light yellow oil (quantitative yield). UPLC (12 min, 254 nm): RT = 6.25 min, 100% purity, ESI [M + H + ]+=705.6

[0712] Step 3: 3-{2-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3-methylbutyryl] 4-Hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]ethoxy}propyl acid

[0713] To a solution of tert-butyl 3-{2-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]ethoxy}propanoate (1.8 g, 2.64 mmol, 1 eq) in DCM (17.6 mL, 0.15 M) was added TFA (13.2 mL, 0.2 M) dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated and the residue was diluted with 50 mL of aqueous NH4OH (until pH = 11), placed in an ultrasonic bath for 0.5 hour, and then placed under stirring only for 1 hour. The resulting syrup was concentrated and purified twice by RF: first, eluting with ACN / H2O to give 0.3 g of the title compound; second, eluting with ACN / H2O (0.1% formic acid) to give 1 g of the title compound.

[0714] After neutralization with NH4OH, the product was obtained as an ammonium salt, which was released with formic acid during a second purification. All amounts were combined to give 1.3 g of the title compound (yield 76%). LCMS (254 nm): RT = 2.29 min, 99% purity, ESI (+) [M+H] + =649.1.

[0715] 1H NMR (300 MHz, chloroform-d) δ8.70 (s, 1H), 7.37 (d, J = 7.8 Hz, 2H), 7.09–7.03 (m, 1H), 6.99 (dd, J = 7.7, 1.6 Hz, 1H), 6.91 (d, J = 1.6 Hz, 1H), 4.76 (t, J = 8.1 Hz, 1H), 4.64–4.51 (m, 3H), 4.41 (dd, J = 14.3, 5.2 Hz, 1H), 4.20 ( t,J=4.2Hz,2H),4.03(d,J=11.3Hz,1H),3.89(td,J=8.6,7.8,4.4Hz,4H),3.77(dd,J=11.3,3.7Hz,1H) ,2.66(ddd,J=19.7,14.9,5.1Hz,2H),2.54(s,3H),2.33–2.14(m,2H),1.41–1.23(m,4H),1.03(s,9H).

[0716] Intermediate 18: 1-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutane (4-(4-Methylthiazol-5-yl)-phenoxy)ethoxy)ethoxy) [ethoxy]propionic acid

[0717] Intermediate 18 was prepared in a similar manner to Intermediate 17 by replacing tert-butyl 3-{2-[2-(2-bromoethoxy)ethoxy]ethoxy}propanoate with tert-butyl 3-(2-hydroxyethoxy)propanoate in step 1 to give the title compound as a white solid. LCMS (254 nm): RT = 2.27 min, 96.35% purity, ESI [M+H] + =736.88.

[0718] 1H NMR (300MHz, DMSO-d6) δ8.98(s,1H),8.51(t,J=6.0Hz,1H),7.41(d,J=7.8Hz,1H),7.31(dd,J=9.2,2.9Hz,1H),7.04(d,J=1 .7Hz,1H),6.97(dd,J=7.7,1.6Hz,1H),5.19(s,1H),4.60(d,J=9.1Hz,1H),4.51(t,J=8.2Hz,1H),4.35(s,1H),4.28(d,J=6 .1Hz,1H),4.25–4.14(m,3H),3.79(dd,J=5.8,3.4Hz,2H),3.66–3.46(m,12H),2.46(s,3H),2.42(t,J=6.3Hz,2H),2.10(dd ,J=13.0,8.0Hz,1H),1.92(ddd,J=13.1,9.0,4.4Hz,1H),1.49–1.28(m,2H),1.21(tq,J=8.4,4.6,3.8Hz,2H),0.96(s,9H).

[0719] C. General protocol for coupling HPK1 binders and LHM building blocks

[0720] The following General Methods AF illustrate the bond formations by which building blocks can be coupled to provide compounds of Formula (I) or Formula (II) and their respective substructures.

[0721] General Procedure A: Connecting SNAR to Harness

[0722]

[0723] Substituted aniline is prepared as follows. To a NMP (0.4M) solution of primary or secondary amine (1 eq.) and DIPEA (4.0 eq.) is added aryl fluoride (1 eq.). The reaction mixture is stirred at 120 ° C for 4 h. At this time, LCMS shows the loss of starting material. The reaction mixture is cooled to room temperature and water (half the volume of NMP) is added. The crude mixture is directly injected on a reversed-phase ISCO and purified via chromatography C to provide the desired product.

[0724] General Procedure B: BOC Deprotection (and tert-Butyl Ester Hydrolysis)

[0725]

[0726] The deprotection of tert-butyl carbamate to generate the primary and secondary amines was performed according to the general procedure; the deprotection of tert-butyl ester to generate the carboxylic acid was performed according to the general procedure: HCl (4N in dioxane, 18 eq.) was added dropwise to a stirred solution of tert-butyl carbamate (or tert-butyl ester) substrate (1 eq.) in DCM (0.23 M) at room temperature. The reaction mixture was stirred for 16 hours and then concentrated to dryness. The resulting product was then used without further purification unless otherwise noted.

[0727] General Procedure C: Ester Saponification

[0728]

[0729] Methyl and ethyl ester saponification reactions were performed according to the following general procedure: The ester starting material (1 eq.) was dissolved in THF (0.25 M) at room temperature. To this solution was added lithium hydroxide (aqueous solution, 0.55 M, 1.1 eq.), and the resulting mixture was stirred vigorously overnight. At this point, LCMS showed loss of starting material, and the reaction was concentrated to dryness to provide the product as a lithium salt.

[0730] General Procedure D: Reductive Amination

[0731]

[0732] To a DCM (0.25M) solution of aldehyde (1 eq.) and amine (1 eq.) was added STAB (3 eq.), and the reaction mixture was stirred at room temperature for 30 minutes to 24 hours until LCMS showed conversion to the desired product. The reaction mixture was quenched by adding saturated sodium bicarbonate solution. The reaction mixture was extracted with DCM (2x), and the combined organic matter was washed with salt water, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo.

[0733] General Procedure E: Amine Alkylation

[0734]

[0735] To the DMF (0.2M) solution of the amine being stirred, potassium carbonate (2eq.) is added, and then alkyl bromide (1.1eq., in 0.57M DMF solution) is added dropwise. The reaction mixture is stirred at room temperature overnight. The reaction mixture is diluted with DCM, and the organic phase is washed with water (2x), salt solution (1x), and dried over sodium sulfate, then filtered and concentrated in vacuo. The crude residue is purified by chromatography B to obtain the required product.

[0736] General Procedure F: BOP Amide Coupling

[0737]

[0738] To a solution of the acid in DMF (0.1 M) was added the amine (1 eq.) and DIPEA (5 eq.). Finally, BOP (1.3 eq.) was added and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with DMF, filtered using a syringe filter, and further purified by RP-HPLC to give the desired product.

[0739] definition

[0740] The following description sets forth exemplary methods, parameters, etc. However, it should be recognized that such description is not intended to limit the scope of the present disclosure, but is provided as a description of exemplary embodiments.

[0741] A dash ("-") that is not between two letters or symbols is used to indicate the point of attachment of a substituent. For example, -C(O)NH2 is attached through a carbon atom. Dashes at the beginning or end of a chemical group are convenient; chemical groups can be described with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates the point of attachment of a group. Unless chemically or structurally required, the order in which chemical groups are written or named does not indicate or imply directionality.

[0742] The prefix "C u-v " indicates that the following group has u to v carbon atoms. For example, "C 1-6 "Alkyl" means an alkyl group having 1 to 6 carbon atoms.

[0743] "About" a value or parameter mentioned herein includes (and describes) embodiments related to the value or parameter itself. In certain embodiments, the term "about" includes an indicative amount ± 10%. In other embodiments, the term "about" includes an indicative amount ± 5%. In certain other embodiments, the term "about" includes an indicative amount ± 1%. In addition, the term "about X" includes a description of "X". In addition, the singular forms "a / a" and "the" include plural referents unless the context clearly dictates otherwise. Therefore, for example, reference to a "compound" includes a plurality of such compounds, and reference to "assay" includes reference to one or more assays known to those skilled in the art and their equivalents.

[0744] "Alkyl" refers to a saturated hydrocarbon chain containing no unsaturation or branching. As used herein, an alkyl group has 1 to 20 carbon atoms (i.e., C 1-20 alkyl), 1 to 12 carbon atoms (i.e., C 1-12 alkyl), 1 to 8 carbon atoms (i.e., C 1-8 alkyl), 1 to 6 carbon atoms (i.e., C 1-6 alkyl) or 1 to 4 carbon atoms (i.e., C 1-4Alkyl). Examples of alkyl include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbon atoms is named by a chemical name or identified by a molecular formula, all positional isomers having that number of carbon atoms are encompassed; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3); "propyl" includes n-propyl (i.e., -(CH2)2CH3)) and isopropyl (i.e., -CH(CH3)2).

[0745] "Alkylene" or "alkylene chain" refers to the group that connects the rest of the molecule to a radical, contains no unsaturation, and has from 1 to 20 carbon atoms, or more typically from 1 to 12 carbon atoms (C 1-12 alkylene), or 1 to 8 carbon atoms (C 1-8 alkylene), or 1 to 3 carbon atoms (C 1-3 An unbranched or branched divalent hydrocarbon chain (alkylene), such as methylene, ethylene, propylene, n-butylene, etc. The alkylene chain can be attached to the rest of the molecule and the radical through one carbon within the chain or through any two carbons within the chain.

[0746] "Alkenyl" refers to a group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), or more typically 2 to 12 carbon atoms (ie, C 2-12 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl) or 2 to 4 carbon atoms (ie, C 2-4 Examples of the alkenyl group include ethenyl, propenyl, butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0747] "Alkenylene" and "alkenylene chain" refer to an unbranched or branched divalent hydrocarbon chain containing at least one double bond and having 2 to 20 carbon atoms, or more typically 2 to 12 carbon atoms, or 2 to 8 carbon atoms, that connects the rest of the molecule to a radical group, for example, vinylene, propenylene, n-butenylene, etc. The alkenylene chain is connected to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbon atoms within the chain.

[0748] "Alkynyl" refers to a group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C 2-20alkynyl), or more typically 2 to 12 carbon atoms (ie, C 2-12 alkynyl), or more typically 2 to 8 carbon atoms (ie, C 2-8 Alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl) or 2 to 4 carbon atoms (ie C 2-4 The term "alkynyl" also includes those groups having one triple bond and one double bond.

[0749] "Alkynylene" and "alkynylene chain" refer to an unbranched or branched divalent hydrocarbon chain containing at least one triple bond and having 2 to 20 carbon atoms, or more typically 2 to 12 carbon atoms, or 2 to 8 carbon atoms, that connects the rest of the molecule to a radical group. The alkynylene chain is connected to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbon atoms within the chain.

[0750] “Alkoxy” refers to the group “alkyl-O—.” Examples of alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0751] "Haloalkoxy" refers to an alkoxy group as defined above wherein one or more hydrogen atoms are replaced by a halogen.

[0752] "Alkylthio" refers to the group "alkyl-S-."

[0753] "Amino" refers to the group -NR y R y , wherein each Ry is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or heteroaryl, each of which is optionally substituted as defined herein.

[0754] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems. As used herein, an aryl group has 6 to 20 ring carbon atoms (i.e., C 6-20 aryl), 6 to 15 carbon ring atoms (i.e., C 6-15 aryl) or 6 to 10 carbon ring atoms (i.e., C 6-10 Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthracenyl. However, aryl does not encompass or overlap in any way with heteroaryl groups as defined below. If one or more aryl groups are fused to a heteroaryl group, the resulting ring system is a heteroaryl group. If one or more aryl groups are fused to a heterocyclyl group, the resulting ring system is a heterocyclyl group.

[0755] "Cyano" refers to the radical -CN.

[0756] "Keto" or "oxo" refers to the group =0.

[0757] "Carbamoyl" refers to an "O-carbamoyl" group, which refers to the group OC(O)NR y R z ; and an "N-carbamoyl" group, which refers to the group -NR y C(O)OR z , wherein Ry and Rz are independently selected from hydrogen, alkyl, aryl, haloalkyl or heteroaryl; each of which may be optionally substituted.

[0758] "Carboxy" or "carboxylic acid" refers to -C(O)OH.

[0759] "Ester" refers to -OC(O)R and -C(O)OR, where R is a substituent; each of which may be optionally substituted as defined herein.

[0760] "Cycloalkyl" refers to a saturated or partially unsaturated cycloalkyl group having a single ring or multiple rings (including fused, bridged, and spiro ring systems). The term "cycloalkyl" includes cycloalkenyl groups (i.e., cyclic groups having at least one double bond). As used herein, a cycloalkyl group has 3 to 15 ring carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl) or 3 to 6 ring carbon atoms (i.e., C 3-6 Cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and bicyclo[2.2.2]octan-1-yl. A cycloalkyl group can be attached to the rest of the molecule via a single ring atom (e.g., as a substituent) or via two ring atoms (e.g., as a linker).

[0761] "Ethylene glycol unit" refers to a divalent monomer having a -CH2CH2O- structure that can be repeated and extended into longer chains. The linker segment can have up to 12 ethylene glycol units, or more typically up to 6 ethylene glycol units.

[0762] "Propylene glycol unit" refers to a divalent monomer having a -CH(CH3)-CH2O- structure that can be repeated and extended into longer chains. The linker segment can have up to 12 propylene glycol units, or more typically up to 6 propylene glycol units.

[0763] "Halogen" or "halo" includes fluorine, chlorine, bromine and iodine.

[0764] "Haloalkyl" refers to an unbranched or branched alkyl as defined above, in which one or more hydrogen atoms are replaced by halogen. For example, when the residue is replaced by more than one halogen, it can be referred to by using a prefix corresponding to the number of connected halogen moieties. Dihaloalkyl and trihaloalkyl refer to an alkyl substituted by two ("two") or three ("three") halogen groups, which can be, but are not necessarily, identical halogens. The example of haloalkyl includes difluoromethyl (-CHF2) and trifluoromethyl (-CF3).

[0765] "Heteroalkyl" refers to an alkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are each independently replaced by the same or different heteroatoms such as N, O, S, etc. The term "heteroalkyl" includes unbranched or branched saturated chains with carbon and heteroatoms. For example, 1, 2 or 3 carbon atoms can be independently replaced by the same or different heteroatoms. Heteroatom groups include but are not limited to -N (R) -, -O-, -S-, -S (O) -, -S (O) 2 -, etc., where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclic radical, each of which can be optionally substituted. Examples of heteroalkyl groups include -OCH 3 , -CHOCH 3 , -SCH 3 , -CH 2 SCH 3 , -NRCH 3 and -CH 2 NRCH 3 , where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl or heteroaryl, each of which can be optionally substituted. As used herein, heteroalkyl groups include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1-3 heteroatoms, 1-2 heteroatoms, or 1 heteroatom.

[0766] "Heteroaryl" refers to a 5-15 membered, or more typically 5-12 membered, aromatic group having a single ring, multiple rings, or multiple fused rings, wherein 1-3 ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. As used herein, a heteroaryl group includes 3 to 12 ring carbon atoms (i.e., C 3-12 heteroaryl) or 3 to 8 carbon ring atoms (ie, C 3-8Heteroaryl);And 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms or 1 ring heteroatom, which are independently selected from nitrogen, oxygen and sulfur. Examples of heteroaryl include pyrimidinyl, purinyl, pyridinyl, pyridazinyl, benzothiazolyl and pyrazolyl. Examples of fused heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolyl, isoquinolyl, benzo[b]thienyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl and imidazo[1,5-a]pyridinyl, wherein the heteroaryl can be combined via any ring of the fused system. Any aromatic ring with a single or multiple fused rings containing at least one heteroatom is considered to be a heteroaryl, regardless of the connection to the rest of the molecule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl as defined above. A heteroaryl group can be attached to the rest of the molecule through a single ring atom (eg, as a substituent) or through two ring atoms (eg, as a linker).

[0767] " Heterocyclic radical " refers to 3-15 yuan with 1-3 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, or more typically 5-12 yuan saturated or unsaturated cyclic alkyl.Term " heterocyclic radical " includes heterocycle alkenyl (that is, heterocyclic radical with at least one double bond), bicyclic heterocyclic radical, bridged heterocyclic radical, fused heterocyclic radical and spiro heterocyclic radical.Heterocyclic radical can be monocyclic or polycyclic, wherein polycyclic can be fused, bridged or spirocyclic.Any non-aromatic ring containing at least one heteroatom is considered to be heterocyclic radical, no matter how connected (that is, can be combined by carbon atoms or heteroatoms).In addition, term heterocyclic radical is intended to contain any non-aromatic ring containing at least one heteroatom, and this ring can be fused with aryl or heteroaryl ring, and no matter how connected with the rest of molecule. As used herein, a heterocyclyl group has 3 to 15 ring atoms (e.g., a 3-15 membered heterocyclyl, a 3-12 membered heterocyclyl, a 4-10 membered heterocyclyl, a 4-8 membered heterocyclyl, or a 4-6 membered heterocyclyl; has 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. The heterocyclyl group may contain one or more oxo and / or thio groups. Examples of heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolane, As used herein, heterocyclic groups include alkyl, azetidinyl, azetidinyl, morpholinyl, thiomorpholinyl, 4-7 membered sultam, 4-7 membered cyclic carbamate, 4-7 membered cyclic carbonate, 4-7 membered cyclic sulfide and morpholinyl. As used herein, heterocyclic groups may include bridged structures (i.e., "bridged heterocyclic groups"), wherein the 4-10 membered ring moieties connected at two non-adjacent atoms of the heterocyclic group have at least one heteroatom, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur. As used herein, bridged heterocyclic groups include bicyclic and tricyclic ring systems. Also herein The term "spiroheterocyclyl" as used herein refers to a ring system in which a 3-10 membered heterocyclyl has one or more additional rings, wherein the one or more additional rings are 3-10 membered cycloalkyl or a 3-10 membered heterocyclyl in which a single atom of the one or more additional rings is also an atom of the 3-10 membered heterocyclyl. Examples of spiroheterocyclyl rings include bicyclic and tricyclic ring systems such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl and 6-oxa-1-azaspiro[3.3]heptane Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolyl, 1-oxo-1,2,3,4-tetrahydroisoquinolyl, 1-oxo-1,2-dihydroisoquinolyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, wherein the heterocyclyl group may be attached via either ring of the fused system. As used herein, a bicyclic heterocyclyl is a heterocyclyl group attached at two points to another cyclic group, wherein the other cyclic group itself may be a heterocyclic group or a carbocyclic group.A heteroaryl group can be attached to the rest of the molecule through a single ring atom (eg, as a substituent) or through two ring atoms (eg, as a linker).

[0768] "Fused" refers to a ring that is joined to an adjacent ring and shares two adjacent ring atoms forming a covalent bond.

[0769] "Bridged" refers to a ring fusion in which non-adjacent atoms in the ring are linked by a divalent substituent such as an alkylene group, an alkylene group containing one or two heteroatoms, or a single heteroatom. Quinuclidinyl and adamantyl are examples of bridged ring systems.

[0770] "Spirocyclic" refers to a ring substituent connected by two bonds at the same carbon atom. Examples of spirocyclic groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, where cyclopentane and piperidine, respectively, are spirocyclic substituents.

[0771] "Hydroxy" or "hydroxyl" refers to the group -OH. "Hydroxyalkyl" refers to an unbranched or branched alkyl group as defined above in which one or more hydrogen atoms are replaced by a hydroxy group.

[0772] "Nitro" refers to the radical -NO2.

[0773] "Imino" refers to a group containing a C=N double bond, such as C=NR y or =NC(O)R y , wherein Ry is selected from hydrogen, alkyl, aryl, cyano, haloalkyl or heteroaryl; each of which may be optionally substituted. The imino group may be a linker fragment attached to the rest of the molecule at carbon and nitrogen, respectively.

[0774] "Sulfonyl" refers to the group -S(O)2R, where R is a substituent or a defined group.

[0775] "Alkylsulfonyl" refers to the group -S(O)2R, where R is a substituent or a defined group.

[0776] "Alkylsulfinyl" refers to the group -S(O)R, where R is a substituent or a defined group.

[0777] "Thiocyanate" - SCN.

[0778] "Thiol" refers to the group -SR, where R is a substituent or a defined group.

[0779] "Thio" or "thione" refers to the group (=S) or (S).

[0780] Certain commonly used alternative chemical names may be used. For example, divalent groups such as divalent "alkyl" groups, divalent "aryl" groups, and the like may also be referred to as "alkylene" groups or "alkylenyl" groups, "arylene" groups or "arylenyl" groups, respectively. Furthermore, unless expressly stated otherwise, when a combination of groups is referred to herein as a moiety (e.g., arylalkyl), the last-mentioned group contains the atoms through which the moiety is attached to the remainder of the molecule.

[0781] The term "optional" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes situations in which the event or situation occurs and situations in which the event or situation does not occur. In addition, the term "optionally substituted" refers to that any one or more hydrogen atoms on a designated atom or group may or may not be replaced by a portion other than hydrogen. "Optionally substituted" can be from zero to the maximum number that may be substituted, and each occurrence is independent. When the term "substituted" is used, it is necessary to substitute on the substitutable hydrogen atom of the substituent shown. Optional substitution may be the same as or different from (required) substitution.

[0782] When a moiety is "optionally substituted" and a general term is mentioned, such as any of "alkyl," "alkenyl," "alkynyl," "haloalkyl," "cycloalkyl," "aryl," or "heteroaryl," then the general term may refer to any of the previously specifically recited terms, such as (C 1-3 Alkyl), (C 4-6 alkyl), -O(C 1-4 Alkyl), (C 3-10 Cycloalkyl),O-(C 3-10 cycloalkyl) and the like. For example, "any aryl" includes "aryl" and "-O(aryl)" as well as examples of aryl groups such as phenyl or naphthyl. In addition, the term "any heterocyclyl" includes the terms "heterocyclyl" and O-(heterocyclyl), as well as examples of heterocyclyl groups such as oxetanyl, tetrahydropyranyl, morpholino, piperidinyl, and the like. In the same manner, the term "any heteroaryl" includes the terms "heteroaryl" and "O-(heteroaryl)", as well as specific heteroaryl groups such as pyridine and the like.

[0783] Some compounds of Formula (I) or Formula (II) may exist as "stereoisomers" or mixtures of stereoisomers. A stereoisomer is a compound composed of the same atoms bonded by the same bonds but having different three-dimensional structures that are not interchangeable. The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and may therefore produce enantiomers (two stereoisomers whose molecules are non-superimposable mirror images of each other), diastereomers, and other stereoisomeric forms that may be defined in terms of absolute stereochemistry as (R)- or (S)-. The present disclosure is intended to include all such possible isomers, as well as their rac mixtures (i.e., equal amounts of (R) and (S) enantiomers) and optically pure forms. Optically active (+) and (-), (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or using conventional techniques, such as HPLC resolution using chiral columns.

[0784] The present disclosure also includes "deuterated analogs" of compounds of formula (I) or (II), wherein 1 to n hydrogens attached to the carbon atom are replaced by deuterium, where n is the number of hydrogens in the molecule. Such compounds exhibit increased metabolic resistance and, therefore, can be used to increase the half-life of any compound of formula (I) or (II) when administered to mammals, particularly humans. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12): 524-527 (1984). Such compounds are synthesized by means well known in the art, for example, by using starting materials in which one or more hydrogens have been replaced by deuterium.

[0785] Deuterium-labeled or substituted therapeutic compounds of the present disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties related to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may provide certain therapeutic advantages caused by greater metabolic stability, such as increased in vivo half-life, reduced dosage requirements and / or improvement in therapeutic index. 18F-labeled compounds may be used for PET or SPECT studies. The isotope-labeled compounds of the present disclosure may generally be prepared by replacing non-isotope-labeled reagents with readily available isotope-labeled reagents by carrying out the procedures disclosed in the schemes or in the examples and preparations described below. It should be understood that deuterium in this context is considered to be a substituent in the compounds of Formula (I) or (II).

[0786] The concentration of such heavier isotopes, particularly deuterium, can be defined by an isotopic enrichment factor. In the compounds of the present disclosure, any atom not specifically designated as a particular isotope is intended to represent any stable isotope of that atom. Unless otherwise indicated, when a position is specifically designated as "H" or "hydrogen," that position is understood to be a hydrogen with its natural abundance isotopic composition. Thus, in the compounds of the present disclosure, any atom specifically designated as deuterium (D) is intended to represent deuterium.

[0787] In many cases, the compounds of this disclosure are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.

[0788] Also provided are pharmaceutically acceptable salts, hydrates, or solvates of the compounds described herein."Pharmaceutically acceptable" or "physiologically acceptable" refers to compounds, salts, compositions, dosage forms, and other materials that can be used to prepare pharmaceutical compositions suitable for veterinary or human pharmaceutical use.

[0789] The term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of the given compound and is not biologically or otherwise undesirable. "Pharmaceutically acceptable salts" or "physiologically acceptable salts" include, for example, salts of inorganic acids and salts of organic acids. In addition, if the compounds described herein are obtained as acid addition salts, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, can be prepared by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional methods for preparing acid addition salts from basic compounds. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkylamines (i.e., NH2(alkyl)), dialkylamines (i.e., HN(alkyl)2), trialkylamines (i.e., N(alkyl)3), substituted alkylamines (i.e., NH2(substituted alkyl)), di(substituted alkyl)amines (i.e., HN(substituted alkyl)2), tri(substituted alkyl)amines (i.e., N(substituted alkyl)3), alkenylamines (i.e., NH2(alkenyl)), dienylamines (i.e., HN(alkenyl)2), ), trialkenylamines (i.e., N(alkenyl)3), substituted alkenylamines (i.e., NH2(substituted alkenyl)), di(substituted alkenyl)amines (i.e., HN(substituted alkenyl)2), tri(substituted alkenyl)amines (i.e., N(substituted alkenyl)3), mono-, di-, or tricycloalkylamines (i.e., NH2(cycloalkyl), HN(cycloalkyl), N(cycloalkyl), mono-, di-, or triarylamines (i.e., NH2(aryl), HN(aryl), N(aryl), or mixed amines, etc. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0790] The term "substituted" means that any one or more hydrogen atoms on a specified atom or group are replaced by one or more substituents other than hydrogen, provided that the normal valence of the specified atom is not exceeded. One or more substituents include but are not limited to alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halogen, haloalkyl, haloalkoxy, assorted alkyl, heteroaryl, heterocyclic radical, hydroxyl, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, mercaptan, thioketone or its combination. By limiting the polymer obtained by substituting with infinite additional other substituents or similar indefinite structures (for example, the aryl of the substituted alkyl, the alkyl itself of the substituted aryl is replaced, and the further substituted assorted alkyl of the substituted aryl replaces etc.) are not intended to be included in this article. Unless otherwise indicated, the maximum number of continuous substitutions in compounds as described herein is 3. For example, the aryl substituted by two other substituted aryls is limited to the aryl substituted by ((substituted aryl) substituted aryl). Similarly, the above definition is not intended to include unallowed substitution patterns (for example, methyl substituted by 5 fluorines or heteroaryl with two adjacent oxygen ring atoms). This unallowed substitution pattern is well known to those skilled in the art. When used to modify a chemical group, the term "substituted" can describe other chemical groups defined herein. Unless otherwise stated, when a group is described as optionally substituted, any substituent of the group itself is unsubstituted. For example, in some embodiments, the term "substituted alkyl" refers to an alkyl group with one or more substituents, and the substituents include hydroxyl, halo, alkoxy, cycloalkyl, heterocyclic radical, aryl and heteroaryl. In other embodiments, one or more substituents can be further replaced by halo, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclic radical, aryl or heteroaryl, each of which is substituted. In other embodiments, the substituents can be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is unsubstituted. It will be appreciated by those skilled in the art that the substituents and other moieties of the compounds of the general formula herein should be selected to provide sufficiently stable compounds, thereby providing pharmaceutically useful compounds that can be formulated into acceptable stable pharmaceutical compositions. Compounds with such stability are considered to fall within the scope of the present invention. It will be appreciated by those skilled in the art that any combination of the above definitions and substituents should not produce inoperable substances or compounds.

[0791] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except in the case where any conventional media or agent is incompatible with the active ingredient, its use in therapeutic compositions is contemplated. Supplementary active ingredients may also be incorporated into the compositions.

[0792] A "solvate" is formed by the interaction of a solvent and a compound. Also provided are solvates of the salts of the compounds described herein. Also provided are hydrates of the compounds described herein.

[0793] Targeted HPK1 degradation

[0794] Compounds of the present disclosure have been shown to degrade HPK1 by cell-based assays.

[0795] Total protein levels of HPK1 were assessed in a robust human cell high-throughput format using the HiBiT HPK1 Jurkat cell line. Remaining HPK1 levels after treatment with HPK1 CTM were reported as D2 achieved at 24 h compared to vehicle-treated controls. max (maximum degradation). As further described in the Biological Examples, the results indicate that HPK1 CTM is able to degrade HPK1. These reductions are not a result of cytotoxicity as measured by concurrent viability assessment (CTG). See also Table 1.

[0796] Pharmaceutical compositions and uses of bifunctional compounds of general formula (I) and (II)

[0797] The bifunctional compounds of formula (I) or formula (II) are demonstrated to degrade HPK1 and are therefore useful in treating disease indications or conditions involving HPK1 function (eg, signaling or scaffolding).

[0798] Various embodiments provide pharmaceutical compositions of a compound of Formula (I) or Formula (II) or any substructure or specific compound of Examples 1-97 and a pharmaceutically acceptable carrier.

[0799] Other embodiments provide methods for treating a disease or condition associated with increased hematopoietic progenitor kinase 1 (HPK1) activity, methods for increasing T cell activation, methods for treating cancer, methods for inhibiting the growth or proliferation of cancer cells, methods for treating or preventing hepatitis B virus (HBV) infection, or methods for treating or preventing human immunodeficiency virus (HIV) infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or Formula (II), any substructure, or a compound of Examples 1-97.

[0800] In more specific embodiments, the cancer is selected from bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, Merkel cell carcinoma, mesothelioma, melanoma, non-small cell lung cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, transitional cell carcinoma, and urothelial carcinoma.

[0801] In some embodiments, the compound of Formula (I) or Formula (II), or any substructure or compound of Examples 1-97, may be administered with a therapeutically effective amount of one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

[0802] In other embodiments, the one or more additional therapeutic agents are selected from: an inducible T cell co-stimulatory molecule (ICOS) agonist, a cytotoxic T lymphocyte antigen 4 (CTLA-4) blocking antibody, a PD1 and / or PD-L1 inhibitor, a cluster of differentiation 47 (CD47) inhibitor, an OX40 agonist, a GITR agonist, a CD27 agonist, a CD28 agonist, a CD40 agonist, a CD137 agonist, a Toll-like receptor 8 (TLR8) agonist, a T cell immunoglobulin and mucin domain-3 (TIM-3) inhibitor, a lymphocyte activation gene 3 (LAG-3) inhibitor, CEACAM1 inhibitors, T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitors, V-domain immunoglobulin (Ig) inhibitors of T cell activation (VISTA) inhibitors, anti-killer IgG-like receptor (KIR) inhibitors, STING agonists, CXC chemokine receptor type 4 (CXCR-4) inhibitors, B7-H3 inhibitors, CD73 inhibitors, inhibitory RNA, IL2 / 15 / 17 fusion proteins, MKNK1 / 2 inhibitors, JAK inhibitors and PI3K inhibitors, or pharmaceutically acceptable salts of any one of the foregoing, or any combination thereof.

[0803] In a more specific embodiment, the one or more additional therapeutic agents are selected from the group consisting of rituximab, doxorubicin, gemcitabine, nivolumab, pembrolizumab, pidilizumab, PDR001, TSR-001, atezolizumab, durvalumab, avelumab, pidilizumab, TSR-042, BMS-986016, ruxolitinib, N-(cyanomethyl)-4-[2-(4-morpholinoanilino)pyrimidin-4-yl]benzamide, XL147, BKM120 , GDC-0941, BAY80-6946, PX-866, CH5132799, XL756, BEZ235 and GDC-0980, wortmannin, LY294002, TGR-1202, AMG-319, GSK2269557, X-339, X-414, RP5090, KAR4141, XL499, OXY111A, IPI-145, IPI-443, GSK2636771, BAY 10824391, bupanib, BYL719, RG7604, MLN1117, WX-037, AEZS-129, PA799, ZSTK474, AS252424, TGX221, TG100115, IC87114, IPI-549, INCB050465, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, (S)-2-(1-(( 9H-purin-6-yl)amino)ethyl)-6-fluoro-3-phenylquinazolin-4(3H)-one, (S)-2-(1-((9H-purin-6-yl)amino)ethyl)-3-(2,6-difluorophenyl)quinazolin-4(3H)-one, (S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile and ipilimumab, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0804] In a more specific embodiment, wherein the one or more additional therapeutic agents are selected from idelalisib, tilarutib, molotinib and entospletinib, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0805] In other embodiments, the one or more additional therapeutic agents are selected from HBV combination drugs, HBV vaccines, HBV DNA polymerase inhibitors, immunomodulators, Toll-like receptor (TLR) modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, hepatitis B surface antigen (HBsAg) inhibitors, cytotoxic T lymphocyte-associated protein 4 (ipi4) inhibitors, cyclophilin inhibitors, HBV viral entry inhibitors, antisense oligonucleotides targeting viral mRNA, short interfering RNA (siRNA) and ddRNAi endonuclease modulators, ribonucleotide reductase inhibitors, HBV E antigen inhibitors, covalently closed circular DNA (cccDNA) inhibitors, farnesoid X receptor agonists, HBV antibodies, CCR2 chemokine antagonists, thymosin agonists, cytokines, nuclear protein regulators, retinoic acid-inducible gene 1 stimulators, NOD2 stimulators, phosphatidylinositol 3-kinase (PI3K) inhibitors, indoleamine-2,3-dioxygenase (IDO) pathway inhibitors, PD-1 inhibitors, PD-L1 inhibitors, recombinant thymosin alpha-1 agonists, Bruton's tyrosine kinase (BTK) inhibitors, KDM inhibitors, HBV replication inhibitors, arginase inhibitors and other HBV drugs, or pharmaceutically acceptable salts of any of the foregoing, or any combination thereof.

[0806] In a more specific embodiment, the one or more additional therapeutic agents are selected from adefovir Tenofovir disoproxil fumarate + emtricitabine Tenofovir disoproxil fumarate Entecavir Lamivudine Tenofovir alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine Clavudine Emtricitabine Pegylated interferon alfa-2b Interferon α1b Interferon alfa-2b Pegylated interferon alfa-2a Interferon α-n1 Ribavirin, interferon beta-1a Bioferon, Ingaron, Inmutag (interferon), Algeron, Interferon-A, Oligotide, Zutectra, Shaferon, Interferon alfa-2b (Axxo), Alfaferone, Interferon alfa-2b, Feron, Interferon alfa 2 (CJ), Bevac, Laferonum, Vipeg, Blauferon-B, Blauferon-A, Intermax alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, alpha interferon 2b, Kalferon, Pegnano, Feronsure, PegiHep, Optipeg A, Realfa 2B, Reliferon, peg-interferon alpha-2b, Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alpha-2b, Andafen, Shanferon, MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2 (Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, Interfen, Sirokin, Fucontai, Calliphora antiviral peptide and Simoleukin; or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0807] In a more specific embodiment, the one or more additional therapeutic agents are selected from entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0808] In a more specific embodiment, the one or more additional therapeutic agents are selected from tenofovir alafenamide, tenofovir alafenamide fumarate and tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0809] In other embodiments, the one or more additional therapeutic agents are selected from the group consisting of: combination drugs for HIV, other drugs for the treatment of HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds targeting the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitors, HIV vif gene regulators, Vif dimerization antagonists, HIV-1 viral infection factor inhibitors, TAT protein inhibitors, HIV-1 Nef regulators, Hck tyrosine kinase regulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nuclear protein inhibitors, splicing factor regulators, COMM domain-containing protein 1 regulators, HIV RNase H inhibitors, reverse cell cycle protein regulators, CDK-9 inhibitors, dendritic ICAM-3 grasping non-integrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, complement factor H regulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin-dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP-dependent RNA helicase DDX3X inhibitors, reverse transcriptase initiation complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy and HIV vaccines, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0810] In a more specific embodiment, the one or more additional therapeutic agents are selected from HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers and other drugs used to treat HIV, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0811] In a more specific embodiment, the one or more additional therapeutic agents are selected from 4′-ethynyl-2-fluoro-2′-deoxyadenosine, bictegravir, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide and tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0812] In a more specific embodiment, the one or more additional therapeutic agents are selected from 4′-ethynyl-2-fluoro-2′-deoxyadenosine, bictegravir, tenofovir alafenamide, tenofovir alafenamide fumarate or tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

[0813] In a more specific embodiment, the one or more additional therapeutic agents are selected from 4′-ethynyl-2-fluoro-2′-deoxyadenosine, bictegravir or a pharmaceutically acceptable salt thereof, tenofovir disoproxil, tenofovir disoproxil hemifumarate or tenofovir disoproxil fumarate, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof. Example

[0814] Purification procedures

[0815] Preparative-scale HPLC was performed using columns such as SunFire Prep C18 OBD, XBridge Prep OBD C18, and Xbridge ShieldRP18 OBD, using solvent systems such as (water-0.1% formic acid) / acetonitrile, (water-10 mmol / L NH4HCO3) / acetonitrile, or (water-10 mmol / L NH4HCO3) / acetonitrile. Chromatography A refers to purification on silica gel, typically in a prepacked column, eluting with a mixture of EtOAc and hexane or petroleum ether; chromatography B refers to elution with a mixture of MeOH and DCM; and chromatography C refers to the use of C18 reverse-phase silica gel, eluting with a mixture of acetonitrile and water. In the biological examples, compounds drawn without stereochemistry were tested as racemic mixtures or mixtures of diastereomers.

[0816] Abbreviations

[0817] The abbreviations used in the examples include the following: BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate); HATU (N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylammonium hexafluorophosphate N-oxide); DMSO (dimethyl sulfoxide); THF (tetrahydrofuran); EtOAc (ethyl acetate); ACN (acetonitrile); Et2O (diethyl ether); DCM (dichloromethane); M eOH (methanol); EtOH (ethanol); DCE (1,2-dichloroethane); TEA (trimethylamine); DIPEA (N,N-diisopropylethylamine); DMF (N,N-dimethylformamide); NMP (N-methyl-2-pyrrolidone); STAB (sodium triacetoxyborohydride); DMP (Dess–Martin periodinane); TFA (trifluoroacetic acid); rt or RT (room temperature); anh (anhydrous); eq. or equiv. (equivalent).

[0818] Example 1

[0819] 5-((6-(1'-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)decanoyl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-6-yl)-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-N-isopropyl-2-methylbenzamide

[0820]

[0821] The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 10-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl]amino}decanoic acid (6.3 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (4.0 mg, 24%); LCMS: C 64 H 78 FN 11 O7 theoretical value 1132.4, measured value 1133.2 [M+H] + .

[0822] Example 2

[0823] 5-((6-(1'-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxopentadec-15-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-6-yl)-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-N-isopropyl-2-methylbenzamide

[0824]

[0825] The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 1-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl]amino}-3,6,9,12-tetraoxopentadecane-15-oic acid (7.4 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (4.3 mg, 25%); LCMS: C 65 H 80 FN 11 O 11 Theoretical value 1209.6, measured value 1233.1 [M+Na] + .

[0826] Example 3

[0827] 5-((6-(1'-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)octanoyl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-6-yl)-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-N-isopropyl-2-methylbenzamide

[0828]

[0829] The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 8-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl]amino}octanoic acid (5.9 mg, WO 2018089736A1) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (5.1 mg, 32%); LCMS: C 62 H 74 FN 11 O7 theoretical value 1103.6, measured value 1105.3 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ11.05(s,1H),9.31(d,J=9.3Hz,1H),8.57(s,1H),8.35(s,1H),8.13(d,J=7.9Hz,1H),7.87(s,1H),7.6 6(d,J=7.7Hz,1H),7.61(d,J=8.3Hz,1H),7.56(d,J=8.4Hz,1H),7.50(d,J=9.7Hz,2H),7.22–6.99(m,2H),6.95(s,1H),6.85(d ,J=8.6Hz,1H),5.32–5.20(m,1H),5.02(dd,J=12.6,5.3Hz,1H),4.26–4.17(m,1H),4.07–3.99(m,1H),3.89–3.67(m,6H),3.20 –3.12(m,3H),3.02–2.72(m,9H),2.66–2.53(m,2H),2.35(s,6H),2.06–1.94(m,1H),1.87–1.48(m,22H),1.09(d,J=6.6Hz,6H).

[0830] Example 4

[0831] 5-((6-(1'-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)decanoyl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-6-yl)-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-N-isopropyl-2-methylbenzamide

[0832]

[0833] Step 1: Synthesis of benzyl 10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl)amino)decanoate. The reaction was carried out according to General Procedure A using benzyl 10-aminodecanoate (11.0 g, 39.7 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione (9.86 g, 35.7 mmol), followed by chromatography B to provide the title compound (4.8 g, 25%).

[0834] Step 2: Synthesis of 10-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}amino)decanoic acid. A mixture of benzyl 10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)amino)decanoate (4.8 g, 9.0 mmol), HCl (2M in ether, 5.0 eq), and 10% Pd / C (20 wt%) in THF (0.03 M) was stirred under a hydrogen balloon for 2 hours. Afterwards, the reaction was sparged with nitrogen for 15 minutes and then filtered through a pad of Celite. The filter cake was then washed with a mixture of TFA:DCM (9:1), and the filtrate was concentrated under reduced pressure to provide the product (3.3 g, 83%).

[0835] Step 3: Synthesis of 5-((6-(1'-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)decanoyl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-6-yl)-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-N-isopropyl-2-methylbenzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg), 10-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}amino)decanoic acid (6.3 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (3.7 mg, 23%); LCMS: C 64 H 78 FN 11 O7 theoretical value 1131.6, measured value 1132.9 [M+H] + .

[0836] Example 5

[0837] 5-((6-(1'-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-6-yl)-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-N-isopropyl-2-methylbenzamide

[0838]

[0839] The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 3-{2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl]amino}ethoxy)ethoxy]ethoxy}propanoic acid (6.8 mg, WO2020038415 A1) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (5.0 mg, 30%); LCMS: C 63 H 76 FN 11 O 10 Theoretical value 1165.6, measured value 1167.3 [M+H] + .

[0840] Example 6

[0841] (2S,4R)-N-(2-((10-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-10-oxodecanyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide

[0842]

[0843] Step 1: Synthesis of tert-butyl 10-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]decanoate. To (2S, 4R) -1- [(2S) -2- [(1- fluorocyclopropyl) formamido] -3,3- dimethylbutanoyl] -4- hydroxy -N- { [2- hydroxy -4- (4- methyl -1,3- thiazol-5-yl) phenyl] methyl} pyrrolidine -2- carboxamide (0.8g, 1.5mmol, 1.0eq) in anhydrous DMF (15mL, 0.1M) solution was added CsCO (0.734g, 2.25mmol, 1.5eq) and tert-butyl 10-bromodecanoate (0.646g, 2.10mmol, 1.4eq). The reaction mixture was purged with argon, sealed and stirred at 25 ° C for 16 hours. The solid was filtered, washed with EtOAc (5mL) and discarded. The filtrate obtained was diluted with water (60mL) and extracted with ethyl acetate (3x20mL). The combined organic layers were washed with brine (20 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give the crude product, which was purified according to chromatography method A to afford the title compound (0.99 g, 87% yield).

[0844] Step 2: Synthesis of 10-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]decanoic acid. To a solution of tert-butyl 10-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]decanoate (0.993 g, 1.31 mmol, 1.0 eq) in anhydrous DCM (6.5 mL, 0.2 M) was added TFA (2.00 mL, 26.2 mmol, 20 eq). The reaction was stirred at 25 °C for 3 hours. The reaction was evaporated in vacuo and the resulting oil was treated with aqueous ammonia (20%, 5 mL). Stirring for 1 hour resulted in the formation of an oil. The supernatant was decanted. The oil was dried in vacuo and purified using chromatography C (20% to 60% acetonitrile / 0.1% aqueous formic acid) to provide the title compound as a solid (0.703 g, 76% yield).

[0845] Step 3: Synthesis of (2S,4R)-N-(2-((10-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-10-oxodecanyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (11 mg), 10-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]decanoic acid (11 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (3.6 mg, 16%); LCMS: C 77 H 100 F2N 12 O8S theoretical value 1390.7, measured value 1393.2 [M+H] + .

[0846] Example 7

[0847] (2S,4R)-1-((S)-2-(7-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin-1'-yl)-7-oxoheptanoylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0848]

[0849] The title compound was synthesized according to General Procedure F using Intermediate 1 (11 mg), 6-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}hexanoic acid (8.9 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (5.2 mg, 28%); LCMS: C71 H 91 FN 12 O7S theoretical value 1274.7, found 1277.3 [M+2H] + .

[0850] Example 8

[0851] (2S,4R)-1-((S)-2-(11-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin-1'-yl)-11-oxoundecanoylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0852]

[0853] The title compound was synthesized according to General Procedure F using Intermediate 1 (11 mg) and 10-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}decanoic acid (9.5 mg, WO 2019207538 A1) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (5.6 mg, 28%); LCMS: C 75 H 99 FN 12 O7S theoretical value 1330.7, found 1333.3 [M+2H] + .

[0854] Example 9

[0855] (2S,4R)-N-(2-(2-(2-(2-(3-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin-1'-yl)-3-oxopropoxy)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide

[0856]

[0857] Step 1: Synthesis of tert-butyl 3-[2-(2-{2-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]ethoxy}ethoxy)ethoxy]propanoate. To a solution of (2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (0.7 g, 1.31 mmol, 1.0 eq) in anhydrous DMF (13 mL, 0.1 M) was added CsCO (0.642 g, 1.97 mmol, 1.5 eq) and tert-butyl 3-{2-[2-(2-bromoethoxy)ethoxy]ethoxy}propanoate (0.897 g, 2.63 mmol, 2.0 eq). The reaction mixture was purged with argon and stirred at 25 ° C for 16 hours. The solid was filtered, washed with EtOAc (5 mL) and discarded. The obtained filtrate was diluted with water (60 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude product which was purified by flash chromatography to give the title compound as a white foam (0.63 g, 61% yield).

[0858] Step 2: Synthesis of 3-[2-(2-{2-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]ethoxy}ethoxy)ethoxy]propanoic acid. To a solution of tert-butyl 3-[2-(2-{2-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]ethoxy}ethoxy)ethoxy]propanoate (0.63 g, 1.3 mmol, 1.0 eq) in anhydrous DCM (6.5 mL, 0.2 M) was added TFA (1.81 g, 15.9 mmol, 20 eq). The reaction was stirred at 25 °C for 2 hours. The reaction was evaporated in vacuo and the resulting oil was treated with aqueous ammonia (20%, 5 mL). Stirring for 1 hour resulted in the formation of an oil. The supernatant was decanted and the oil was dried in vacuo and purified using chromatography C (20% to 60% acetonitrile / 0.1% aqueous formic acid) to afford the title compound as a white solid (0.502 g, 87% yield).

[0859] Step 3: Synthesis of (2S,4R)-N-(2-(2-(2-(2-(3-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin-1'-yl)-3-oxopropoxy)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (15 mg), 3-[2-(2-{2-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]ethoxy}ethoxy)ethoxy]propanoic acid (15 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (8.3 mg, 29%); LCMS: C 76 H 98 F2N 12 O 11 S theoretical value 1424.7, measured value 1425.1 [M+H]+ .

[0860] Example 10

[0861] (2S,4R)-1-((S)-2-(9-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin-1'-yl)-9-oxononanoylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0862]

[0863] The title compound was synthesized according to General Procedure F using Intermediate 1 (13 mg), 9-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-9-oxononanoic acid (11 mg, WO 2019207538A1) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (11.9 mg, 50%); LCMS: C 73 H 95 FN 12 Theoretical value of O7S is 1302.7, and the measured value is 1303.9 [M+H] + . 1H NMR (500MHz, DMSO-d6) δ9.36(d,J=9.9Hz,1H),8.98(s,1H),8.70(s,1H),8.41(s,1H),8.37(d,J=7.8Hz,1H),8.14(d,J=7.8Hz,1H),7.87 (s,1H),7.78(d,J=9.3Hz,1H),7.66(d,J=7.9Hz,1H),7.60(d,J=8.2Hz,1H),7.51(d,J=8.4Hz,2H),7.46–7.42(m,2H),7.42–7.33(m,2H), 7.18(d,J=12.1Hz,1H),5.30(t,J=6.7Hz,1H),4.92(q,J=7.1Hz,1H),4.54–3.32(m,13H),3.04–2.71(m,6H),2.45(s,3H),2.36(s,5H),2. 26(dt,J=14.7,7.5Hz,1H),2.12(dt,J=14.1,7.2Hz,1H),2.01(t,J=10.5Hz,1H),1.91–1.20(m,31H),1.09(d,J=6.6Hz,6H),0.94(s,9H).

[0864] Example 11

[0865] 5-((6-(1'-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-6-yl)-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-N-isopropyl-2-methylbenzamide

[0866]

[0867] The title compound was synthesized according to General Procedure F using Intermediate 1 (15 mg) and 3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoic acid (9 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (15.5 mg, 70%); LCMS: C 59 H 68 FN 11 O8 theoretical value 1077.5, measured value 1078.9 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ11.07(s,1H),9.36(d,J=9.1Hz,1H),8.76(s,1H),8.44(s,1H),8.13(d,J=7.8Hz,1H),7.86(s,1H),7.61 (dd,J=26.4,7.9Hz,4H),7.48(d,J=8.8Hz,2H),7.17(t,J=10.9Hz,2H),7.04(d,J=7.0Hz,1H),6.61(s,1H),5.36–5.29(m,1H),5 .04(dd,J=12.9,5.4Hz,1H),4.19(dd,J=16.6,8.4Hz,1H),4.08–3.97(m,1H),3.94–3.81(m,2H),3.74(t,J=6.7Hz,4H),3.64(t, J=5.4Hz,2H),3.56–3.32(m,4H),3.04–2.60(m,6H),2.36(s,3H),2.07–1.92(m,1H),1.92–1.29(m,18H),1.09(d,J=6.5Hz,9H).

[0868] Example 12

[0869] 5-((6-(1'-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaodecane-18-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-6-yl)-3-isopropyl-3H-imidazo[4,5-c]pyridin-4-yl)amino)-4-fluoro-N-isopropyl-2-methylbenzamide

[0870]

[0871] The title compound was synthesized according to General Procedure F using Intermediate 1 (15 mg) and 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecan-18-oic acid (11 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (19 mg, 52%); LCMS: C 67 H 84 FN 11 O 12 Theoretical value 1253.6, measured value 1255.0 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ11.09(s,1H),9.35(s,1H),8.65(d,J=10.3Hz,1H),8.39(s,1H),8.13(d,J=7.8Hz,1H),7. 86(s,1H),7.74–7.43(m,5H),7.16(dd,J=21.5,10.4Hz,2H),7.09–6.98(m,1H),6.60(s,1H),5.36–5.24(m,1H),5. 05(dd,J=12.8,5.5Hz,1H),4.24–4.16(m,1H),4.02(dd,J=13.6,6.8Hz,1H),3.91–3.80(m,4H),3.79–3.58(m,8H), 3.58–3.35(m,16H),3.01–2.54(m,9H),2.36(s,3H),2.06–1.98(m,1H),1.88–1.31(m,18H),1.09(d,J=6.5Hz,6H).

[0872] Example 13

[0873] (2S,4R)-N-(2-((8-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-8-oxooctyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide

[0874]

[0875] Step 1: Synthesis of tert-butyl 8-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]octanoate. To (2S, 4R) -1- [(2S) -2- [(1- fluorocyclopropyl) formamido] -3,3- dimethylbutanoyl] -4- hydroxy -N- { [2- hydroxy -4- (4- methyl -1,3- thiazol-5-yl) phenyl] methyl} pyrrolidine -2- formamide (1.4g, 2.6mmol, 1.0eq) in anhydrous DMF (17.5mL, 0.15M) solution, add 8- bromooctanoic acid tert-butyl ester (1.03g, 3.68mmol, 1.4eq) and CsCO (1.29g, 3.94mmol, 1.5eq). The reaction mixture is sealed and stirred at room temperature overnight. The reaction mixture is then diluted and filtered with EtOAc (20mL). The filtrate obtained is diluted with water (60mL) and extracted with ethyl acetate (3x 20mL). The combined organic layers were washed with brine (20 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give the crude product, which was purified by chromatography B to afford the title compound as a solid (1.84 g, 96%).

[0876] Step 2: Synthesis of 8-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]octanoic acid. To a solution of tert-butyl 8-[2-({[(2S,4R)-1-[(2S)-2-[(1-fluorocyclopropyl)formamido]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidin-2-yl]formamido}methyl)-5-(4-methyl-1,3-thiazol-5-yl)phenoxy]octanoate (1.84 g, 2.51 mmol, 1.0 eq) in anhydrous DCM (12.6 mL, 0.2 M) was added TFA (1.29 g, 3.94 mmol, 1.5 eq) under argon. The reaction mixture was stirred at room temperature for 2 h and evaporated to dryness. The crude residue was triturated with aqueous ammonia (10 mL) for 1 h. The aqueous phase was decanted, the oil was dried in vacuo, and purified using chromatography C (20% to 60% acetonitrile / 0.1% aqueous formic acid) to give the title compound (1.32 g, 78%).

[0877] Step 3: Synthesis of (2S,4R)-N-(2-((8-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-8-oxooctyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide.

[0878] The title compound was synthesized according to General Procedure F using Intermediate 1 (11 mg), 8-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)octanoic acid (11 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (10.7 mg, 53%); LCMS: C 75 H 96 F2N 12 O8S theoretical value 1362.7, found 1364.5 [M+2H] + ; 1H NMR(500MHz,DMSO-d6)δ9.33(d,J=9.5Hz,1H),8.98(s,1H),8.62(s,1H),8.49 (t,J=6.0Hz,1H),8.37(s,1H),8.13(d,J=7.8Hz,1H),7.87(s,1H),7.66(d,J= 7.9Hz,1H),7.61(d,J=8.3Hz,1H),7.53–7.45(m,2H),7.40(d,J=7.8Hz,1H),7 .28(dd,J=9.2,2.8Hz,1H),7.17(d,J=12.2Hz,1H),7.04–6.98(m,1H),6.95(d d,J=7.8,1.6Hz,1H),5.28(p,J=6.5Hz,1H),4.59(d,J=9.2Hz,1H),4.52(t,J= 8.2Hz,1H),4.38–4.16(m,4H),4.10–3.98(m,4H),3.89–3.59(m,5H),3.02–2. 73(m,7H),2.46(s,3H),2.36(s,5H),2.08(t,J=10.3Hz,1H),1.96–1.88(m,1H ),1.88–1.29(m,29H),1.26–1.15(m,3H),1.09(d,J=6.6Hz,6H),0.95(s,9H).

[0879] Example 14

[0880] (2S,4R)-1-((S)-2-(2-(4-(3-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-3-oxopropyl)piperidin-1-yl)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0881]

[0882] Step 1: Synthesis of tert-butyl 3-[1-(2-methoxy-2-oxoethyl)piperidin-4-yl]propanoate. The title compound was synthesized according to General Procedure E using tert-butyl 3-(piperidin-4-yl)propanoate (300 mg, 1.4 mmol) and methyl 2-bromoacetate (230 mg, 1.5 mmol) as starting materials. The title compound was obtained using Chromatography Method C (400 mg, 99%).

[0883] Step 2: Synthesis of {4-[3-(tert-Butoxy)-3-oxopropyl]piperidin-1-yl}acetic acid. The title compound was synthesized according to General Procedure C using tert-butyl 3-[1-(2-methoxy-2-oxoethyl)piperidin-4-yl]propanoate (400 mg, 1.4 mmol) as starting material. The title compound was obtained and used without purification (370 mg, 97%).

[0884] Step 3: Synthesis of tert-butyl 3-[1-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperidin-4-yl]propanoate. The title compound was synthesized according to General Procedure F using {4-[3-(tert-butoxy)-3-oxopropyl]piperidin-1-yl}acetic acid (113 mg, 0.42 mmol) and (1R,4S)-2-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]cyclopentane-1-carboxamide hydrochloride (200 mg, 0.42 mmol) as starting materials. The crude material was purified via chromatography B to give the title compound (280 mg, 96%).

[0885] Step 4: Synthesis of 3-[1-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperidin-4-yl]propanoic acid. The title compound was synthesized according to General Procedure B using tert-butyl 3-[1-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperidin-4-yl]propanoate (270 mg, 0.39 mmol) as the starting material. The title compound was obtained and used without purification (220 mg, 89%).

[0886] Step 5: Synthesis of (2S,4R)-1-((S)-2-(2-(4-(3-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-3-oxopropyl)piperidin-1-yl)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (12 mg), 3-(1-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)piperidin-4-yl)propanoic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (8.1 mg, 28%); LCMS: C 74 H 96 FN 13 O7S theoretical value 1329.7, found 1331.5 [M+2H] + ; 1 H NMR(500MHz,DMSO-d6)δ9.49(s,2H),8.99(s,1H),8.73(d,J=9.1Hz,1H),8.67(s,1H),8.39(d,J=9.3Hz,2H),8.14(d,J=7.9Hz,1H),7 .87(s,1H),7.66(d,J=7.8Hz,1H),7.60(d,J=8.2Hz,1H),7.54–7.41(m,5H),7.41–7.27(m,2H),7.18(d,J=12.2Hz,1H),5.33–5.25(m ,1H),4.92(t,J=7.2Hz,1H),4.57(d,J=9.1Hz,1H),4.43(t,J=8.2Hz,1H),4.31(s,1H),4.24–4.16(m,1H),4.07–3.93(m,1H),3.67–3 .28(m,4H),3.08–2.71(m,9H),2.47–2.32(m,8H),2.08–1.99(m,1H),1.93–1.32(m,33H),1.15–1.04(m,6H),0.96(d,J=13.7Hz,9H).

[0887] Example 15

[0888] (3R)-1-((1S,3S)-3-(1'-acetyl-6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxospiro[indole-3,4'-piperidin]-1-yl)cyclobutyl)-N-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl)amino)nonyl)piperidine-3-carboxamide

[0889]

[0890] Step 1: Synthesis of 5-((9-aminononyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione. The reaction was carried out according to General Procedure A using tert-butyl 9-aminononylcarbamate (8.2 g, 32 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione (8.0 g, 29 mmol). The product of this reaction was subjected to General Procedure B to provide the title compound (3.25 g, 23% over two steps).

[0891] Step 2: Synthesis of (3R)-1-((1s,3S)-3-(1'-acetyl-6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxospiro[indolin-3,4'-piperidin]-1-yl)cyclobutyl)-N-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)nonyl)piperidine-3-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 2 (12 mg), 5-((9-aminononyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (10.6 mg, 45%); LCMS: C 66 H 81 FN 12 O8 theoretical value 1188.6, found value 1191.2 [M+2H] + ; 1H NMR (500MHz, DMSO-d6) δ11.05(s,1H),9.56(s,1H),8.64(s,1H),8.38(s,1H),8.22–8.09(m,1H),8.05(t,J=5.5Hz, 1H),7.87(d,J=7.5Hz,1H),7.71–7.44(m,6H),7.17(dd,J=12.1,6.5Hz,2H),6.93(s,2H),6.84(dt,J=8.4,2.8Hz,2 H),5.29(p,J=6.7Hz,1H),5.07–4.97(m,1H),4.20(t,J=8.3Hz,1H),4.03(dq,J=13.1,6.6Hz,1H),3.93–3.45(m,4H ),3.20–2.97(m,8H),2.57(d,J=18.8Hz,3H),2.36(s,3H),2.07(s,3H),2.02–1.19(m,30H),1.09(d,J=6.6Hz,6H).

[0892] Example 16

[0893] (R)-1-((1S,3S)-3-(1'-acetyl-6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxospiro[dihydroindole-3,4'-piperidin-1-yl)cyclobutyl)-N-(7-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)heptyl)piperidine-3-carboxamide

[0894]

[0895] Step 1: Synthesis of (2S,4R)-N-(2-((7-aminoheptyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide. The title compound was synthesized according to the procedure outlined in Example 9, Steps 1-2, using tert-butyl (7-bromoheptyl)carbamate as the starting material in Step 1.

[0896] Step 2: Synthesis of (R)-1-((1s,3S)-3-(1'-acetyl-6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxospiro[dihydroindole-3,4'-piperidin-1-yl)cyclobutyl)-N-(7-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)heptyl)piperidine-3-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 2 (12 mg), (2S,4R)-N-(2-((7-aminoheptyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (7.7 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (6.2 mg, 34%); LCMS: C 77 H 99 F2N 13 O9S theoretical value 1419.7, found 1422.4 [M+2H] + ; 1HNMR(500MHz,DMSO-d6)δ9.55(s,1H),8.98(s,1H),8.76(s,1H),8.50(t,J=6.0 Hz,1H),8.43(s,1H),8.13(d,J=8.0Hz,1H),8.10–8.05(m,1H),7.86(d,J=6.5Hz ,1H),7.67–7.44(m,4H),7.40(d,J=7.8Hz,1H),7.28(dd,J=9.6,2.7Hz,1H),7.1 8(dd,J=12.0,6.7Hz,1H),6.99(t,J=2.7Hz,1H),6.95(dd,J=7.8,1.6Hz,1H),5. 31(p,J=6.6Hz,1H),4.59(d,J=9.2Hz,1H),4.51(t,J=8.2Hz,1H),4.37–4.14(m, 4H),4.07–3.99(m,4H),3.91–3.34(m,6H),3.13–2.73(m,8H),2.65–2.57(m,1H) ,2.45(s,3H),2.37(d,J=2.2Hz,3H),2.07(s,4H),1.91(ddd,J=13.2,9.2,4.5Hz ,3H),1.86–1.56(m,14H),1.56–1.15(m,14H),1.09(d,J=6.6,6H),0.95(s,9H).

[0897] Example 17

[0898] (R)-1-((1S,3S)-3-(1'-acetyl-6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxospiro[dihydroindole-3,4'-piperidin-1-yl)cyclobutyl)-N-(9-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)nonyl)piperidine-3-carboxamide

[0899]

[0900] Step 1: Synthesis of (2S,4R)-N-(2-((9-aminononyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide. The title compound was synthesized according to the procedure outlined in Example 9, Steps 1-2, using tert-butyl (9-bromononyl)carbamate as the starting material in Step 1.

[0901] Step 2: Synthesis of (R)-1-((1s,3S)-3-(1'-acetyl-6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxospiro[dihydroindole-3,4'-piperidin-1-yl)cyclobutyl)-N-(9-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)nonyl)piperidine-3-carboxamide

[0902] The title compound was synthesized according to General Procedure F using Intermediate 2 (12 mg), (2S,4R)-N-(2-((9-aminononyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (7.7 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (5.3 mg, 28%); LCMS: C 79 H 103 F2N 13 O9S theoretical value 1447.8, found 1449.5 [M+2H] + ; 1HNMR(500MHz,DMSO-d6)δ8.98(s,1H),8.68(s,1H),8.49(t,J=6.0Hz,1H),8.39(s,1H),8.12(d,J= 8.1Hz,1H),8.05(t,J=5.9Hz,1H),7.86(d,J=7.8Hz,1H),7.65(d,J=8.0Hz,1H),7.58(dd,J=8.3,4 .7Hz,1H),7.50(d,J=8.6Hz,2H),7.40(d,J=7.8Hz,1H),7.28(dd,J=9.2,2.8Hz,1H),7.18(dd,J=1 2.1,6.7Hz,1H),7.02–6.97(m,1H),6.95(d,J=7.8Hz,1H),5.29(p,J=6.6Hz,1H),4.59(d,J=9.2Hz, 1H),4.51(t,J=8.2Hz,1H),4.35(s,1H),4.28(dd,J=16.5,6.0Hz,1H),4.19(dd,J=16.6,5.2Hz,2H ),4.09–3.98(m,5H),3.86(s,2H),3.77–3.68(m,2H),3.66–3.55(m,3H),3.41(s,1H),3.12–2.78(m ,8H),2.59(s,1H),2.45(s,3H),2.36(d,J=2.4Hz,3H),2.07(s,3H),1.96–1.87(m,3H),1.86–1.63 (m,8H),1.59(dd,J=6.6,4.0Hz,6H),1.46–1.16(m,17H),1.09(dd,J=6.6,2.0Hz,6H),0.95(s,9H).

[0903] Example 18

[0904] (2S,4R)-1-((S)-2-(2-(4-(2-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-2-oxoethyl)piperazin-1-yl)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0905]

[0906] Step 1: Synthesis of tert-butyl 4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazine-1-carboxylate. The title compound was synthesized according to General Procedure F using [4-(tert-butoxycarbonyl)piperazin-1-yl]acetic acid (900 mg, 3.68 mmol) and (1R,4S)-2-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]cyclopentane-1-carboxamide hydrochloride (1.77 g, 3.68 mmol). Chromatography B provided the title compound (2.1 g, 85%).

[0907] Step 2: Synthesis of (2S,4R)-1-[(2S)-3,3-dimethyl-2-[2-(piperazin-1-yl)acetylamino]butanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide dihydrochloride. The reaction was carried out according to General Procedure B using tert-butyl 4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazine-1-carboxylate (2.1 g, 3.13 mmol) to provide the title compound (2.0 g, 99%).

[0908] Step 3: Synthesis of methyl 2-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazin-1-yl]acetate. The title compound was synthesized according to General Procedure E using (2S,4R)-1-[(2S)-3,3-dimethyl-2-[2-(piperazin-1-yl)acetylamino]butanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide dihydrochloride (1.34 g, 1.57 mmol) and methyl 2-bromoacetate (264 mg, 1.72 mmol) as starting materials. Chromatography B afforded the title compound (0.590 g, 59%).

[0909] Step 4: Synthesis of [4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazin-1-yl]acetic acid. The reaction was carried out according to General Procedure C using methyl 2-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazin-1-yl]acetate (589 mg, 0.92 mmol) to provide the title compound (0.566 g, 98%).

[0910] Step 5: Synthesis of (2S,4R)-1-((S)-2-(2-(4-(2-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-2-oxoethyl)piperazin-1-yl)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (11.5 mg), [4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazin-1-yl]acetic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (8.2 mg, 36%); LCMS: C 72 H 93 FN 14 O7S theoretical value 1316.6, found 1317.6 [M+2H] + ; 1H NMR(500MHz,DMSO-d6)δ9.52(d,J=9.5Hz,1H),8.99(s,1H),8.66(s,1H),8.40(d,J=8.5Hz,2H),8.14(d,J=7.8Hz,1H),7.88(s,1H), 7.68(d,J=7.7Hz,1H),7.59(d,J=8.3Hz,1H),7.53–7.40(m,4H),7.37(d,J=8.1Hz,2H),7.18(d,J=12.1Hz,1H),5.29(q,J=6.6Hz,1H) ,4.91(t,J=7.2Hz,1H),4.54(d,J=9.4Hz,1H),4.43(t,J=8.2Hz,1H),4.33–3.32(m,22H),3.03–2.92(m,1H),2.92–2.76(m,6H),2.4 5(s,3H),2.36(s,3H),2.05(t,J=10.3Hz,1H),1.92–1.52(m,18H),1.43(dd,J=53.2,7.0Hz,4H),1.09(d,J=6.6Hz,6H),0.97(s,9H).

[0911] Example 19

[0912] (2S,4R)-1-((S)-2-(5-(1-(2-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-2-oxoethyl)piperidin-4-yl)pentanoylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0913]

[0914] Step 1: Synthesis of tert-butyl 4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidine-1-carboxylate. The title compound was synthesized according to General Procedure F using 5-[1-(tert-butoxycarbonyl)piperidin-4-yl]pentanoic acid (107 mg, 0.37 mmol) and (1R,4S)-2-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]cyclopentane-1-carboxamide hydrochloride (150 mg, 0.31 mmol) as starting materials. Chromatography C afforded the title compound (0.220 g, 99%).

[0915] Step 2: Synthesis of (2S,4R)-1-[(2S)-3,3-dimethyl-2-[5-(piperidin-4-yl)pentanoylamino]butyryl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride. The reaction was carried out according to General Procedure B using tert-butyl 4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidine-1-carboxylate (0.220 g, 0.31 mmol) to provide the title compound (0.194 g, 99%).

[0916] Step 3: Synthesis of methyl 2-[4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidin-1-yl]acetate. The reaction was carried out using (2S,4R)-1-[(2S)-3,3-dimethyl-2-[5-(piperidin-4-yl)pentanoylamino]butanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (168 mg, 0.26 mmol) and methyl 2-bromoacetate (40 mg, 0.26 mmol) according to General Procedure E. Chromatography B afforded the title compound (69.9 mg, 39%).

[0917] Step 4: Synthesis of [4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidin-1-yl]acetic acid. The reaction was carried out according to General Procedure C using methyl 2-[4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidin-1-yl]acetate (69.9 mg, 0.10 mmol) to provide the title compound (67 mg, 98%).

[0918] Step 5: Synthesis of (2S,4R)-1-((S)-2-(5-(1-(2-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-2-oxoethyl)piperidin-4-yl)pentanoylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (11.5 mg), [4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidin-1-yl]acetic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (8.2 mg, 46%); LCMS: C 76 H 100 FN 13 O7S theoretical value 1357.8, found 1359.5 [M+2H] + ; 1H NMR (500MHz, DMSO-d6) δ9.42(s,1H),8.99(s,1H),8.61(s,1H),8.40–8.33(m,2H),8.13(d,J=7.8Hz,1H),7.88(s,1H),7.80(d,J= 9.2Hz,1H),7.68(d,J=7.7Hz,1H),7.60(d,J=8.2Hz,1H),7.52(s,1H),7.49–7.32(m,6H),7.17(d,J=12.1Hz,1H),5.31–5.25(m,1 H),4.92(t,J=7.2Hz,1H),4.53(d,J=9.2Hz,1H),4.45–4.27(m,6H),4.24–3.30(m,17H),3.22(s,1H),3.02–2.73(m,10H),2.45(s ,4H),2.36(s,3H),2.31–2.23(m,1H),2.13(d,J=8.3Hz,1H),2.01(s,1H),1.93–1.35(m,30H),1.09(d,J=6.6Hz,6H),0.94(s,9H).

[0919] Example 20

[0920] (2S,4R)-1-((S)-2-(5-(1-(3-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-3-oxopropyl)piperidin-4-yl)pentanoylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[0921]

[0922] Step 1: Synthesis of methyl 3-[4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidin-1-yl]propanoate. The reaction was carried out using (2S,4R)-1-[(2S)-3,3-dimethyl-2-[5-(piperidin-4-yl)pentanoylamino]butanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (168 mg, 0.26 mmol) and methyl 3-bromopropionate (43 mg, 0.26 mmol) according to General Procedure E. Chromatography B afforded the title compound (47 mg, 26%).

[0923] Step 2: Synthesis of 3-[4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidin-1-yl]propanoic acid. The reaction was carried out according to General Procedure C using methyl 3-[4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidin-1-yl]propanoate (47 mg, 0.07 mmol) to provide the title compound (46 mg, 98%).

[0924] Step 3: Synthesis of (2S,4R)-1-((S)-2-(5-(1-(3-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-3-oxopropyl)piperidin-4-yl)pentanoylamino)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (5.2 mg), 3-[4-(4-{[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}butyl)piperidin-1-yl]propanoic acid (5 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (2.5 mg, 24%); LCMS: C 77 H 102 FN 13 O7S theoretical value 1371.8, found 1374.9 [M+3H] + ; 1H NMR(500MHz,DMSO-d6)δ9.40(s,1H),8.99(s,1H),8.59(s,1H),8.36(d,J=9.3Hz ,2H),8.13(d,J=7.8Hz,1H),7.88(s,1H),7.80(d,J=9.3Hz,1H),7.68(d,J=7.8Hz ,1H),7.61(d,J=8.3Hz,1H),7.52(s,1H),7.50–7.41(m,3H),7.38(d,J=8.2Hz,2 H),7.17(d,J=12.1Hz,1H),5.31–5.25(m,1H),4.95–4.88(m,1H),4.53(d,J=9.3H z,1H),4.41(t,J=8.0Hz,1H),4.29(s,1H),4.20(t,J=8.2Hz,1H),4.07–3.99(m, 1H),3.96–3.30(m,12H),3.02–2.73(m,11H),2.45(s,3H),2.36(s,3H),2.31–2.2 3(m,1H),2.12(dt,J=13.9,6.4Hz,1H),2.01(t,J=10.4Hz,1H),1.88–1.44(m,22 H),1.38(d,J=7.0Hz,3H),1.34–1.18(m,6H),1.09(d,J=6.6Hz,6H),0.94(s,9H).

[0925] Example 21

[0926] 5-{[6-(1'-{2-[4-(3-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}propyl)piperazin-1-yl]acetyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[0927]

[0928] Step 1: Synthesis of tert-butyl 2-[4-(prop-2-yn-1-yl)piperazin-1-yl]acetate. To a solution of tert-butyl 2-(piperazin-1-yl)acetate (1.5 g, 7.5 mmol) in ACN (50.0 mL) was added 3-bromoprop-1-yne (893 mg, 7.50 mmol) and Cs2CO3 (2.4 g, 7.50 mmol). The resulting mixture was stirred at room temperature for 3 h. After completion of the reaction, the mixture was filtered. The filtrate was concentrated under vacuum. The residue was purified by chromatography A to provide tert-butyl 2-[4-(prop-2-yn-1-yl)piperazin-1-yl]acetate (1.1 g, 62%) as a yellow oil.

[0929] Step 2: Synthesis of tert-butyl 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-4-yl)prop-2-ynyl)piperazin-1-yl)acetate. To a solution of 4-bromo-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione (1.3 g, 3.86 mmol) in DMF (18.0 mL) was added tert-butyl 2-(4-(prop-2-ynyl)piperazin-1-yl)acetate (1.4 g, 5.6 mmol), Pd(PPh3)2Cl2 (423 mg, 0.60 mmol), DIPEA (12.0 mL), and CuI (251 mg, 1.32 mmol). The resulting mixture was stirred at 75°C for 4 h. After completion of the reaction, the resulting mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was evaporated in vacuo. The residue was purified by chromatography B to provide tert-butyl 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)prop-2-ynyl)piperazin-1-yl)acetate (2.5 g, 70%) as a solid.

[0930] Step 3: Synthesis of tert-butyl 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propyl)piperazin-1-yl)acetate. To a solution of tert-butyl 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)prop-2-ynyl)piperazin-1-yl)acetate (2.1 g, 4.25 mmol) in ethanol (50.0 mL) was added 10% Pd / C (0.42 g, dried). The resulting mixture was stirred at room temperature under H2 for 16 h. After completion of the reaction, the reaction mixture was filtered. The filtrate was evaporated in vacuo to afford tert-butyl 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propyl)piperazin-1-yl)acetate (1.6 g, crude) as a solid.

[0931] Step 4: Synthesis of 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propyl)piperazin-1-yl)acetic acid 2,2,2-trifluoroacetic acid. To a solution of tert-butyl 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propyl)piperazin-1-yl)acetate (2.1 g, 4.2 mmol) in dichloromethane (20.0 mL) was added trifluoroacetic acid (20.0 mL). The resulting mixture was stirred at room temperature for 4 h. The resulting mixture was concentrated in vacuo. The residue was purified by Pre-HPLC using the following conditions: Column: XSelect CSH Prep C18 OBD column, 5 um, 19 x 150 mm; Mobile phase A: water (0.05% TFA), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: 5% B to 20% B in 7 min; 254 / 220 nm; Rt: 6.05 min to provide 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propyl)piperazin-1-yl)acetic acid 2,2,2-trifluoroacetic acid (398 mg, 21%) as a solid.

[0932] Step 5: Synthesis of 5-{[6-(1'-{2-[4-(3-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}propyl)piperazin-1-yl]acetyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (17.9 mg), 2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propyl)piperazin-1-yl)acetic acid 2,2,2-trifluoroacetic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (12.4 mg, 46%); LCMS: C 63 H 75 FN 12 O7 theoretical value 1130.6, found value 1133.3 [M+2H] + ; 1H NMR (500MHz, DMSO-d6) δ11.14(s,1H),9.49(s,1H),8.63(s,1H),8.39(s,1H),8.13(d,J=7.8Hz,1H),7.88(s,1H),7.82(d,J=6.7Hz ,2H),7.75(dd,J=6.6,2.2Hz,1H),7.67(d,J=7.6Hz,1H),7.60(d,J=8.2Hz,1H),7.51(s,1H),7.47(d,J=7.8Hz,1H),7.17(d,J=12. 2Hz,1H),5.34–5.24(m,1H),5.14(dd,J=12.8,5.5Hz,1H),4.24–4.14(m,1H),4.04(dt,J=13.8,6.7Hz,1H),3.96–3.07(m,10H),3. 01–2.72(m,13H),2.65–2.52(m,3H),2.36(s,4H),2.10–1.92(m,4H),1.91–1.50(m,16H),1.48–1.38(m,1H),1.09(d,J=6.5Hz,6H).

[0933] Example 22

[0934] 5-[(6-{1'-[2-(2-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-2,7-diazaspiro[3.5]nonan-7-yl)acetyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[0935]

[0936] Step 1: Synthesis of tert-butyl 7-[2-(benzyloxy)-2-oxoethyl]-2,7-diazaspiro[3.5]nonane-2-carboxylate. To a solution of tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate (5.0 g, 22 mmol, 1.0 eq) in DMF (85 mL, 0.26 M) was added CsCO (14.4 g, 44.2 mmol, 2.0 eq) and benzyl 2-bromoacetate (5.06 g, 22.1 mmol, 1.0 eq). The reaction mixture was stirred at rt for 3 h. At this time, DMF was evaporated to dryness, and the crude product was dissolved in water and extracted with EtO (350 mL x 2), washed with brine, and evaporated to dryness to give a crude residue, which was then purified by chromatography A to provide the title compound (6.25 g, 76%).

[0937] Step 2: Synthesis of benzyl 2-{2,7-diazaspiro[3.5]nonan-7-yl}acetate trifluoroacetate. To a solution of tert-butyl 7-[2-(benzyloxy)-2-oxoethyl]-2,7-diazaspiro[3.5]nonan-2-carboxylate (6.25 g, 16.7 mmol, 1.0 eq) in DCM (56 mL, 0.3 M) was added trifluoroacetic acid (25.5 mL, 114 mmol, 20.0 eq). The reaction mixture was stirred at room temperature overnight. The volatiles were then evaporated to dryness, and the crude product was triturated with Et2O to afford 8.23 ​​g of the title compound as a TFA salt (quantitative yield).

[0938] Step 3: Synthesis of Benzyl 2-{2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-2,7-diazaspiro[3.5]nonan-7-yl}acetate. To a solution of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione (7.5 g, 27.1 mmol, 1 eq) in DMSO (54.3 mL, 0.5 M) was added Benzyl 2-{2,7-diazaspiro[3.5]nonan-7-yl}acetate trifluoroacetate (7.7 g, 30 mmol, 1.1 eq) and DIPEA (10.7 mL, 81.4 mmol, 3 eq) under anhydrous conditions. The reaction mixture was stirred at 70°C for 48 h. The reaction mixture was poured into ice-cold water (250 mL) and extracted with ethyl acetate. The combined organic layers were washed with ice-cold water (200 mL x 2), washed with Na2SO4, and concentrated under reduced pressure. The crude residue was purified by chromatography A to obtain 3.6 g of the title compound (25% yield).

[0939] Step 4: Synthesis of 2-{2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-2,7-diazaspiro[3.5]non-7-yl}acetic acid trifluoroacetate. To a solution of benzyl 2-{2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-2,7-diazaspiro[3.5]non-7-yl}acetate (2.5 g, 4.7 mmol) in 5% trifluoroacetic acid in DCM (47 mL, 0.1 M) was added Pd / C 10% (500 mg, 20 wt%). The reaction mixture was purged with argon and then with hydrogen three times, and the mixture was stirred under a hydrogen atmosphere (balloon) for 1 hour. The reaction mixture was filtered through celite and evaporated to dryness to afford 2.08 g of the title compound (80% yield).

[0940] Step 5: Synthesis of 5-[(6-{1'-[2-(2-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-2,7-diazaspiro[3.5]nonan-7-yl)acetyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (11.8 mg, 62%); LCMS: C 63 H 73 FN 12 O7 theoretical value 1128.6, found value 1131.3 [M+2H] + ; 1H NMR (500MHz, DMSO-d6) δ11.07(s,1H),9.63(s,1H),9.52(s,1H),8.61(s,1H),8.39(s,1H),8.13(d,J=7.8Hz,1H),7.89(s,1H),7.69(d,J=8.1 Hz,2H),7.60(d,J=8.2Hz,1H),7.52(s,1H),7.47(d,J=7.8Hz,1H),7.17(d,J=12.1Hz,1H),6.81(d,J=2.0Hz,1H),6.69(dd,J=8.4,2.1Hz,1H), 5.28(p,J=6.6Hz,1H),5.06(dd,J=12.8,5.5Hz,1H),4.39(s,1H),4.20(p,J=8.4Hz,1H),4.08–3.57(m,10H),3.57–3.34(m,2H),3.17–2.77(m ,8H),2.59(d,J=17.3Hz,1H),2.54(s,3H),2.36(s,3H),2.23–1.95(m, 4H), 1.94–1.53 (m, 15H), 1.42 (q, J = 11.6Hz, 1H), 1.10 (d, J = 6.6Hz, 6H).

[0941] Example 23

[0942] 5-[(6-{1'-[2-(4-{2-[(3RS)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperazin-1-yl)acetyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[0943]

[0944] Step 1: Synthesis of tert-butyl 2-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}acetate. To a solution of tert-butyl piperazin-1-yl acetate dihydrochloride (4.46 g, 16.3 mmol, 1.1 eq) in DMSO (29.7 mL, 0.5 M) was added DIPEA (3.93 mL, 22.5 mmol, 2 eq) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (4.1 g, 14.8 mmol, 1 eq). The reaction mixture was heated at 90° C. under argon for 40 h. A bright yellow precipitate formed and was filtered off. The filter cake was then washed twice with water. The filtrate was extracted twice with DCM. The combined DCM layers were concentrated in vacuo and combined with the precipitate. The crude product was purified by chromatography B to afford the title compound as a yellow solid (5.49 g, 81% yield).

[0945] Step 2: Synthesis of 2-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}acetic acid trifluoroacetate. To a solution of tert-butyl 2-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}acetate (5.49 g, 12.0 mmol, 1 eq) in DCM (100 mL, 0.12 M) was added TFA (50.6 mL, 661 mmol, 55 eq). The reaction mixture was stirred at room temperature for 16 hours and then concentrated under reduced pressure. The resulting bright yellow sticky solid was sonicated with 200 mL of anhydrous ether and stirred for 1 hour. The resulting precipitate was filtered, washed twice with anhydrous Et2O, and dried under reduced pressure to give a bright yellow solid (6.55 g, quantitative).

[0946] Step 3: Synthesis of 5-[(6-{1'-[2-(4-{2-[(3RS)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperazin-1-yl)acetyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide.

[0947] The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (13 mg, 70%); LCMS: C 60 H 69 FN 12 O7 theoretical value 1088.5, found value 1090.4 [M+2H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.10(s,1H),10.18(s,1H),9.53(s,1H),8.62(s,1H),8.39(s,1H),8.14(d,J=7.8Hz,1H),7.89(s,1H) ,7.79(d,J=8.5Hz,1H),7.72–7.65(m,1H),7.60(d,J=8.2Hz,1H),7.53–7.44(m,3H),7.36(dd,J=8.7,2.3Hz,1H),7.17(d,J=12 .1Hz,1H),5.28(p,J=6.7Hz,1H),5.10(dd,J=12.7,5.5Hz,1H),4.46(s,1H),4.26–4.11(m,1H),4.08–3.18(m,10H),3.04–2.73 (m,8H),2.64–2.54(s,4H),2.36(s,3H),2.10–1.99(m,1H),1.92–1.52(m,17H),1.41(d,J=13.0Hz,1H),1.09(d,J=6.5Hz,6H).

[0948] Example 24

[0949] 5-[(6-{1'-[1-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidin-4-yl)azetidine-3-carbonyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[0950]

[0951] Step 1: Synthesis of benzyl 4-{3-[(tert-butoxy)carbonyl]azetidin-1-yl}piperidine-1-carboxylate. To a solution of tert-butyl azetidine-3-carboxylate (4.5 g, 29 mmol, 1.0 eq) and 1-(benzyloxycarbonyl)-4-piperidone (7.35 g, 31.5 mmol, 1.10 eq) in DCE (136 mL, 0.2 M) was added acetic acid (2.46 mL, 42.9 mmol, 1.5 eq), and the reaction mixture was stirred at RT for 1 h. NaBH(OAc) (9.71 g, 45.8 mmol, 1.6 eq) was then added, and the mixture was stirred at room temperature overnight. The reaction mixture was then quenched with a NaHCO3 aqueous solution, extracted with DCM (3x), washed with brine, dried over Na2SO4, and concentrated to dryness. The colorless oil was purified by chromatography B to afford 9.39 g (88% yield) of the title compound.

[0952] Step 2: Synthesis of tert-butyl 1-(piperidin-4-yl)azetidine-3-carboxylate. A solution of benzyl 4-{3-[(tert-butoxy)carbonyl]azetidine-1-yl}piperidine-1-carboxylate (9.39 g, 25.1 mmol, 1.0 eq) in MeOH (250 mL, 0.1 M) was degassed and filled with argon three times. Pd(OH)2 (0.7 g, 5.0 mmol, 0.2 eq) was then added, and the mixture was degassed again and filled with argon three times. Afterwards, the reaction mixture was degassed and charged with a H2 balloon and stirred at room temperature overnight. The reaction mixture was filtered through a pad of celite, and the filtrate was concentrated to give 5.81 g (96% yield) of the title compound.

[0953] Step 3: Synthesis of tert-butyl 1-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperidin-4-yl}azetidine-3-carboxylate. To a solution of 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-2,3-dihydro-1H-isoindole-1,3-dione (6.05 g, 21.9 mmol, 1.0 eq) in DMSO (43.8 mL, 0.5 M) was added tert-butyl 1-(piperidin-4-yl)azetidine-3-carboxylate (5.79 g, 24.1 mmol, 1.1 eq) and DIPEA (7.63 mL, 43.8 mmol, 2.0 eq). The reaction mixture was then moved to a preheated bath to 90°C and stirred overnight under an argon atmosphere. The reaction was quenched with water, extracted with DCM (3x) and the organic phase washed with ice-cold water.The crude product was purified by FC eluting with DCM:acetone (0-10%) to give 6.95 g (64% yield) of the title compound.

[0954] Step 4: Synthesis of 1-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperidin-4-yl}azetidine-3-carboxylic acid hydrochloride. To a solution of tert-butyl 1-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperidin-4-yl}azetidine-3-carboxylate (4.95 g, 9.97 mmol, 1.0 eq) in anhydrous DCM (100 mL, 0.1 M) was added 2M HCl in Et2O (50 mL, 100 mmol, 10.0 eq). The reaction mixture was then stirred at room temperature for 2 hours. Add another portion of HCl in Et2O solution (50mL, 100mmol, 10.0eq) and stir the reaction for an additional 3 hours. The precipitate is filtered off and redissolved in DCM, followed by addition of 2M HCl in Et2O solution (50mL, 100mmol, 10.0eq) and the reaction mixture is sonicated for 45 minutes. The precipitated solid is filtered off, washed with Et2O, and dried in vacuo to give 4.83g (quantitative yield) of the title compound as the HCl salt.

[0955] Step 5: Synthesis of 5-[(6-{1'-[1-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidin-4-yl)azetidine-3-carbonyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (11.8 mg) and rac-1-(1-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindole-5-yl}piperidin-4-yl)azetidine-3-carboxylic acid (7 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (6.5 mg, 36%); LCMS: C 63 H 73 FN 12 O7 theoretical value 1128.6, found value 1130.7 [M+2H] + ; 1H NMR (500MHz, DMSO-d6) δ11.08(s,1H),9.49(s,1H),8.61(s,1H),8.38(s,1H),8.13(d,J=7.8Hz,1H),7.88(s,1H),7.76– 7.65(m,2H),7.60(dd,J=8.2,3.6Hz,1H),7.53–7.45(m,2H),7.42(s,1H),7.32(d,J=8.2Hz,1H),7.17(d,J=12.0Hz,1H), 5.37–5.20(m,1H),5.08(dd,J=12.7,5.5Hz,1H),4.46–4.20(m,2H),4.22–4.14(m,4H),4.06–3.32(m,11H),3.05–2.73( m,8H),2.65–2.53(m,2H),2.36(s,3H),2.15–1.98(m,3H),1.92–1.50(m,17H),1.50–1.34(m,3H),1.09(d,J=6.6Hz,6H).

[0956] Example 25

[0957] 5-[(6-{1'-[1-(1-{2-[(3RS)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidine-4-carbonyl)pyrrolidine-3-carbonyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[0958]

[0959] Step 1: Synthesis of 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidine-4-carboxylic acid. The reaction was carried out according to General Procedure A using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (400 mg, 1.45 mmol) and tert-butyl piperidine-4-carboxylate (350 mg, 1.89 mmol) as starting materials. The crude material was purified by chromatography B. Using this material, following General Procedure B, the title compound (0.378 mg, 68%) was produced after chromatography C.

[0960] Step 2: Synthesis of 1-(1-{2-[-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}piperidine-4-carbonyl)pyrrolidine-3-carboxylic acid. The reaction was carried out according to General Procedure F using 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidine-4-carboxylic acid (50 mg, 0.13 mmol) and tert-butyl pyrrolidine-3-carboxylate (27 mg, 0.16 mmol) and purified using Chromatography B. The material was then processed according to General Procedure B and the title compound (40 mg, 64%) was isolated after Chromatography C.

[0961] Step 3: 6-{1'-[1-(1-{2-[(3RS)-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}piperidine-4-carbonyl)pyrrolidine-3-carboxylic acid Synthesis of [(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-carbonyl)pyrrolidine-3-carboxylic acid) (7 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (5.1 mg, 31%); LCMS: C 65 H 75 FN 12 O8 theoretical value 1170.6, found value 1172.5 [M+2H] + ; 1H NMR (500MHz, DMSO-d6) δ11.08(s,1H),9.34(s,1H),8.68(s,1H),8.40(s,1H),8.13(dd,J=7.8,4.5Hz,1H),7. 87(d,J=2.9Hz,1H),7.74–7.63(m,2H),7.63–7.47(m,3H),7.35(dd,J=10.7,6.8Hz,2H),7.18(d,J=12.0Hz,1H ),5.37–5.23(m,1H),5.10(dd,J=12.9,5.3Hz,1H),4.26–3.26(m,8H),3.03–2.73(m,8H),2.71–2.54(m,8H), 2.36(d,J=6.0Hz,4H),2.22–1.98(m,3H),1.92–1.50(m,21H),1.50–1.36(m,1H),1.09(dd,J=6.6,4.1Hz,6H).

[0962] Example 26

[0963] 4-Fluoro-2-methyl-5-[(6-{2-oxo-1'-[1-[(1R,4R)-4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carbonyl]-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide

[0964]

[0965] Step 1: Synthesis of (trans)-4-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}cyclohexane-1-carboxylic acid. The reaction was carried out according to General Procedure A using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (100 mg, 0.36 mmol) and (trans)-4-aminocyclohexane-1-carboxylic acid (104 mg, 0.72 mmol) as starting materials. Chromatography C provided the title compound (40 mg, 28%).

[0966] Step 2: Synthesis of 1-[(trans)-4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carboxylic acid. The reaction was carried out according to General Procedure F using (trans)-4-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}cyclohexane-1-carboxylic acid (32 mg, 0.08 mmol) and tert-butyl pyrrolidine-3-carboxylate (16.5 mg, 0.10 mmol) and purified using Chromatography C. The material was then processed according to General Procedure B, and the title compound (23 mg, 58%) was isolated after Chromatography C.

[0967] Step 3: Synthesis of 4-fluoro-2-methyl-5-[(6-{2-oxo-1'-[1-[(1r,4r)-4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carbonyl]-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10.5 mg) and 1-[(trans)-4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carboxylic acid (7 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (5.9 mg, 34%); LCMS: C 66 H 77 FN 12 O8 theoretical value 1184.6, measured value 1185.9 [M+H] + ; 1H NMR(500MHz,DMSO-d6)δ11.11(s,1H),9.34(s,1H),8.67(s,1H),8.41(s,1H),8.15(d,J=8.0Hz,1H),7 .89(d,J=2.5Hz,1H),7.78–7.48(m,5H),7.33–7.14(m,2H),7.05(d,J=7.0Hz,1H),6.18(d,J=8.1Hz,1 H),5.38–5.25(m,1H),5.06(dd,J=12.8,5.5Hz,1H),4.22–3.24(m,8H),3.09–2.69(m,8H),2.69–2.54 (m,4H),2.37(s,3H),2.21–1.94(m,6H),1.91–1.48(m,22H),1.48–1.29(m,3H),1.11(d,J=6.4Hz,6H).

[0968] Example 27

[0969] 4-Fluoro-2-methyl-5-[(6-{2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1'-[1-[(1S,4S)-4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carbonyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide

[0970]

[0971] Step 1: Synthesis of 1-[(cis)-4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carboxylic acid. Synthesis was performed analogously to Example 26, Steps 1 and 2, starting from (cis)-4-aminocyclohexane-1-carboxylic acid to provide the title compound.

[0972] Step 2: Synthesis of 4-fluoro-2-methyl-5-[(6-{2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1′-[1-[(1s,4s)-4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carbonyl]-1,2-dihydrospiro[indole-3,4′-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 1-[(cis)-4-({2-[(3RS)-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carboxylic acid (7 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (9.7 mg, 58%); LCMS: C 66 H 77 FN 12 O8 theoretical value 1184.6, measured value 1185.9 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ11.10(s,1H),9.36(s,1H),8.69(s,1H),8.41(s,1H),8.14(d,J=7.8Hz,1H),7.87 (d,J=4.5Hz,1H),7.75–7.47(m,5H),7.16(dd,J=18.2,10.4Hz,2H),7.05(d,J=7.0Hz,1H),6.53(s,1H),5 .39–5.20(m,1H),5.07(dd,J=12.9,5.4Hz,1H),4.24–3.21(m,9H),3.03–2.73(m,8H),2.65–2.52(m,5H), 2.36(s,3H),2.16–2.02(m,2H),1.90–1.50(m,26H),1.41(q,J=14.2,13.6Hz,1H),1.10(d,J=6.6Hz,6H).

[0973] Example 28

[0974] 5-[(6-{1'-[2-(7-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-2,7-diazaspiro[3.5]non-2-yl)acetyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[0975]

[0976] Step 1: Synthesis of 2,7-diazaspiro[3.5]nonan-2-ylacetic acid hydrochloride. Synthesis was performed according to General Procedure E followed by General Procedure B using tert-butyl 2,7-diazaspiro[3.5]nonan-7-carboxylate (400 mg, 1.77 mmol) and tert-butyl 2-bromoacetate (379 mg, 1.94 mmol) as starting materials. The title compound was isolated (331 mg, 84% over two steps) without further purification.

[0977] Step 2: Synthesis of (7-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]-2,7-diazaspiro[3.5]nonan-2-yl)acetic acid. The reaction was carried out according to General Procedure A using 2,7-diazaspiro[3.5]nonan-2-ylacetic acid hydrochloride (331 mg, 1.50 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (414 mg, 1.50 mmol) as starting materials. Chromatography C afforded the title compound (50 mg, 8%).

[0978] Step 3: Synthesis of 5-[(6-{1'-[2-(7-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-2,7-diazaspiro[3.5]non-2-yl)acetyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (13.5 mg) and (7-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl]-2,7-diazaspiro[3.5]nonan-2-yl)acetic acid (8 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (6.2 mg, 30%); LCMS: C 63 H 73 FN 12 O7 theoretical value 1128.6, measured value 1129.9 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.07(d,J=4.3Hz,1H),10.30(d,J=37.2Hz,1H),9.48(s,1H),8.59(s,1H),8.37(s,1H),8.13 (d,J=7.8Hz,1H),7.89(s,1H),7.70(t,J=7.9Hz,2H),7.61(d,J=8.3Hz,1H),7.52(s,1H),7.46(d,J=7.9Hz,1H),7.17( d,J=12.2Hz,1H),6.97–6.80(m,1H),5.35–5.20(m,1H),5.10–5.01(m,1H),4.54(d,J=17.4Hz,1H),4.25–3.13(m,9H), 3.04–2.68(m,9H),2.65–2.52(m,6H),2.36(s,3H),2.23–1.52(m,22H),1.41(d,J=13.6Hz,1H),1.09(d,J=6.4Hz,6H).

[0979] Example 29

[0980] 5-{[6-(1'-{2-[(3S)-1-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]pyrrolidin-3-yl}methyl)piperidin-3-yl]acetyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[0981]

[0982] Step 1: Synthesis of tert-butyl 3-{[(3S)-3-(2-methoxy-2-oxoethyl)piperidin-1-yl]methyl}pyrrolidine-1-carboxylate. The reaction was carried out according to General Procedure D using tert-butyl 3-formylpyrrolidine-1-carboxylate (1.00 g, 5.02 mmol), methyl 2-[(3S)-piperidin-3-yl]acetate hydrochloride (972 mg, 5.02 mmol), and TEA (1.54 mL, 11.0 mmol). Following this procedure, the title compound (1.6 g, 94%) was used without further purification.

[0983] Step 2: Synthesis of [(3S)-1-(pyrrolidin-3-ylmethyl)piperidin-3-yl]acetic acid. A saponification reaction was carried out according to General Procedure C using tert-butyl 3-{[(3S)-3-(2-methoxy-2-oxoethyl)piperidin-1-yl]methyl}pyrrolidine-1-carboxylate (1.60 g, 4.70 mmol) as the starting material. The product of this reaction was directly subjected to General Procedure B to produce the title compound (1.06 g, quantitative).

[0984] Step 3: Synthesis of 2-((3S)-1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl)pyrrolidin-3-yl)methyl)piperidin-3-yl)acetic acid. The reaction was carried out according to General Procedure A using [(3S)-1-(pyrrolidin-3-ylmethyl)piperidin-3-yl]acetic acid (328 mg, 0.72 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (200 mg, 0.72 mmol) as starting materials. Chromatography C afforded the title compound (214 mg, 61%).

[0985] Step 4: Synthesis of 5-{[6-(1'-{2-[(3S)-1-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]pyrrolidin-3-yl}methyl)piperidin-3-yl]acetyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (7.3 mg), 2-((3S)-1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperidin-3-yl)acetic acid (5 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (2.8 mg, 23%); LCMS: C 66 H 79 FN 12 O7 theoretical value 1170.6, measured value 1172.1 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ10.99(s,1H),8.49(s,1H),8.27(s,1H),8.05(d,J=7.9Hz,1H),7.79(s,1H),7.60(dd, J=14.7,8.1Hz,2H),7.52(d,J=8.1Hz,1H),7.46–7.37(m,2H),7.09(d,J=12.2Hz,1H),6.87(s,1H),6.76(d,J= 8.2Hz,1H),5.23–5.11(m,1H),4.98(dd,J=13.0,5.4Hz,1H),4.16–4.07(m,1H),4.01–3.91(m,1H),3.81–3.05 (m,8H),2.99–2.65(m,14H),2.57–2.46(m,4H),2.36–2.12(m,10H),2.03–1.28(m,30H),1.01(d,J=6.6Hz,6H).

[0986] Example 30

[0987] 4-Fluoro-2-methyl-5-[(6-{2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1'-[1-[(1S,3S)-3-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)cyclobutanecarbonyl]pyrrolidine-3-carbonyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide

[0988]

[0989] Step 1: Synthesis of (cis)-3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}cyclobutane-1-carboxylic acid. The reaction was carried out according to General Procedure A using 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (150 mg, 0.54 mmol) and (cis)-3-aminocyclobutane-1-carboxylic acid hydrochloride (82 mg, 0.54 mmol) as starting materials. Chromatography C provided the title compound (50 mg, 25%).

[0990] Step 2: Synthesis of 1-[(cis)-3-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)cyclobutanecarbonyl]pyrrolidine-3-carboxylic acid. The reaction was carried out according to General Procedure F using (cis)-3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}cyclobutane-1-carboxylic acid (18 mg, 0.05 mmol) and tert-butyl pyrrolidine-3-carboxylate (10 mg, 0.06 mmol) as starting materials. The product of this reaction was then subjected to General Procedure B, which provided the title compound (8 mg, 40%) after chromatography C.

[0991] Step 3: Synthesis of 4-fluoro-2-methyl-5-[(6-{2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1'-[1-[(1s,3s)-3-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)cyclobutanecarbonyl]pyrrolidine-3-carbonyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (12.7 mg) and 1-((cis)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)cyclobutane-1-carbonyl)pyrrolidine-3-carboxylic acid (8 mg, 0.02 mmol) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (9.3 mg, 45%); LCMS: C 64 H 73 FN 12 O8 theoretical value 1156.6, measured value 1157.9 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.10(s,1H),9.35(s,1H),8.66(s,1H),8.40(s,1H),8.13(d,J=7.8Hz,1H),7.87(d,J =3.6Hz,1H),7.71–7.63(m,1H),7.63–7.47(m,4H),7.18(d,J=12.1Hz,1H),7.10–7.03(m,2H),6.45(s,1H),5. 29(p,J=6.6Hz,1H),5.06(dd,J=12.7,5.4Hz,1H),4.25–3.19(m,8H),3.08–2.74(m,8H),2.72–2.56(m,4H),2. 54(s,3H),2.36(s,3H),2.18–2.01(m,5H),1.91–1.53(m,18H),1.41(d,J=12.9Hz,1H),1.10(d,J=6.6Hz,6H).

[0992] Example 31

[0993] 5-{[6-(1'-{2-[(3S)-1-{[1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pyrrolidin-3-yl]methyl}piperidin-3-yl]acetyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[0994]

[0995] Step 1: Synthesis of tert-butyl 3-{[(3S)-3-(2-methoxy-2-oxoethyl)piperidin-1-yl]methyl}pyrrolidine-1-carboxylate. The reaction was carried out according to General Procedure D using tert-butyl 3-formylpyrrolidine-1-carboxylate (1.00 g, 5.02 mmol), methyl 2-[(3S)-piperidin-3-yl]acetate hydrochloride (972 mg, 5.02 mmol), and methyl 2-[(3S)-piperidin-3-yl]acetate hydrochloride (972 mg, 5.02 mmol). Following this procedure, the title compound (1.6 g, 94%) was used without further purification.

[0996] Step 2: Synthesis of [(3S)-1-(pyrrolidin-3-ylmethyl)piperidin-3-yl]acetic acid. A saponification reaction was carried out according to General Procedure C using tert-butyl 3-{[(3S)-3-(2-methoxy-2-oxoethyl)piperidin-1-yl]methyl}pyrrolidine-1-carboxylate (1.60 g, 4.70 mmol) as the starting material. The product of this reaction was directly subjected to General Procedure B to produce the title compound (1.06 g, quantitative).

[0997] Step 3: Synthesis of 2-((3S)-1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pyrrolidin-3-yl)methyl)piperidin-3-yl)acetic acid. The reaction was carried out according to General Procedure A using [(3S)-1-(pyrrolidin-3-ylmethyl)piperidin-3-yl]acetic acid (819 mg, 1.81 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (500 mg, 1.81 mmol) as starting materials. Chromatography C afforded the title compound (490 mg, 48%).

[0998] Step 4: Synthesis of 5-{[6-(1'-{2-[(3S)-1-{[1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pyrrolidin-3-yl]methyl}piperidin-3-yl]acetyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (14 mg), 2-((3S)-1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)pyrrolidin-3-yl)methyl)piperidin-3-yl)acetic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (8.1 mg, 29%); LCMS: C 66 H 79 FN 12 O7 theoretical value 1170.6, measured value 1171.8 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ11.07(s,1H),9.49(s,1H),9.17(s,1H),8.65(s,1H),8.40(s,1H),8.14(d,J=7.8Hz,1 H),7.87(s,1H),7.69–7.54(m,3H),7.49(d,J=8.5Hz,2H),7.21–7.15(m,2H),7.12(d,J=8.8Hz,1H),5.35–5.24 (m,1H),5.07(dd,J=12.8,5.5Hz,1H),4.20(dd,J=16.4,8.3Hz,1H),4.10–3.98(m,1H),3.93–3.08(m,10H),3.0 7–2.66(m,10H),2.65–2.52(m,4H),2.42–2.32(m,4H),2.22(s,1H),2.06–1.29(m,25H),1.09(d,J=6.5Hz,6H).

[0999] Example 32

[1000] 5-({6-[1'-(1-{2-[(3S)-1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-3-yl]acetyl}pyrrolidine-3-carbonyl)-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl]-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1001]

[1002] Step 1: Synthesis of [(3S)-1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-3-yl]acetic acid. The reaction was carried out according to General Procedure A using (3S)-piperidin-3-ylacetic acid (143 mg, 1.00 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (276 mg, 1.00 mmol) as starting materials. Chromatography C provided the title compound (190 mg, 48%).

[1003] Step 2: Synthesis of 1-{2-[(3S)-1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-3-yl]acetyl}pyrrolidine-3-carboxylic acid. The reaction was carried out according to General Procedure F using [(3S)-1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-3-yl]acetyl}pyrrolidine-3-carboxylic acid (20 mg, 0.05 mmol) and tert-butyl pyrrolidine-3-carboxylate (8.6 mg, 0.05 mmol) as starting materials. The crude material from this reaction was directly subjected to General Procedure B to provide the title compound (10 mg, 40%).

[1004] Step 3: Synthesis of 5-({6-[1'-(1-{2-[(3S)-1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-3-yl]acetyl}pyrrolidine-3-carbonyl)-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl]-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (14.5 mg) and 1-(2-((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-3-yl)acetyl)pyrrolidine-3-carboxylic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (7.5 mg, 31%); LCMS: C 66 H 77 FN 12 O8 theoretical value 1184.6, measured value 1185.9 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.08(s,1H),9.34(s,1H),8.70(d,J=4.9Hz,1H),8.41(s,1H),8.13(d,J=7.7Hz,1H),7.87(d,J=2 .8Hz,1H),7.71–7.62(m,2H),7.61–7.46(m,3H),7.41(t,J=8.8Hz,1H),7.31(d,J=6.9Hz,1H),7.18(d,J=12.0Hz,1H),5.30 (p,J=6.6Hz,1H),5.10(dd,J=9.7,4.5Hz,1H),4.25–4.15(m,1H),4.08–3.99(m,1H),3.40(d,J=11.0Hz,10H),3.03–2.65(m ,8H),2.54(s,3H),2.36(s,3H),2.31–1.91(m,8H),1.93–1.50(m,20H),1.41(q,J=10.5,8.2Hz,1H),1.10(d,J=6.5Hz,6H).

[1005] Example 33

[1006] 5-{[6-(1'-{1-[(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)methyl]azetidine-3-carbonyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1007]

[1008] Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-[4-(hydroxymethyl)piperidin-1-yl]isoindole-1,3-dione. The reaction was carried out according to General Procedure A using piperidin-4-ylmethanol (208 mg, 1.80 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (500 mg, 1.81 mmol) as starting materials. Chromatography B provided the title compound (500 mg, 74%).

[1009] Step 2: Synthesis of 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidine-4-carbaldehyde. To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-[4-(hydroxymethyl)piperidin-1-yl]isoindole-1,3-dione (100 mg, 0.27 mmol) in DCM (1.35 mL) was added DMP (228 mg, 0.54 mmol). After stirring for 90 minutes, silica gel was added to the reaction and the solvent was removed under reduced pressure. The material was then purified by chromatography A to provide the title compound (32 mg, 32%).

[1010] Step 3: Synthesis of 1-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-4-yl}methyl)azetidine-3-carboxylic acid. Reductive amination was performed according to General Procedure D using tert-butyl azetidine-3-carboxylate (6.4 mg, 0.04 mmol) and 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidine-4-carbaldehyde (15 mg, 0.04 mmol) as starting materials. The crude material from this reaction was directly processed using General Procedure B. Following chromatography C, the title compound (8 mg, 43%) was obtained.

[1011] Step 4: Synthesis of 5-{[6-(1'-{1-[(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)methyl]azetidine-3-carbonyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (12.44 mg) and 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)azetidine-3-carboxylic acid (8 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (8.2 mg, 36%); LCMS: C 64 H 75 FN 12 O7 theoretical value 1142.6, measured value 1144.0 [M+H] + ; 1 HNMR(500MHz,DMSO-d6)δ11.09(s,1H),9.45(s,1H),8.62(s,1H),8.39(s,1H),8.13(d,J=7.8Hz,1H),7.88(s,1H) ,7.75–7.63(m,2H),7.60(d,J=8.1Hz,1H),7.55–7.45(m,2H),7.39–7.30(m,2H),7.17(d,J=12.0Hz,1H),5.29(q,J =6.4Hz,1H),5.09(dd,J=12.8,5.5Hz,1H),4.51–4.40(m,1H),4.29–4.18(m,2H),4.10–3.13(m,10H),3.03–2.71(m ,10H),2.66–2.52(m,3H),2.36(s,3H),2.03(s,1H),1.91–1.51(m,20H),1.51–1.36(m,3H),1.09(d,J=6.5Hz,6H).

[1012] Example 34

[1013] 5-{[6-(1'-{1-[2-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)acetyl]azetidine-3-carbonyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1014]

[1015] Step 1: Synthesis of (1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}piperidin-4-yl)acetic acid. The reaction was carried out according to General Procedure A using piperidin-4-ylacetic acid (273 mg, 1.91 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (527 mg, 1.91 mmol) as starting materials. Chromatography C provided the title compound (546 mg, 71%).

[1016] Step 2: Synthesis of 1-{2-[(3S)-1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidin-3-yl]acetyl}azetidine-3-carboxylic acid. The reaction was carried out according to General Procedure F using (1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}piperidin-4-yl)acetic acid (25 mg, 0.06 mmol) and tert-butyl azetidine-3-carboxylate (10 mg, 0.06 mmol). The crude material from this reaction was then subjected directly to General Procedure B to provide the title compound (22 mg, 73%).

[1017] Step 3: Synthesis of 5-{[6-(1'-{1-[2-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)acetyl]azetidine-3-carbonyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg), 1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)acetyl)azetidine-3-carboxylic acid (6.3 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (5.5 mg, 23%); LCMS: C 65 H 75 FN 12 O8 theoretical value 1170.6, measured value 1172.1 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.08(s,1H),9.31(s,1H),8.64(s,1H),8.38(s,1H),8.13(dd,J=8.1,2.3Hz,1H),7.87(s,1H),7.72– 7.63(m,2H),7.63–7.48(m,3H),7.33(t,J=7.7Hz,2H),7.18(d,J=11.2Hz,1H),5.33–5.24(m,1H),5.14–5.05(m,1H),4.32(dd, J=18.5,8.1Hz,1H),4.25–4.16(m,1H),4.10–3.99(m,1H),4.00–3.93(m,1H),3.73–3.35(m,10H),3.03–2.75(m,10H),2.67–2 .55(m,2H),2.36(d,J=4.3Hz,4H),2.13–1.97(m,3H),1.93–1.52(m,18H),1.41(q,J=13.3,11.2Hz,2H),1.09(d,J=4.0Hz,6H).

[1018] Example 35

[1019] 5-({6-[1'-(1-{[1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pyrrolidin-3-yl]methyl}azetidine-3-carbonyl)-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl]-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1020]

[1021] Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-[3-(hydroxymethyl)pyrrolidin-1-yl]isoindole-1,3-dione. The reaction was carried out according to General Procedure A using pyrrolidin-3-ylmethanol (220 mg, 2.17 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (500 mg, 1.81 mmol) as starting materials and heating at 80°C. Chromatography B provided the title compound (462 mg, 71%).

[1022] Step 2: Synthesis of 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]pyrrolidine-3-carbaldehyde. To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-[3-(hydroxymethyl)pyrrolidin-1-yl]isoindole-1,3-dione (100 mg, 0.28 mmol) in DCM (1.40 mL) was added DMP (237 mg, 0.56 mmol). After stirring for 90 minutes, silica gel was added to the reaction and the solvent was removed under reduced pressure. The material was then purified by chromatography A to provide the title compound (58 mg, 58%).

[1023] Step 3: Synthesis of 1-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]pyrrolidin-3-yl}methyl)azetidine-3-carboxylic acid. The reaction was carried out according to General Procedure D using 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]pyrrolidine-3-carbaldehyde (20 mg, 0.06 mmol), tert-butyl azetidine-3-carboxylate (13.3 mg, 0.08 mmol), and TEA (0.020 mL, 0.12 mmol). The crude material was then processed according to General Procedure B. Chromatography C provided the title compound (18.3 mg, 74%).

[1024] Step 4: Synthesis of 5-({6-[1'-(1-{[1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pyrrolidin-3-yl]methyl}azetidine-3-carbonyl)-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl]-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (28 mg) and 1-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]pyrrolidin-3-yl}methyl)azetidine-3-carboxylic acid (18 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (4.4 mg, 9.4%); LCMS: C 63 H 73 FN 12 O7 theoretical value 1128.6, measured value 1130.0 [M+H] + ; 1 HNMR (500MHz, DMSO-d6) δ11.07(s,1H),9.49(s,1H),8.60(d,J=8.2Hz,1H),8.38(s,1H),8.13(d,J=7.9Hz,1H),7.88(d,J=2.2Hz, 1H),7.70–7.64(m,1H),7.61(dd,J=8.6,7.1Hz,2H),7.55–7.43(m,2H),7.17(dt,J=11.9,3.7Hz,2H),7.11(d,J=8.4Hz,1H),5.27( q,J=6.5Hz,1H),5.07(d,J=7.3Hz,1H),4.50–4.37(m,1H),4.31–4.15(m,2H),4.08–3.91(m,4H),3.84–3.29(m,10H),3.02–2.74(m ,8H),2.66–2.55(m,2H),2.36(s,3H),2.19–1.95(m,2H),1.89–1.48(m,18H),1.41(q,J=11.2,10.0Hz,1H),1.09(d,J=6.5Hz,6H).

[1025] Example 36

[1026] 5-{[6-(1'-{1-[2-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)acetyl]piperidine-4-carbonyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1027]

[1028] Step 1: Synthesis of 1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)piperidin-4-yl)acetyl)piperidine-4-carboxylic acid. The reaction was carried out according to General Procedure F using (1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}piperidin-4-yl)acetyl)piperidine-4-carboxylic acid (25 mg, 0.06 mmol) and tert-butyl piperidine-4-carboxylate (12 mg, 0.06 mmol). The crude material from this reaction was then subjected to General Procedure B. Chromatography C afforded the title compound (22 mg, 69%).

[1029] Step 2: Synthesis of 5-{[6-(1'-{1-[2-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)acetyl]piperidine-4-carbonyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (15 mg) and 1-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)acetyl)piperidine-4-carboxylic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (16.4 mg, 68%); LCMS: C 67 H 79 FN 12 O8 theoretical value 1198.6, measured value 1199.9 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ11.08(s,1H),9.37(s,1H),8.67(s,1H),8.40(s,1H),8.13(d,J=7.8Hz,1H),7.87(s,1H),7.71–7.64( m,2H),7.59(d,J=8.1Hz,1H),7.52(d,J=8.4Hz,2H),7.33(dd,J=10.8,7.8Hz,2H),7.18(d,J=12.1Hz,1H),5.29(q,J=6.8Hz,1 H),5.09(dd,J=12.8,5.5Hz,1H),4.44(s,1H),4.24–4.17(m,1H),4.03(h,J=6.8Hz,1H),3.96–3.37(m,10H),3.11(t,J=12.5H z,1H),3.00–2.71(m,9H),2.70–2.55(m,2H),2.36–2.29(m,4H),2.06–2.00(m,1H),1.88–1.33(m,27H),1.10(d,J=6.5Hz,6H).

[1030] Example 37

[1031] 5-{[6-(1'-{1-[(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)methyl]piperidine-4-carbonyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1032]

[1033]

[0146] Step 1: Synthesis of 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)piperidin-4-yl)methyl)piperidine-4-carboxylic acid. The reaction was carried out according to General Procedure D using 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidine-4-carbaldehyde (15 mg, 0.04 mmol) and tert-butyl piperidine-4-carboxylate (7.5 mg, 0.04 mmol). The crude material from this reaction was then subjected to General Procedure B followed by chromatography C to provide the title compound (17.8 mg, 91%).

[1034] Step 2: Synthesis of 5-{[6-(1'-{1-[(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)methyl]piperidine-4-carbonyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (7.3 mg) and 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidine-4-carboxylic acid (5 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (8.2 mg, 64%); LCMS: C 66 H 79 FN 12 O7 theoretical value 1170.6, measured value 1172.0 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ11.09(s,1H),9.48(s,1H),8.98(s,1H),8.63(s,1H),8.39(s ,1H),8.14(d,J=7.8Hz,1H),7.88(s,1H),7.74–7.63(m,2H),7.60(d,J=8.2Hz,1H),7 .52(d,J=5.5Hz,2H),7.36(d,J=7.6Hz,2H),7.18(d,J=12.1Hz,1H),5.32–5.18(m,1H ),5.09(dd,J=12.8,5.4Hz,1H),4.24–3.11(m,10H),3.09–2.71(m,14H),2.66–2.56(m 1H), 2.36 (s, 3H), 2.10–1.36 (m, 28H), 1.10 (d, J = 6.6Hz, 6H). .

[1035] Example 38

[1036] 5-[(6-{1'-[1-[(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)methyl]pyrrolidine-3-carbonyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1037]

[1038]

[0146] Step 1: Synthesis of 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl)piperidin-4-yl)methyl)pyrrolidine-3-carboxylic acid. The reaction was carried out according to General Procedure D using 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperidine-4-carbaldehyde (15 mg, 0.04 mmol) and tert-butyl pyrrolidine-3-carboxylate (6.8 mg, 0.04 mmol). The crude material from this reaction was then subjected to General Procedure B followed by chromatography C to provide the title compound (16.8 mg, 91%).

[1039] Step 2: Synthesis of 5-[(6-{1'-[1-[(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}piperidin-4-yl)methyl]pyrrolidine-3-carbonyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (9.5 mg) and 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)pyrrolidine-3-carboxylic acid (6 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (10.5 mg, 61%); LCMS: C 65 H 77 FN 12 O7 theoretical value 1156.6, measured value 1157.9 [M+H] + ; 1H NMR(500MHz,DMSO-d6)δ11.09(s,1H),9.69–9.44(m,2H),8.64(s,1H),8.40(s,1H),8.14(dd,J=7.9 ,2.5Hz,1H),7.89(d,J=3.6Hz,1H),7.78–7.63(m,2H),7.63–7.42(m,3H),7.42–7.27(m,2H),7.18( d,J=12.2Hz,1H),5.28(q,J=6.6Hz,1H),5.09(dd,J=12.7,5.5Hz,1H),4.21–3.06(m,11H),3.02–2. 67(m,10H),2.67–2.55(m,1H),2.38–2.33(m,4H),2.09–1.29(m,28H),1.10(dd,J=6.6,2.4Hz,6H).

[1040] Example 39

[1041] 5-[(6-{1'-[1-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidine-4-carbonyl)azetidine-3-carbonyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1042]

[1043] Step 1: Synthesis of 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidine-4-carboxylic acid. The reaction was carried out according to General Procedure A using tert-butyl piperidine-4-carboxylate (402 mg, 2.17 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (500 mg, 1.81 mmol). Chromatography B was then performed, and the resulting material was subjected to General Procedure B. Chromatography C provided the title compound (440 mg, 63%).

[1044] Step 2: Synthesis of 1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)piperidine-4-carbonyl)azetidine-3-carboxylic acid. The reaction was carried out according to General Procedure F using 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidine-4-carboxylic acid (10 mg, 0.03 mmol) and tert-butyl azetidine-3-carboxylate (4 mg, 0.03 mmol). The crude material from this reaction was subjected to General Procedure B followed by chromatography C to provide the title compound (10 mg, 82%).

[1045] Step 3: Synthesis of 5-[(6-{1'-[1-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidine-4-carbonyl)azetidine-3-carbonyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine-4-carbonyl)azetidine-3-carboxylic acid (6.8 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (7.2 mg, 44%); LCMS: C 64 H 73 FN 12 O8 theoretical value 1156.6, measured value 1157.8 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ11.07(s,1H),9.39(s,1H),8.73(d,J=6.2Hz,1H),8.43(s,1H),8.13(d,J=7.8 Hz,1H),7.87(d,J=2.6Hz,1H),7.74–7.61(m,2H),7.62–7.45(m,3H),7.33(s,1H),7.30–7.13(m,2H),5 .30(q,J=6.5Hz,1H),5.07(dd,J=12.7,5.5Hz,1H),4.45–4.34(m,1H),4.24–3.35(m,11H),3.15–2.68( m,10H),2.65–2.55(m,2H),2.36(s,3H),2.05–1.93(m,1H),1.88–1.32(m,23H),1.09(d,J=6.5Hz,6H).

[1046] Example 40

[1047] 5-[(6-{1'-[1-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidine-4-carbonyl)pyrrolidine-3-carbonyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1048]

[1049] Step 1: Synthesis of 1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl)piperidine-4-carbonyl)pyrrolidine-3-carboxylic acid. The reaction was carried out according to General Procedure F using 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole-5-yl]piperidine-4-carboxylic acid (10 mg, 0.03 mmol) and tert-butyl pyrrolidine-3-carboxylate (4.4 mg, 0.03 mmol). The crude material from this reaction was subjected to General Procedure B followed by chromatography C to provide the title compound (10 g, 80%).

[1050] Step 2: Synthesis of 5-[(6-{1'-[1-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidine-4-carbonyl)pyrrolidine-3-carbonyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine-4-carbonyl)pyrrolidine-3-carboxylic acid (8.4 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (12.1 mg, 75%); LCMS: C 65 H 75 FN 12 O8 theoretical value 1170.6, measured value 1172.0 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.07(s,1H),9.37(s,1H),8.70(s,1H),8.41(s,1H),8.14(d,J=7.5Hz,1H),7.87(d,J =4.8Hz,1H),7.67(dd,J=8.4,4.5Hz,2H),7.62–7.46(m,3H),7.34(t,J=2.5Hz,1H),7.25(dd,J=8.6,2.7Hz,1H ),7.18(d,J=12.1Hz,1H),5.30(p,J=6.6Hz,1H),5.07(dd,J=12.7,5.4Hz,1H),4.24–3.26(m,11H),3.15–2.73 (m,11H),2.64–2.53(m,2H),2.37–2.34(m,3H),2.19–1.51(m,25H),1.41(d,J=13.0Hz,1H),1.11–1.07(m,6H).

[1051] Example 41

[1052] 5-[(6-{1'-[1-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidine-4-carbonyl)piperidine-4-carbonyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1053]

[1054] Step 1: Synthesis of 1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl)piperidine-4-carbonyl)piperidine-4-carboxylic acid. The reaction was carried out according to General Procedure F using 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidine-4-carboxylic acid (10 mg, 0.03 mmol) and tert-butyl piperidine-4-carboxylate (4.6 mg, 0.03 mmol). The crude material from this reaction was subjected to General Procedure B followed by chromatography C to provide the title compound (8.4 g, 66%).

[1055] Step 2: Synthesis of 5-[(6-{1'-[1-(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidine-4-carbonyl)piperidine-4-carbonyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidine]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine-4-carbonyl)piperidine-4-carboxylic acid (8.4 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (8.8 mg, 54%); LCMS: C 66 H 77 FN 12 O8 theoretical value 1184.6, measured value 1185.9 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ11.08(s,1H),9.37(s,1H),8.72(s,1H),8.42(s,1H),8.14(d,J=7.8Hz,1H),7.88(s,1H),7.67(d,J= 8.5Hz,2H),7.59(d,J=8.1Hz,1H),7.52(d,J=11.0Hz,2H),7.34(d,J=2.2Hz,1H),7.25(dd,J=8.8,2.3Hz,1H),7.18(d,J=12.1 Hz,1H),5.34–5.25(m,1H),5.07(dd,J=12.8,5.4Hz,1H),4.45–4.38(m,1H),4.25–4.15(m,1H),4.12–3.29(m,10H),3.20–2. 72(m,13H),2.69–2.55(m,2H),2.37(s,3H),2.07–1.97(m,1H),1.89–1.46(m,24H),1.47–1.35(m,2H),1.10(d,J=6.6Hz,6H).

[1056] Example 42

[1057] 5-{[6-(1'-{1-[2-(7-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-2,7-diazaspiro[3.5]non-2-yl)acetyl]piperidine-4-carbonyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1058]

[1059] Step 1: Synthesis of 2,7-diazaspiro[3.5]nonan-2-ylacetic acid hydrochloride. The reaction was carried out according to General Procedure E using tert-butyl 2,7-diazaspiro[3.5]nonan-7-carboxylate (400 mg, 1.77 mmol) and tert-butyl 2-bromoacetate (379 mg, 1.94 mmol) as starting materials. The crude residue was then processed according to General Procedure B to provide the title compound (300 mg, 77%).

[1060] Step 2: Synthesis of (7-{2-[(2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-5-yl}-2,7-diazaspiro[3.5]nonan-2-yl)acetic acid. The reaction was carried out according to general procedure A using 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (414 mg, 1.50 mmol) and 2,7-diazaspiro[3.5]nonan-2-ylacetic acid hydrochloride (330 mg, 1.50 mmol) as starting materials. Chromatography C afforded the title compound (50 mg, 8%).

[1061]

[0146] Step 3: Synthesis of 1-(2-(7-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-2-yl)acetyl)piperidine-4-carboxylic acid. The reaction was carried out according to General Procedure F using (7-{2-[(2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindolin-5-yl}-2,7-diazaspiro[3.5]nonan-2-yl)acetyl)piperidine-4-carboxylic acid (20 mg, 0.05 mmol) and tert-butyl piperidine-4-carboxylate (9.2 mg, 0.05 mmol) as starting materials. The crude material from this reaction was then subjected to General Procedure B followed by chromatography C to afford the title compound (10 mg, 40%).

[1062] Step 4: Synthesis of 5-{[6-(1'-{1-[2-(7-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-2,7-diazaspiro[3.5]non-2-yl)acetyl]piperidine-4-carbonyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg), 1-(2-(7-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-2-yl)acetyl)piperidine-4-carboxylic acid (7.2 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (6.7 mg, 39%); LCMS: C 69 H 82 FN 13 O8 theoretical value 1239.6, measured value 1240.9 [M+H] + ; 1H NMR(500MHz,DMSO-d6)δ11.07(s,1H),10.28–10.07(m,1H),9.44(s,1H),8.62(s,1H),8.38(s,1H),8.14(d,J=7.8Hz ,1H),7.88(s,1H),7.73–7.63(m,2H),7.60(d,J=8.5Hz,1H),7.50(d,J=11.5Hz,2H),7.39–7.26(m,1H),7.17(d,J=1 2.1Hz,1H),6.97–6.78(m,1H),5.28(q,J=6.7Hz,1H),5.07(dd,J=13.0,5.0Hz,1H),4.61–4.28(m,2H),4.25–4.15(m ,1H),4.08–3.99(m,2H),3.97–2.69(m,20H),2.65–2.55(m,1H),2.36(s,3H),2.20–1.33(m,30H),1.12–0.99(m,6H).

[1063] Example 43

[1064] 5-[(6-{1'-[23-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)-3,6,9,12,15,18,21-heptaoxatriacosan-1-yl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1065]

[1066] Step 1: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((23-hydroxy-3,6,9,12,15,18,21-heptaoxatriacosyl)amino)isoindole-1,3-dione. The reaction was carried out according to General Procedure A using 23-amino-3,6,9,12,15,18,21-heptaoxatriacosan-1-ol (1.34 g, 3.62 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (1.0 g, 3.62 mmol) as starting materials. Chromatography B afforded the title compound (700 mg, 31%).

[1067] Step 2: Synthesis of 23-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21-heptaoxatriacosyl 4-methylbenzenesulfonate. To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-((23-hydroxy-3,6,9,12,15,18,21-heptaoxatriacosyl)amino)isoindolin-1,3-dione (2.5 g, 4.0 mmol) and pyridine (316 mg, 4.0 mmol) in DCM (15 mL) was added p-toluenesulfonyl chloride (838 mg, 4.4 mmol). The reaction was then stirred overnight before water was added. The organic phase was removed and the aqueous phase was extracted with DCM (2x), then the combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. Chromatography B provided the title compound (220 mg, 7%).

[1068] Step 3: Synthesis of 5-[(6-{1'-[23-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)-3,6,9,12,15,18,21-heptaoxatriacosan-1-yl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized by combining Intermediate 1 (19.7 mg, 1 eq), 23-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21-heptaoxatriacosyl 4-methylbenzenesulfonate (23 mg, 1 eq), sodium iodide (3.97 mg, 1 eq) and potassium carbonate (18.3 mg, 5 eq) in ACN (0.05 M) and heating the reaction mixture at 80° C. for 16 hours. The reaction mixture was filtered and purified by reverse phase HPLC to provide the title compound (15.1 mg, 33%); LCMS: C 70 H 92 FN 11 O 13 Theoretical value 1313.7, measured value 1315.0 [M+H] + ; 1H NMR(500MHz,DMSO-d6)δ11.09(s,1H),9.65–9.39(m,2H),8.61(d,J=3.6Hz,1H),8.39(d,J=21.9Hz,1H),8.14 (d,J=7.9Hz,1H),7.90(d,J=25.4Hz,1H),7.77–7.48(m,4H),7.26–7.06(m,3H),7.04(d,J=7.0Hz,1H),6.59( s,1H),5.28(s,1H),5.05(dd,J=12.9,5.4Hz,1H),4.27–3.29(m,36H),2.99–2.75(m,8H),2.58(d,J=19.6Hz, 2H), 2.38–2.25 (m, 5H), 2.17 (s, 1H), 2.05–1.48 (m, 16H), 1.41 (q, J = 11.9, 10.7Hz, 1H), 1.10 (d, J = 6.5Hz, 6H).

[1069] Example 44

[1070] 5-({6-[1'-(2-{4-[4-({[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)ethyl]carbamoyl}methyl)phenyl]piperazin-1-yl}acetyl)-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl]-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1071]

[1072] Step 1: Synthesis of ethyl 2-(4-{4-[2-(tert-butoxy)-2-oxoethyl]piperazin-1-yl}phenyl)acetate. Under argon, tert-butyl (piperazin-1-yl)acetate (0.89 g, 4.4 mmol, 1.2 eq), palladium(II) acetate (0.083 g, 0.37 mmol, 0.1 eq) and Xphos (0.176 g, 0.37 mmol, 0.1 eq) were added to a stirred solution of ethyl 4-bromophenylacetate (0.90 g, 3.7 mmol, 1.0 eq) in toluene (22 mL, 0.2 M). The mixture was diluted with water (20 mL) and then extracted with ethyl acetate (3x). The combined organic fractions were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by chromatography A to give 0.9 g (67% yield) of the title compound.

[1073] Step 2: Synthesis of potassium 2-{4-[4-(2-ethoxy-2-oxoethyl)phenyl]piperazin-1-yl}acetate. Ethyl 2-(4-{4-[2-(tert-butoxy)-2-oxoethyl]piperazin-1-yl}phenyl)acetate (0.61 g, 1.7 mmol, 1.0 eq) was dissolved in THF (12 mL, 0.14 M) and potassium trimethylsilanolate (0.216 g, 1.68 mmol, 1.0 eq) was added. The reaction mixture was stirred overnight (progress monitored by UPLC). The precipitated white solid was filtered and dried to obtain 415 mg (72% yield) of the title compound.

[1074]

[0269] Step 3: Synthesis of {4-[4-({[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)ethyl]carbamoyl}methyl)phenyl]piperazin-1-yl}acetic acid. The reaction was carried out according to General Procedure F using potassium 2-{4-[4-(2-ethoxy-2-oxoethyl)phenyl]piperazin-1-yl}acetate (57 mg, 0.17 mmol) and 4-[(2-aminoethyl)amino]-2-[2,6-dioxopiperidin-3-yl]isoindole-1,3-dione hydrochloride (60 mg, 0.17 mmol) as starting materials. The crude material from this reaction was subjected to General Procedure B and purified according to Chromatography C to afford the title compound (40 mg, 41%).

[1075] Step 4: Synthesis of 5-({6-[1′-(2-{4-[4-({[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)ethyl]carbamoyl}methyl)phenyl]piperazin-1-yl}acetyl)-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4′-piperidin]-6-yl]-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl}amino)-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg), {4-[4-({[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)ethyl]carbamoyl}methyl)phenyl]piperazin-1-yl}acetic acid (10 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (14.1 mg, 80%); LCMS: C 70 H 81 FN 14 O8 theoretical value 1264.6, found value 1266.9 [M+2H] + ;1 H NMR(500MHz,DMSO-d6)δ11.11(s,1H),9.99(s,1H),9.50(s,1H),8.66(s,1H),8.41(s,1H),8.23(t,J=5.7Hz,1H),8 .14(d,J=7.9Hz,1H),7.89(s,1H),7.69(d,J=7.8Hz,1H),7.64–7.42(m,4H),7.25–7.08(m,5H),7.04(d,J=7.0Hz,1H ),6.92(d,J=8.4Hz,2H),6.74(s,1H),5.36–5.21(m,1H),5.07(dd,J=12.8,5.4Hz,1H),4.54–3.04(m,17H),3.04–2. 72(m,8H),2.68–2.55(m,1H),2.36(s,3H),2.04(dd,J=10.2,4.9Hz,1H),1.92–1.38(m,21H),1.10(d,J=6.6Hz,6H).

[1076] Example 45

[1077] 5-{[6-(1'-{1-[(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidin-4-yl)methyl]piperidine-4-carbonyl}-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1078]

[1079]

[0146] Step 1: Synthesis of 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidine-4-carboxylic acid. The reaction was carried out according to General Procedure D using 1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl]piperidine-4-carbaldehyde (15 mg, 0.04 mmol) and tert-butyl piperidine-4-carboxylate (7.4 mg, 0.04 mmol). The crude material from this reaction was then subjected to General Procedure B followed by chromatography C to provide the title compound (15.4 mg, 80%).

[1080] Step 2: Synthesis of 5-{[6-(1'-{1-[(1-{2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}piperidin-4-yl)methyl]piperidine-4-carbonyl}-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl]amino}-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidine-4-carboxylic acid (6.5 mg) as starting materials. The crude material was purified by reverse phase HPLC to provide the title compound (14.3 mg, 74.1%); LCMS: C 66 H 79 FN 12 O7 theoretical value 1170.6, measured value 1171.4 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ11.08(s,1H),9.49(s,1H),8.99(s,1H),8.64(s,1H),8.40(s,1H),8.14(d,J=7.8Hz,1H),7 .88(s,1H),7.68(dd,J=10.1,8.0Hz,2H),7.59(d,J=8.2Hz,1H),7.51(d,J=6.1Hz,2H),7.37(d,J=2.2Hz,1H),7.28 (dd,J=8.8,2.1Hz,1H),7.17(d,J=12.2Hz,1H),5.37–5.20(m,1H),5.07(dd,J=12.8,5.4Hz,1H),4.25–3.36(m,12H ),3.19–2.74(m,8H),2.66–2.53(m,2H),2.36(s,3H),2.20–1.49(m,27H),1.47–1.21(m,4H),1.10(d,J=6.6Hz,6H).

[1081] Example 46

[1082] N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-7-(2-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-1'-yl)-2-oxoethyl)-7-azaspiro[3.5]nonane-2-carboxamide

[1083]

[1084] Step 1: Synthesis of N-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)ethyl]-7-azaspiro[3.5]nonane-2-carboxamide. The reaction was carried out according to General Procedure F using 4-[(2-aminoethyl)amino]-2-[2,6-dioxopiperidin-3-yl]isoindole-1,3-dione hydrochloride (55 mg, 0.16 mmol) and 7-(tert-butoxycarbonyl)-7-azaspiro[3.5]nonane-2-carboxylic acid (46 mg, 0.17 mmol). The crude material from this reaction was then subjected to General Procedure B followed by chromatography C to provide the title compound (56 mg, 77%).

[1085]

[0266] Step 2: Synthesis of (2-{[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)ethyl]carbamoyl}-7-azaspiro[3.5]nonan-7-yl)acetic acid. The title compound was synthesized according to General Procedure E using N-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)ethyl]-7-azaspiro[3.5]nonane-2-carboxamide (28 mg, 0.06 mmol) and tert-butyl 2-bromoacetate (12 mg, 0.06 mmol). The crude material of this reaction was then subjected to General Procedure B followed by chromatography C to afford the title compound (28 mg, 89%).

[1086] Step 3: Synthesis of N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-7-(2-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1s,3s)-3-(piperidin-1-yl)cyclobutyl)spiro[indolin-3,4'-piperidin]-1'-yl)-2-oxoethyl)-7-azaspiro[3.5]nonane-2-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (12.7 mg, 0.02 mmol) and (2-{[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)ethyl]carbamoyl}-7-azaspiro[3.5]nonan-7-yl)acetic acid (9.0 mg, 0.02 mmol), followed by reverse phase HPLC to provide the title compound (4.9 mg, 20%); LCMS: C 67 H 80 FN 13 O8 theoretical value 1213.6, measured value 1214.7 [M+H] + ; 1 H NMR (500 MHz, methanol-d4) δ 8.73 (s, 1H), 8.08–7.97 (m, 1H), 7.82–7.67 (m, 2H), 7.63 (s, 1H), 7.57 (t, J = 7.8 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.19–7.11 (m, 2H), 7.08 (d, J = 7.0 Hz, 1H), 5.29 (p, J = 6.5Hz,1H),5.10–5.02(m,1H),4.40–4.03(m,4H),4.03–3.87(m,2H),3.72–3.57(m,2H),3.5 7–3.38(m,9H),3.15–2.62(m,11H),2.43(s,3H),2.22–1.48(m,26H),1.14(d,J=6.6Hz,6H).

[1087] Example 47

[1088] (2S,4R)-1-[(2S)-2-(2-{4-[4-(2-{6-[4-({2-fluoro-4-methyl-5-[(propan-2-yl)carbamoyl]phenyl}amino)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-6-yl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-1'-yl}-2-oxoethyl)phenyl]piperazin-1-yl}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide

[1089]

[1090] Step 1: Synthesis of tert-butyl 2-(4-(4-(2-ethoxy-2-oxoethyl)phenyl)piperazin-1-yl)acetate. tert-Butyl (piperazin-1-yl)acetate (0.89 g, 4.4 mmol, 1.2 eq), palladium(II) acetate (0.083 g, 0.37 mmol, 0.1 eq), and Xphos (0.176 g, 0.37 mmol, 0.1 eq) were added to a stirred solution of ethyl 4-bromophenylacetate (0.90 g, 3.7 mmol, 1.0 eq) in anhydrous toluene (22 mL, 0.2 M) under argon. The reaction mixture was then purged with argon for 3 minutes, moved to a preheated bath to 100° C., and stirred for 16 hours. UPLC indicated the formation of the title compound. The mixture was diluted with water (20 mL) and then extracted with ethyl acetate (3×). The combined organic fractions were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by chromatography A to afford 0.9 g (67% yield) of the title compound.

[1091] Step 2: Synthesis of 2-{4-[4-(2-ethoxy-2-oxoethyl)phenyl]piperazin-1-yl}acetic acid. Tert-butyl 2-(4-(4-(2-ethoxy-2-oxoethyl)phenyl)piperazin-1-yl)acetate (0.13 g, 0.36 mmol, 1.0 eq) was dissolved in anhydrous DCM (1.3 mL), followed by the addition of TFA (0.275 mL, 10.0 eq) and stirring at RT for 4 h. UPLC indicated residual SM. An additional 10 eq of TFA was added, and the reaction mixture was stirred for an additional 2 h. The reaction mixture was evaporated to dryness to afford 0.13 g (86% yield) of the title compound as a TFA salt.

[1092] Step 3: Synthesis of ethyl 2-{4-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazin-1-yl]phenyl}acetate. The title compound was synthesized using (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (50 mg, 0.10 mmol) and {4-[4-(2-ethoxy-2-oxoethyl)phenyl]piperazin-1-yl}acetic acid (53 mg, 0.12 mmol) according to General Procedure F. The crude material was purified using chromatography B to give the title compound (75 mg, 98%).

[1093] Step 4: Synthesis of {4-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazin-1-yl]phenyl}acetic acid. The title compound was synthesized using ethyl 2-{4-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazin-1-yl]phenyl}acetate (75 mg, 0.10 mmol) according to General Procedure C. This material was used without purification.

[1094] Step 5: Synthesis of (2S,4R)-1-[(2S)-2-{2-[4-(4-{2-[6-(4-{[2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl]amino}-3-isopropylimidazo[4,5-c]pyridin-6-yl)-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]spiro[indole-3,4'-piperidin]-1'-yl]-2-oxoethyl}phenyl)piperazin-1-yl]acetamido}-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (15.8 mg, 0.02 mmol) and {4-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperazin-1-yl]phenyl}acetic acid (15 mg, 0.02 mmol), followed by reverse phase HPLC to provide the title compound (13 mg, 44%); LCMS: C 78 H 97 FN 14 O7S theoretical value 1392.7, measured value 1393.8 [M+H] + ; 1 H NMR(500MHz, methanol-d4)δ8.92–8.80(m,2H),8.08–8.01(m,1H),7.80–7.67(m,2H), 7.64–7.53(m,1H),7.49–7.25(m,7H),7.19–7.02(m,2H),5.30(p,J=6.6Hz,1H), 5.02(t,J=6.9Hz,1H),4.61–4.24(m,2H),4.21–3.39(m,23H),3.19–2.81(m,7H) ,2.50–2.37(m,6H),2.26–2.18(m,1H),2.07–1.45(m,22H),1.15–1.06(m,15H).

[1095] Example 48

[1096] (2S,4R)-1-((2S)-2-(2-(3-(3-(6-(4-((2-fluoro-5-(isopropylcarbamoyl)-4-methylphenyl)amino)-3-isopropyl-3H-imidazo[4,5-c]pyridin-6-yl)-2-oxo-1-((1S,3S)-3-(piperidin-1-yl)cyclobutyl)spiro[dihydroindole-3,4'-piperidin]-1'-yl)-3-oxopropyl)piperidin-1-yl)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide

[1097]

[1098] Step 1: Synthesis of ethyl 3-[1-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperidin-3-yl]propanoate. The reaction was carried out according to General Procedure F using (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (110 mg, 0.23 mmol) and [3-(3-ethoxy-3-oxopropyl)piperidin-1-yl]acetic acid (56 mg, 0.23 mmol) as starting materials. Purification using chromatography B gave the title compound (128 mg, 83%).

[1099] Step 2: Synthesis of 3-[1-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperidin-3-yl]propanoic acid. The reaction was carried out according to General Procedure C using ethyl 3-[1-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperidin-3-yl]propanoate (128 mg, 0.19 mmol) as starting material. The residue was used in the next step without purification.

[1100] Step 3: Synthesis of (2S,4R)-1-[(2S)-2-{2-[(3RS)-3-(3-{6-[4-({2-fluoro-4-methyl-5-[(propan-2-yl)carbamoyl]phenyl}amino)-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-6-yl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-1'-yl}-3-oxopropyl)piperidin-1-yl]acetamido}-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide. The title compound was synthesized using Intermediate 1 (12 mg, 0.02 mmol) and 3-[1-({[(2S)-1-[(2S,4R)-4-hydroxy-2-{[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methyl)piperidin-3-yl]propanoic acid (10 mg, 0.02 mmol) according to General Procedure F, followed by reverse phase HPLC to provide the title compound (10.9 mg, 43%); LCMS: C 74 H 96 FN 13 O7S theoretical value 1329.5, found 1331.2 [M+2H] + ; 1 H NMR (500 MHz, acetonitrile-d3) δ8.84–8.73 (m, 1H), 8.67 (s, 1H), 8.06–7.96 (m, 1H), 7.96–7.86 (m, 1H), 7.75–7.67 (m, 1H), 7.53–7.13 (m, 10H), 6.68 (d, J = 7.8 Hz, 1H), 5.23–5.10 (m, 1H), 4.96 (s, 1H), 4.71–4.57 (m, 1H), 4.57–4.45(m,1H),4.44–4.32(m,1H),4.32–4.00(m,3H),3.98–3.58(m,8H),3.58–3.39(m,6H),3.09–2 .39(m,10H),2.12(d,J=5.1Hz,2H),1.92–1.38(m,28H),1.16(d,J=6.6Hz,8H),1.02(d,J=8.4Hz,10H).

[1101] Example 49

[1102] 5-[(6-{1'-[1-{1-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)acetyl]piperidine-4-carbonyl}pyrrolidine-3-carbonyl]-2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide

[1103]

[1104] Step 1: Synthesis of benzyl 1-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)acetyl]piperidine-4-carboxylate. The title compound was synthesized according to General Procedure F using ({2-[-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)acetic acid (175 mg, 0.39 mmol) and benzyl piperidine-4-carboxylate (86 mg, 0.39 mmol). The crude material was purified using chromatography B to yield the title compound (200 mg, 96%).

[1105] Step 2: Synthesis of 1-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)acetyl]piperidine-4-carboxylic acid. The title compound was synthesized by adding palladium on carbon (15 mg, 10 wt %) to benzyl 1-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)acetyl]piperidine-4-carboxylate (200 mg, 0.38 mmol). Ethyl acetate (2 mL) and ethanol (2 mL) were then added, and H2 gas was bubbled through the stirred mixture for 5 minutes. The reaction was then stirred under a balloon of H2 for 5 hours, then purged with nitrogen and filtered through celite, washing with ethyl acetate. The filtrate was concentrated and purified according to chromatography C to give the title compound (120 mg, 72%).

[1106] Step 3: Synthesis of 1-{1-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)acetyl]piperidine-4-carbonyl}pyrrolidine-3-carboxylic acid. The title compound was synthesized according to General Procedure F using 1-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)acetyl]piperidine-4-carboxylic acid (44 mg, 0.10 mmol) and tert-butyl pyrrolidine-3-carboxylate (19 mg, 0.11 mmol). The crude material was purified using chromatography C followed by General Procedure B to provide the title compound (22 mg, 41%).

[1107] Step 4: Synthesis of 5-[(6-{1'-[1-{1-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)acetyl]piperidine-4-carbonyl}pyrrolidine-3-carbonyl]-2-oxo-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-4-fluoro-2-methyl-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (13 mg, 0.02 mmol) and 1-{1-[2-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)acetyl]piperidine-4-carbonyl}pyrrolidine-3-carboxylic acid (10 mg, 0.02 mmol), followed by reverse phase HPLC to provide the title compound (13.6 mg, 60%); LCMS: C 67 H 78 FN 13 O9 theoretical value 1227.6, found 1230.0 [M+2H] + ; 1H NMR (500MHz, DMSO-d6) δ11.11(s,1H),9.31(s,1H),8.64(s,1H),8.39(s,1H),8.14(d,J=7.9Hz,1H),7.89(d,J=4.6Hz,1H),7.68( d,J=6.8Hz,1H),7.62(t,J=8.2Hz,2H),7.60–7.50(m,2H),7.19(d,J=12.0Hz,1H),7.15–7.01(m,3H),5.30(p,J=7.6,7.1Hz,1H), 5.08(dd,J=12.8,5.4Hz,1H),4.42(d,J=12.0Hz,1H),4.22(q,J=19.3,17.2Hz,5H),4.08–4.01(m,2H),3.49–3.22(m,8H),3.20–2 .69(m,13H),2.62(d,J=3.7Hz,1H),2.37(s,3H),2.20–2.03(m,3H),1.93–1.54(m,17H),1.50–1.33(m,2H),1.11(d,J=6.6Hz,6H).

[1108] Example 50

[1109] 4-Fluoro-2-methyl-5-[(6-{2-oxo-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1'-[(1S,4S)-4-[4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)piperidine-1-carbonyl]cyclohexanecarbonyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide

[1110]

[1111] Step 1: Synthesis of tert-butyl 4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]piperidine-1-carboxylate: To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione (4.0 g, 14 mmol, 1 eq.) and tert-butyl 4-aminopiperidine-1-carboxylate (3.48 g, 17.3 mmol, 1.2 eq.) in DMSO (20 mL) was added DIPEA (5.61 g, 43.4 mmol, 3 eq.). The resulting mixture was stirred at 80° C. overnight and then cooled to room temperature. The precipitated solid was collected by filtration and washed with water (3×50 mL). This provided the title compound as a solid (4.0 g, 61%).

[1112] Step 2: Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(piperidin-4-ylamino)isoindole-1,3-dione: The title compound was obtained following General Procedure B using tert-butyl 4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]piperidine-1-carboxylate (4.0 g, 8.8 mmol) as the starting material. The title compound was isolated after chromatography C (2.4 g, 77%).

[1113] Step 3: Synthesis of (1s,4s)-4-[4-([2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl]amino)piperidine-1-carbonyl]cyclohexane-1-carboxylic acid: To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-(piperidin-4-ylamino)isoindole-1,3-dione (1.3 g, 3.65 mmol, 1 eq.) and TEA (2.21 g, 21.9 mmol, 6 eq.) in DMF (8 mL) was added (1s,4s)-cyclohexane-1,4-dicarboxylic acid (0.63 g, 3.7 mmol, 1 eq.). The resulting mixture was stirred at room temperature under nitrogen atmosphere for 30 min. To the above mixture was added T3P (3.48 g, 5.47 mmol, 1.5 eq., 50% w / w solution in EtOAc) at 0°C. Water was then added, and the reaction mixture was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by chromatography C. This provided the title compound (230.2 mg, 7.65% yield).

[1114] Step 4: Synthesis of 4-fluoro-2-methyl-5-[(6-{2-oxo-1'-[(1r,4r)-4-[4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)piperidine-1-carbonyl]cyclohexanecarbonyl]-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg) and (1s,4s)-4-[4-([2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl]amino)piperidine-1-carbonyl]cyclohexane-1-carboxylic acid (7.2 mg), followed by reverse phase HPLC to provide the title compound (11.5 mg, 64%); LCMS: C 67 H 79 FN 12 Theoretical value of O8: 1198.6, measured value: 1200.0 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.09(s,1H),9.34(s,1H),8.70(s,1H),8.41(s,1H),8.14(d,J=7.8Hz,1H),7.87(d, J=2.3Hz,1H),7.74–7.47(m,5H),7.31–7.14(m,2H),7.05(dd,J=14.7,7.0Hz,1H),6.23(dd,J=55.9,8.2Hz,1H ),5.30(p,J=6.7Hz,1H),5.08–5.01(m,1H),4.32(d,J=13.1Hz,3H),4.26–4.14(m,4H),4.09–3.15(m,9H),3.0 7–2.72(m,8H),2.72–2.57(m,2H),2.36(s,3H),2.20–1.89(m,4H),1.89–1.27(m,23H),1.10(d,J=6.6Hz,6H).

[1115] Example 51

[1116] 4-Fluoro-2-methyl-5-[(6-{2-oxo-1'-[(1R,4R)-4-[4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)piperidine-1-carbonyl]cyclohexanecarbonyl]-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide

[1117]

[1118] Step-1: Synthesis of (1r,4r)-4-[4-([2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl]amino)piperidine-1-carbonyl]cyclohexane-1-carboxylic acid: To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-(piperidin-4-ylamino)isoindole-1,3-dione (1.7 g, 4.8 mmol, 1 eq.) and TEA (2.9 g, 29 mmol, 6 eq.) in DMF (8 mL) was added trans-cyclohexane-1,4-dicarboxylic acid (0.82 g, 4.8 mmol, 1 equiv.). The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 30 min. To the above mixture was added T3P (4.56 g, 7.16 mmol, 1.50 equiv., 50% w / w solution in EtOAc) at 0°C. The resulting mixture was stirred at room temperature overnight. Water was then added, and the reaction mixture was extracted with EtOAc (3×10 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by C18 reverse phase column with ACN / H2O (2 / 1). This gave (1r,4r)-4-[4-([2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindole-4-yl]amino)piperidine-1-carbonyl]cyclohexane-1-carboxylic acid as a yellow solid (252 mg, 10% yield).

[1119] Step 2: Synthesis of 4-fluoro-2-methyl-5-[(6-{2-oxo-1'-[(1r,4r)-4-[4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)piperidine-1-carbonyl]cyclohexanecarbonyl]-1-[(1s,3s)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide. The title compound was synthesized according to General Procedure F using Intermediate 1 (10 mg, 0.01 mmol) and (1r,4r)-4-[4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-4-yl}amino)piperidine-1-carbonyl]cyclohexane-1-carboxylic acid (7.2 mg, 0.01 mmol), followed by reverse phase HPLC to provide the title compound (10.2 mg, 60%); LCMS: C 67 H 79 FN 12 Theoretical value of O8: 1198.6, measured value: 1200.0 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.11(s,1H),9.30(d,J=9.4Hz,1H),8.65(s,1H),8.39(s,1H),8.15(d,J=7.8Hz,1H),7.89(s,1H),7.68(d,J=7.8Hz, 1H),7.63(t,J=7.4Hz,2H),7.57–7.51(m,2H),7.26(d,J=8.7Hz,1H),7.19(d,J=12.0Hz,1H),7.08(d,J=7.0Hz,1H),6.30(d,J=8.3Hz,1H),5. 33–5.27(m,1H),5.07(dd,J=12.6,5.4Hz,1H),4.35(s,1H),4.26–4.19(m,1H),4.05(q,J=6.8Hz,2H),3.53(q,J=8.2Hz,2H),3.41(d,J=11.5H z,3H),3.29–3.15(m,2H),3.05–2.72(m,11H),2.67–2.55(m,1H),2.38 (s,3H),2.07–1.93(m,3H),1.89–1.29(m,27H),1.11(d,J=6.5Hz,6H).

[1120] Example 52

[1121] 4-Fluoro-2-methyl-5-[(6-{2-oxo-1'-[(3R)-1-[(1R,4R)-4-({2-[2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}amino)cyclohexanecarbonyl]pyrrolidine-3-carbonyl]-1-[(1S,3S)-3-(piperidin-1-yl)cyclobutyl]-1,2-dihydrospiro[indole-3,4'-piperidin]-6-yl}-3-(propan-2-yl)-3H-imidazo[4,5-c]pyridin-4-yl)amino]-N-(propan-2-yl)benzamide

[1122]

[1123] Step 1: Synthesis of 1-benzyl 3-tert-butyl (3R)-pyrrolidine-1,3-dicarboxylate. To a mixture of (3R)-1-[(benzyloxy)carbonyl]pyrrolidine-3-carboxylic acid (5.0 g, 20 mmol, 1 eq.) in DCM (10 mL) was added (Z)-N,N-diisopropyl tert-butoxyformamidine (12 g, 64 mmol) at 0°C. The resulting mixture was stirred at room temperature overnight. The reaction was concentrated. The residue was purified by chromatography B to provide the title compound (2.6 g, 42% yield) as a colorless oil.

[1124] Step 2: Synthesis of tert-butyl (3R)-pyrrolidine-3-carboxylate. To a stirred mixture of 1-benzyl 3-tert-butyl (3R)-pyrrolidine-1,3-dicarboxylate (2.5 g, 8.2 mmol, 1 eq.) in THF (15 mL) was added Pd / C (1 g). The resulting mixture was stirred at room temperature for 1 h under a hydrogen atmosphere. The resulting mixture was purged with N2 gas for 15 minutes and then filtered. The filtrate was concentrated under reduced pressure. This gave the title compound (1.4 g, crude product) as an oil.

[1125] Step 3: Synthesis of tert-butyl (3R)-1-[(1r,4r)-4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]cyclohexanecarbonyl]pyrrolidine-3-carboxylate To a stirred mixture of (1r,4r)-4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]cyclohexane-1-carboxylate (500 mg, 1.25 mmol, 1 eq.) in DMF (5 mL) was added HATU (713 mg, 1.88 mmol, 1.5 eq.) and DIPEA (485 mg, 3.75 mmol, 3 eq.) at room temperature. After 30 minutes, (3R)-pyrrolidine-3-carboxylic acid tert-butyl ester (214mg, 1.25mmol, 1eq.) was added to the obtained mixture at room temperature and stirred for 3h. The obtained mixture was extracted with EtOAc (3x 30mL). The combined organic layer was washed with water (3x 20mL), dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by chromatography C to provide (3R)-1-[(1r, 4r)-4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl] amino] cyclohexanecarbonyl] pyrrolidine-3-carboxylic acid tert-butyl ester (220mg, 32% yield).

[1126] Step 4: Synthesis of (3R)-1-[(1r,4r)-4-([2-[2,6-dioxopiperidin-3-yl]-1,3-dioxoisoidol-4-yl]amino)cyclohexanecarbonyl]pyrrolidine-3-carboxylic acid. The reaction was carried out according to General Procedure B using tert-butyl (...

Claims

1. A compound having the following structure (I): or a pharmaceutically acceptable salt thereof, in: m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3, 4, 5 or 6; A is C 3-7 a monocyclic cycloalkyl ring or a 4-6 membered monocyclic heterocyclyl ring having 1 or 2 heteroatoms independently selected from N, O and S; L is a linker moiety having a length of 2 to 24 consecutive covalently bonded atoms selected from C, O, N and S; LHM is the ligase bundle part; R 11 for i) is selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy; or ii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, iii) -S(O) 2 C 1-6 alkyl, iv) -S(O) 2 C 3-7 Monocyclic cycloalkyl, v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 The monocyclic cycloalkyl group is optionally substituted, or vi)-C(O)R 21 ; Each R 12 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy; R 21 for i) H, ii) C 3-7 A monocyclic or bridged bicyclic cycloalkyl radical, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, wherein the C 1-3 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, iii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, iv) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is substituted by 1-3 heteroatoms independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, v)-NH 2 , vi)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, vii)-N(C 1-6 Alkyl) 2 , where each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, viii) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 The monocyclic cycloalkyl group is optionally substituted, or ix) C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from the following: a) – CN, b)–OH, c) halogens, d) C 1-3 Alkoxy, e)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, f) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 The alkoxy groups are optionally substituted, and g) -OC(O)C optionally substituted with one -OH 1-6 alkyl; R 3 and R 13 Each is H, or R 3 and R 13 Together they form = O; X is -NR 15 R 16 , where R 15 and R 16 Independently i) H, ii) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, iii) a 4-7 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, iv) -C(O)C 1-6 Alkyl, wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or v)C 1-6 Alkyl, which is optionally substituted by 1-6 groups independently selected from the following: a) – CN, b)–OH, c) halogens, d) C 1-3 Alkoxy, e)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 The alkoxy groups are optionally substituted, and f) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 The alkoxy group is optionally substituted; or X is a 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclic group is surrounded by 1-5 R 18 optionally substituted; Each R 18 Independently i)-CN, ii) halogen, iii) -OH, iv) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, vi) -COOH, or vii)-C(O)N(R 22 ) 2 , where each R 22 are independently H or C 1-6 alkyl; X 1 N or CR 17 ; R 4 , R 5 , R 6 , R 10 and R 17 are independently H, halogen, C 1-3 Alkyl or C 1-3 Alkoxy; R 7 for i) H, ii) C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 The monocyclic cycloalkyl group is optionally substituted, or iii) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted; Z is -O-, -C(R 8 ) 2 -or-NR 8 -; Each R 8 are independently H or C 1-3 alkyl; R 9a , R 9b , R 9c , R 9d and R 9e Independently i) H, ii) halogen, iii) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, iv)-NH 2 , v)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, vi)-N(C 1-6 alkyl) 2 , where each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, vii)-P(O)(C 1-6 alkyl) 2 , where each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, viii)-S(O) 2 C 1-6 alkyl, ix)-S(O) 2 N(R 23 ) 2 , where each R 23 are independently H or C 1-6 alkyl, x)C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from the following: a) -OH, b) halogens, c)C 1-3 Alkoxy, d) C 3-7 Monocyclic cycloalkyl, e) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from oxo and C 1-3 The alkyl groups are optionally substituted, and f)-NR 20 C(O)OC 1-3 Alkyl, where R 20 H or C 1-3 alkyl, xi)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, xii) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, xiii) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, xiv) -COOH, xv)-C(O)N(R 19 ) 2 ,or xvi)-C 1-3 Alkylene-C(O)N(R 19 ) 2 , Where: R 9a , R 9b , R 9c , R 9d and R 9e One or more of -C(O)N(R 19 ) 2 or -C 1-3 Alkylene-C(O)N(R 19 ) 2 ;as well as Each R 19 Independently i) H, ii)-S(O) 2 C 1-6 alkyl, iii) C 1-6 Alkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, iv) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-6 Alkyl and C 1-6 Alkoxy groups are optionally substituted, wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or v) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-6 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted.

2. The compound of claim 1, wherein Z is NH, X 1 For CH, R 6 is H, and the compound has the structure of general formula (Ia):

3. The compound of claim 1 or claim 2, wherein the compound has the structure of general formula (Ib):

4. The compound according to any one of claims 1 to 3, in Each R 9a , R 9b , R 9c , R 9d and R 9e are independently H, halogen, C 1-6 Alkyl or -C(O)N(R 19 ) 2 , where R 19 C 1-6 alkyl; R 4 , R 5 and R 10 Each is H; and R 7 C 1-6 alkyl.

5. The compound of any one of claims 1 to 4, wherein R 3 and R 13 Together they form =O.

6. The compound of any one of claims 1 to 5, wherein X is piperidinyl.

7. The compound of any one of claims 1 to 6, wherein n is 0 and p is 0.

8. Compounds having the general formula (II): or a pharmaceutically acceptable salt thereof, in m is 0, 1, 2, 3, 4 or 5; n is 0, 1, 2, 3, 4, 5 or 6; B is a 4-10 membered monocyclic, fused bicyclic, bridged bicyclic or spirocyclic heterocyclyl ring having 1-3 heteroatoms independently selected from N, O and S; L is a linker moiety having a length of 2 to 24 consecutive covalently bonded atoms selected from C, O, N and S; LHM is the ligase bundle part; R 1 and R 2 One of them is H, -CN, -OH, halogen or C 1-6 Alkyl, and R 1 and R 2 The other is H, halogen or C 1-6 Alkyl, where each C 1-6 The alkyl group is optionally substituted by 1 to 3 groups independently selected from -OH and halogen, or R 1 and R 2 Together with the carbon to which they are attached, they form C 3-7 A monocyclic cycloalkyl group or a 4-6 membered monocyclic heterocyclyl group having 1 or 2 heteroatoms independently selected from N, O and S, wherein said C 3-7 The monocyclic cycloalkyl group and the 4-6 membered monocyclic heterocyclic group are each represented by one R 11 are optionally substituted and each is independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, or R 1 and R 2 Together they form = O; R 11 i) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, i)-S(O) 2 C 1-6 alkyl, ii)-S(O) 2 C 3-7 Monocyclic cycloalkyl, iii) C 1-6 Alkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 The monocyclic cycloalkyl group is optionally substituted, or iv)-C(O)R 21 ; R 21 for i) H, ii) C 3-7 A monocyclic or bridged bicyclic cycloalkyl radical, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, wherein the C 1-3 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, iii) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, iv) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is substituted by 1-3 heteroatoms independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, v)-NH 2 , vi)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, vii)-N(C 1-6 alkyl) 2 , where each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, viii) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 The monocyclic cycloalkyl group is optionally substituted, or ix) C 1-6 Alkyl, which is optionally substituted by 1-3 groups independently selected from the following: a)-CN, b) -OH, c) halogens, d) C 1-3 Alkoxy, e)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -CN, -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, f) a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 The alkoxy groups are optionally substituted, and g) -OC(O)C optionally substituted with one -OH 1-6 alkyl; R 3 and R 13 Each is H, or R 3 and R 13 Together they form = O; Each R 12 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy; Each R 18 Independently i)-CN, ii) halogen, iii) -OH, iv) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, v)C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, vi) -COOH, or vii)-C(O)N(R 22 ) 2 , where each R 22 are independently H or C 1-6 alkyl; X 1 N or CR 17 ; R 4 , R 5 , R 6 , R 10 and R 17 are independently H, halogen, C 1-3 Alkyl or C 1-3 Alkoxy; R 7 for i) H, ii) C 1-6 Alkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkoxy and C 3-7 The monocyclic cycloalkyl group is optionally substituted, or iii) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted; Z is -O-, -C(R 8 ) 2 -or-NR 8 -; Each R 8 are independently H or C 1-3 alkyl; R 9a , R 9b , R 9c , R 9d and R 9e Independently i) H, ii) halogen, iii) C 1-6 Alkoxy, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, iv)-NH 2 , v)-NH(C 1-6 alkyl), wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, vi)-N(C 1-6 alkyl) 2 , where each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, vii)-P(O)(C 1-6 alkyl) 2 , where each C 1-6 The alkyl groups may be the same or different, and each C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, viii)-S(O) 2 C 1-6 alkyl, ix)-S(O) 2 N(R 23 ) 2 , where each R 23 are independently H or C 1-6 alkyl, x)C 1-6 The alkyl group is optionally substituted with 1-3 groups independently selected from: a) -OH, b) halogens, c)C 1-3 Alkoxy, d) C 3-7 Monocyclic cycloalkyl, e) a 5-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from oxo and C 1-3 The alkyl groups are optionally substituted, and f)-NR 20 C(O)OC 1-3 Alkyl, where R 20 H or C 1-3 alkyl, xi)C 3-7 Monocyclic cycloalkyl, which is substituted by 1-3 independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, xii) a 5-6 membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from N, O and S, wherein the 5-6 membered monocyclic heteroaryl group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, xiii) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-3 heteroatoms independently selected from -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted, xiv) -COOH, xv)-C(O)N(R 19 ) 2 ,or xvi)-C 1-3 Alkylene-C(O)N(R 19 ) 2 , Where R 9a , R 9b , R 9c , R 9d and R 9e One or more of -C(O)N(R 19 ) 2 or -C 1-3 Alkylene-C(O)N(R 19 ) 2 ;as well as Each R 19 Independently i) H, ii)-S(O) 2 C 1-6 alkyl, iii) C 1-6 Alkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-3 Alkoxy and C 3-7 Monocyclic cycloalkyl groups are optionally substituted, iv) C 3-7 Monocyclic cycloalkyl, which is substituted by 1-6 independently selected from -CN, -OH, halogen, C 1-6 Alkyl and C 1-6 Alkoxy groups are optionally substituted, wherein the C 1-6 The alkyl group is substituted by 1 to 3 groups independently selected from -CN, -OH, halogen and C 1-3 Alkoxy groups are optionally substituted, or v) a 4-6 membered monocyclic heterocyclic group having 1-3 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is substituted by 1-6 heteroatoms independently selected from -CN, -OH, halogen, oxo, C 1-3 Alkyl and C 1-3 Alkoxy groups are optionally substituted.

9. The compound of claim 8, wherein Z is NH, X 1 For CH, R 6 is H, and the compound has the structure of general formula (IIa):

10. The compound of claim 8 or claim 9, wherein the compound has the structure of general formula (IIb):

11. The compound according to any one of claims 8 to 10, in R 9a , R 9b , R 9c , R 9d and R 9e are independently H, halogen, C 1-6 Alkyl or -C(O)N(R 19 ) 2 ; where R 19 C 1-6 alkyl; R 4 , R 5 and R 10 Each is H; and R 7 C 1-6 alkyl.

12. A compound as described in any one of claims 8 to 11, wherein R 3 and R 13 Together they form =O; and R 1 and R 2 Together with the carbon to which they are attached, they form a 4-6 membered monocyclic heterocyclic group having 1 or 2 heteroatoms independently selected from N, O and S, wherein the 4-6 membered monocyclic heterocyclic group is replaced by one R 11 Optionally substituted.

13. A pharmaceutical composition comprising the compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

14. The pharmaceutical composition of claim 13, further comprising one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

15. Use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease or condition associated with increased hematopoietic progenitor kinase 1 (HPK1) activity in an individual in need thereof.

16. Use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for increasing T cell activation in an individual in need thereof.

17. Use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer in an individual in need thereof.

18. The method of claim 17, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, Merkel cell carcinoma, mesothelioma, melanoma, non-small cell lung cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, transitional cell carcinoma, and urothelial carcinoma.

19. Use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for inhibiting the growth or proliferation of cancer cells in an individual in need thereof.

20. The use of claim 19, wherein the compound is combined with a therapeutically effective amount of one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

21. The use of claim 20, wherein the one or more additional therapeutic agents are selected from: inducible T cell co-stimulatory molecule (ICOS) agonists, cytotoxic T lymphocyte antigen 4 (CTLA-4) blocking antibodies, PD1 and / or PD-L1 inhibitors, cluster of differentiation 47 (CD47) inhibitors, OX40 agonists, GITR agonists, CD27 agonists, CD28 agonists, CD40 agonists, CD137 agonists, Toll-like receptor 8 (TLR8) agonists, T cell immunoglobulin and mucin domain-3 (TIM-3) inhibitors, lymphocyte activation gene 3 (LAG-3) inhibitors. Inhibitors, CEACAM1 inhibitors, T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitors, V domain-containing immunoglobulin (Ig) inhibitors of T cell activation (VISTA) inhibitors, anti-killer IgG-like receptor (KIR) inhibitors, STING agonists, CXC chemokine receptor type 4 (CXCR-4) inhibitors, B7-H3 inhibitors, CD73 inhibitors, inhibitory RNA, IL2 / 15 / 17 fusion proteins, MKNK1 / 2 inhibitors, JAK inhibitors and PI3K inhibitors, or pharmaceutically acceptable salts of any of the foregoing, or any combination thereof.

22. The use of claim 20, wherein the one or more additional therapeutic agents are selected from the group consisting of: rituximab, doxorubicin, gemcitabine, nivolumab, pembrolizumab, pidilizumab, PDR001, TSR-001, atezolizumab, durvalumab, avelumab, pidilizumab, TSR-042, BMS-986016, ruxolitinib, N-(cyanomethyl)-4-[2-(4-morpholinoanilino)pyrimidin-4-yl]benzamide, XL147, BK M120, GDC-0941, BAY80-6946, PX-866, CH5132799, XL756, BEZ235 and GDC-0980, wortmannin, LY294002, TGR-1202, AMG-319, GSK2269557, X-339, X-414, RP5090, KAR4141, XL499, OXY111A, IPI-145, IPI-443, GSK2636771, BAY 10824391, bupanisib, BYL719, RG7604, MLN1117, WX-037, AEZS-129, PA799, ZSTK474, AS252424, TGX221, TG100115, IC87114, IPI-549, INCB050465, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, (S)-2-(1-(( 9H-purin-6-yl)amino)ethyl)-6-fluoro-3-phenylquinazolin-4(3H)-one, (S)-2-(1-((9H-purin-6-yl)amino)ethyl)-3-(2,6-difluorophenyl)quinazolin-4(3H)-one, (S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile and ipilimumab, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

23. The use of claim 20, wherein the one or more additional therapeutic agents are selected from idelalisib, tilarutib, molotinib and entospletinib, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

24. Use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing hepatitis B virus (HBV) infection in an individual in need thereof.

25. The use of claim 24, wherein the compound is combined with a therapeutically effective amount of one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

26. The method of claim 25, wherein the one or more additional therapeutic agents are selected from HBV co-drugs, HBV vaccines, HBV DNA polymerase inhibitors, immunomodulators, Toll-like receptor (TLR) modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, hepatitis B surface antigen (HBsAg) inhibitors, cytotoxic T lymphocyte-associated protein 4 (ipi4) inhibitors, cyclophilin inhibitors, HBV viral entry inhibitors, antisense oligonucleotides targeting viral mRNA, short interfering RNA (siRNA) and ddRNAi endonuclease regulators, ribonucleotide reductase inhibitors, HBV E antigen inhibitors, covalently closed circular DNA (cccDNA) inhibitors, farnesoid X receptor agonists, HBV antibodies, CCR2 chemokine antagonists, thymosin agonists, cytokines, nuclear protein regulators, retinoic acid-inducible gene 1 stimulators, NOD2 stimulators, phosphatidylinositol 3-kinase (PI3K) inhibitors, indoleamine-2,3-dioxygenase (IDO) pathway inhibitors, PD-1 inhibitors, PD-L1 inhibitors, recombinant thymosin alpha-1 agonists, Bruton's tyrosine kinase (BTK) inhibitors, KDM inhibitors, HBV replication inhibitors, arginase inhibitors and other HBV drugs, or pharmaceutically acceptable salts of any of the foregoing, or any combination thereof.

27. The use of claim 25, wherein the one or more additional therapeutic agents are selected from adefovir, tenofovir disoproxil fumarate + emtricitabine, tenofovir disoproxil fumarate, entecavir, lamivudine, tenofovir alafenamide, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, telbivudine, emtricitabine, pegylated interferon alpha-2b, interferon alpha 1b, interferon alpha 2b, pegylated interferon alpha-2a, interferon alpha-n1, ribavirin, interferon beta-1a, Bioferon, Ingaron, Inmutag, A lgeron, Interferon-A, Oligotide, Zutectra, Shaferon, Interferon alpha-2b, Alfaferone, Interferon alpha-2b, Feron, Interferon alpha 2, Bevac, Laferonum, Vipeg, Blauferon-B, Blauferon-A, Intermax alpha, Realdiron, Lanstion, Pegaferon, PDferon-B, alpha interferon 2b, Kalferon, Pegnano, Feronsure, PegiHep, Optipeg A, Realfa 2B, Reliferon, peg interferon alpha-2b, Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon alpha-2b, Andafen, Shanferon, MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2, Layfferon, Ka Shu Ning, Shang Sheng Lei Tai, Interfen, Serogen, Fukangtai, Calliphora antiviral peptide and Simoleukin; or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

28. The use according to claim 25, wherein the one or more additional therapeutic agents are selected from entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide hemifumarate, telbivudine and lamivudine, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

29. The use according to claim 25, wherein the one or more additional therapeutic agents are selected from tenofovir alafenamide, tenofovir alafenamide fumarate and tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

30. Use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing human immunodeficiency virus (HIV) infection in an individual in need thereof.

31. The use of claim 30, wherein the compound is combined with a therapeutically effective amount of one or more additional therapeutic agents or pharmaceutically acceptable salts thereof.

32. The use of claim 31, wherein the one or more additional therapeutic agents are selected from the group consisting of: combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversal agents, compounds targeting HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitors, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infection factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nuclear protein inhibitors, splicing factor modulators, COMM domain-containing protein 1 modulators, HIV ribonuclease H inhibitors, reverse cell cycle protein regulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing non-integrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, complement factor H regulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin-dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP-dependent RNA helicase DDX3X inhibitors, reverse transcriptase initiation complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy and HIV vaccines, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

33. The use of claim 31, wherein the one or more additional therapeutic agents are selected from HIV protease inhibitory compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers and other drugs used to treat HIV, or pharmaceutically acceptable salts of any of the foregoing, or any combination thereof.

34. The use according to claim 31, wherein the one or more additional therapeutic agents are selected from 4'-ethynyl-2-fluoro-2'-deoxyadenosine, bictegravir, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide and tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

35. The use according to claim 31, wherein the one or more additional therapeutic agents are selected from 4'-ethynyl-2-fluoro-2'-deoxyadenosine, bictegravir, tenofovir alafenamide, tenofovir alafenamide fumarate or tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.

36. The use according to claim 31, wherein the one or more additional therapeutic agents are selected from 4'-ethynyl-2-fluoro-2'-deoxyadenosine, bictegravir or a pharmaceutically acceptable salt thereof, tenofovir disoproxil, tenofovir disoproxil hemifumarate or tenofovir disoproxil fumarate, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.